{
    "question": "In patients undergoing prostate biopsy, can the omission of periprocedural antibiotic prophylaxis during transperineal biopsy safely maintain non-inferior infection rates across different risk categories, or are there specific subgroups such as immunocompromised or catheterized patients who may still require prophylaxis?",
    "parameters": {
        "n_runs": 5,
        "llm_confidence": 0.8,
        "min_cluster_size": 4
    },
    "pdf_names": [
        "LeitliniePAP2024.pdf",
        "EAU-Guidelines-on-Urological-infections-2025_2025-05-24-110339_pxmf.pdf",
        "RandomizedTrial3.pdf",
        "RandomizedTrial2.pdf",
        "RandomizedTrial1.pdf",
        "EAU-Guideline_Urological_Infections_Paper.pdf",
        "RandomizedTrial4.pdf",
        "EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf",
        "LL_Prostatakarzinom_Langversion_8.0.pdf",
        "SystematicReview6.pdf",
        "SystematicReview4.pdf",
        "SystematicReview5.pdf",
        "SystematicReview1.pdf",
        "SystematicReview2.pdf",
        "SystematicReview3.pdf"
    ],
    "raw_nuggets": {
        "EAU-Guidelines-on-Urological-infections-2025_2025-05-24-110339_pxmf.pdf": [
            "A systematic review and meta-analysis of eight non-RCTs reported comparable rates of post-biopsy infections in patients undergoing transperineal biopsy irrespective if antibiotic prophylaxis was given or not [613]. In addition, two recently published RCTs have reported comparably low post-biopsy infection rates for transperineal biopsy regardless of whether antibiotic prophylaxis was administered or not [615, 616].",
            "There is a growing body of evidence to suggest that antibiotic prophylaxis may not be required for transperineal biopsy; however, as all recommendations on prostate biopsy are based on level 1a evidence, the Panel has chosen to wait until a number of ongoing RCTs report their study findings before making a recommendation on this.",
            "A systematic review and meta-analysis of eight non-RCTs reported no significant differences between patients receiving or not receiving antibiotic prophylaxis in terms of post-biopsy infection (0.11% vs. 0.31%) and sepsis (0.13% vs. 0.09%), for the transperineal approach [613].",
            "This is in line with another systematic review and meta-analysis of 112 individual patient cohorts which also showed no significant difference in the number of patients experiencing post-transperineal biopsy infection with 1.35% of 29,880 patients receiving antibiotic prophylaxis and 1.22% of 4,772 not receiving antibiotic prophylaxis (p = 0.8) [614].",
            "In addition, two recently published RCTs have reported comparably low post-biopsy infection rates for transperineal biopsy regardless of whether antibiotic prophylaxis was administered or not [615, 616].",
            "There is a growing body of evidence to suggest that antibiotic prophylaxis may not be required for transperineal biopsy; however, as all recommendations on prostate biopsy are based on level 1a evidence, the Panel has chosen to wait until a number of ongoing RCTs report their study findings before making a recommendation on this.",
            "A systematic review and meta-analysis of eight non-RCTs reported no significant differences between patients receiving or not receiving antibiotic prophylaxis in terms of post-biopsy infection (0.11% vs. 0.31%) and sepsis (0.13% vs. 0.09%), for the transperineal approach [613]. This is in line with another systematic review and meta-analysis of 112 individual patient cohorts which also showed no significant difference in the number of patients experiencing post-transperineal biopsy infection with 1.35% of 29,880 patients receiving antibiotic prophylaxis and 1.22% of 4,772 not receiving antibiotic prophylaxis (p = 0.8) [614]. In addition, two recently published RCTs have reported comparably low post-biopsy infection rates for transperineal biopsy regardless of whether antibiotic prophylaxis was administered or not [615, 616].",
            "There is a growing body of evidence to suggest that antibiotic prophylaxis may not be required for transperineal biopsy",
            "A systematic review and meta-analysis of eight non-RCTs reported no significant differences between patients receiving or not receiving antibiotic prophylaxis in terms of post-biopsy infection (0.11% vs. 0.31%) and sepsis (0.13% vs. 0.09%), for the transperineal approach [613]. This is in line with another systematic review and meta-analysis of 112 individual patient cohorts which also showed no significant difference in the number of patients experiencing post-transperineal biopsy infection with 1.35% of 29,880 patients receiving antibiotic prophylaxis and 1.22% of 4,772 not receiving antibiotic prophylaxis (p = 0.8) [614]. In addition, two recently published RCTs have reported comparably low post-biopsy infection rates for transperineal biopsy regardless of whether antibiotic prophylaxis was administered or not [615, 616].",
            "There is a growing body of evidence to suggest that antibiotic prophylaxis may not be required for transperineal biopsy; however, as all recommendations on prostate biopsy are based on level 1a evidence, the Panel has chosen to wait until a number of ongoing RCTs report their study findings before making a recommendation on this.",
            "Patients who are more likely to develop urosepsis include elderly patients, diabetics, immunosuppressed patients, such as transplant recipients and patients receiving cancer chemotherapy or corticosteroids.",
            "Identifying bacteriuria prior to diagnostic and therapeutic procedures aims to reduce the risk of infectious complications by controlling any pre-operative detected bacteriuria and to optimise antimicrobial coverage in conjunction with the procedure.",
            "Screen for and treat asymptomatic bacteriuria prior to urological procedures breaching the mucosa.",
            "In patients subjected to placement/exchanges of nephrostomy tubes and indwelling ureteral stents, ABU is considered a risk factor for infectious complications [98].",
            "A urine culture must therefore be taken prior to such interventions and in case of ABU, pre-operative treatment is recommended.",
            " A systematic review and meta-analysis of eight non-RCTs reported no significant differences between patients receiving or not receiving antibiotic prophylaxis in terms of post-biopsy infection (0.11% vs. 0.31%) and sepsis (0.13% vs. 0.09%), for the transperineal approach [613]. This is in line with another systematic review and meta-analysis of 112 individual patient cohorts which also showed no significant difference in the number of patients experiencing post-transperineal biopsy infection with 1.35% of 29,880 patients receiving antibiotic prophylaxis and 1.22% of 4,772 not receiving antibiotic prophylaxis (p = 0.8) [614]. In addition, two recently published RCTs have reported comparably low post-biopsy infection rates for transperineal biopsy regardless of whether antibiotic prophylaxis was administered or not [615, 616]. ",
            " There is a growing body of evidence to suggest that antibiotic prophylaxis may not be required for transperineal biopsy; however, as all recommendations on prostate biopsy are based on level 1a evidence, the Panel has chosen to wait until a number of ongoing RCTs report their study findings before making a recommendation on this. ",
            " Screen for and treat asymptomatic bacteriuria prior to urological procedures breaching the mucosa. Strong "
        ],
        "LeitliniePAP2024.pdf": [
            "Bislang besteht hinsichtlich einer Empfehlung zur Antibiotikaprophylaxe bei der transperinealen Prostatabiopsie keine Einigkeit.",
            "Castellani et al. (2022) publizierten eine Metaanalyse mit geringer Evidenzsicherheit (acht komparative Studien, davon vier retrospektiv und vier prospektiv, aber keine RCT), die Infektionsraten nach perinealer Prostatabiopsie mit versus ohne PAP verglichen (0,11 % mit PAP vs. 0,31 % ohne PAP; p = 0,29).",
            "Inzwischen wurden zwei RCTs in diesem Setting publiziert, die keine h\u00f6here Rate an Infektionen, Fieber oder Sepsis f\u00fcr das Weglassen der PAP zeigten [Jacewicz 2022; Chernyscheva 2021].",
            "Einschlusskriterien waren erh\u00f6hter bzw. steigender PSA-Wert, suspekter digital-rektaler Tastbefund, Patienten unter \u201eactive surveillance\u201c, Patienten mit V.a. Rezidiv nach Radiatio bzw. nach HIFU (Hochintensiver Fokussierter Ultraschall).",
            "Ausgeschlossen wurden Patienten mit aktiver Harnwegsinfektion bzw. rezidivierenden Harnwegsinfektionen, Patienten mit liegendem Dauerkatheter, Immunsupprimierte und Patienten mit hohem Endokarditisrisiko sowie Patienten nach thromboembolischen Ereignissen.",
            "Urologie 2: Bei der transperinealen Prostatabiopsie, MRT-Fusionsbiopsie, kann auf eine Antibiotikaprophylaxe verzichtet werden.",
            "Hier soll pr\u00e4operativ ein sicherer Ausschluss eines Harnwegsinfekts sowie eine gr\u00fcndliche Desinfektion des Perineums mit Chlorhexidin oder Octenidindihydrochlorid/Phenoxyethanol erfolgen.",
            "Im Zweifelsfall und bei Risikopatienten sollte eine Antibiotika-prophylaxe mit Cefuroxim i.m. bzw. i.v. bzw. alternativ mit Ampicillin/Sulbactam 30 Minuten pr\u00e4operativ erfolgen.",
            "Die Ergebnisse der RCT zeigten bei Einsatz von PAP gegen\u00fcber keiner PAP eine nicht statistisch signifikante Reduktion der Entwicklung von Harnwegsinfektionen (OR 0,33 [0,03-3,19]).",
            "Sepsis oder hospitalisierungsbed\u00fcrftige Harnwegsinfektionen traten weder bei Personen mit PAP noch bei solchen ohne PAP auf.",
            "Bislang besteht hinsichtlich einer Empfehlung zur Antibiotikaprophylaxe bei der transperinealen Prostatabiopsie keine Einigkeit.",
            "Inzwischen wurden zwei RCTs in diesem Setting publiziert, die keine h\u00f6here Rate an Infektionen, Fieber oder Sepsis f\u00fcr das Weglassen der PAP zeigten [Jacewicz 2022; Chernyscheva 2021].",
            "Allerdings wurden aus den Studien Patienten mit aktiver Harnwegsinfektion bzw. rezidivierenden Harnwegsinfektionen, Patienten mit liegendem Dauerkatheter, Immunsupprimierte und Patienten mit hohem Endokarditisrisiko sowie Patienten nach thromboembolischen Ereignissen ausgeschlossen.",
            "Risikopatienten",
            "sollte",
            "Bei der transperinealen Prostatabiopsie, MRT-Fusionsbiopsie, kann auf eine Antibiotikaprophylaxe verzichtet werden. Hier soll pr\u00e4operativ ein sicherer Ausschluss eines Harnwegsinfekts sowie eine gr\u00fcndliche Desinfektion des Perineums mit Chlorhexidin oder Octenidindihydrochlorid/Phenoxyethanol erfolgen.",
            "Im Zweifelsfall und bei Risikopatienten sollte eine Antibiotikaprophylaxe mit Cefuroxim i.m. bzw. i.v. bzw. alternativ mit Ampicillin/Sulbactam 30 Minuten pr\u00e4operativ erfolgen.",
            "Bei der transperinealen Prostatabiopsie, MRT-Fusionsbiopsie, kann auf eine Antibiotikaprophylaxe verzichtet werden.",
            "Hier soll pr\u00e4operativ ein sicherer Ausschluss eines Harnwegsinfekts sowie eine gr\u00fcndliche Desinfektion des Perineums mit Chlorhexidin oder Octenidindihydrochlorid/Phenoxyethanol erfolgen.",
            "Es wurde eine neue systematische Literaturrecherche durchgef\u00fchrt, bei der eine geeignete RCT [Jacewicz et al. 2022] identifiziert werden konnte. Die Ergebnisse der RCT zeigten bei Einsatz von PAP gegen\u00fcber keiner PAP eine nicht statistisch signifikante Reduktion der Entwicklung von Harnwegsinfektionen (OR 0,33 [0,03-3,19]). Sepsis oder hospitalisierungsbed\u00fcrftige Harnwegsinfektionen traten weder bei Personen mit PAP noch bei solchen ohne PAP auf.",
            "Patienten mit aktiver Harnwegsinfektion bzw. rezidivierenden Harnwegsinfektionen, Patienten mit liegendem Dauerkatheter, Immunsupprimierte und Patienten mit hohem Endokarditisrisiko sowie Patienten nach thromboembolischen Ereignissen",
            "Im Zweifelsfall und bei Risikopatienten sollte eine Antibiotikaprophylaxe mit Cefuroxim i.m. bzw. i.v. bzw. alternativ mit Ampicillin/Sulbactam 30 Minuten pr\u00e4operativ erfolgen.",
            "Bei der transperinealen Prostatabiopsie, MRT-Fusionsbiopsie, kann auf eine Antibiotikaprophylaxe verzichtet werden.",
            "Hier soll pr\u00e4operativ ein sicherer Ausschluss eines Harnwegsinfekts sowie eine gr\u00fcndliche Desinfektion des Perineums mit Chlorhexidin oder Octenidindihydrochlorid/Phenoxyethanol erfolgen.",
            "Im Zweifelsfall und bei Risikopatienten sollte eine Antibiotikaprophylaxe mit Cefuroxim i.m. bzw. i.v. bzw. alternativ mit Ampicillin/Sulbactam 30 Minuten pr\u00e4operativ erfolgen.",
            "F\u00fcr die transperineale Prostatabiopsie ohne PAP wurden inzwischen zwei RCTs publiziert, die keine h\u00f6here Rate an Infektionen, Fieber oder Sepsis f\u00fcr das Weglassen der PAP zeigten [Jacewicz 2022; Chernyscheva 2021].",
            "Sepsis oder hospitalisierungsbed\u00fcrftige Harnwegsinfektionen traten weder bei Personen mit PAP noch bei solchen ohne PAP auf.",
            "Einschlusskriterien [f\u00fcr die Jacewicz 2022 Studie] waren erh\u00f6hter bzw. steigender PSA-Wert, suspekter digital-rektaler Tastbefund, Patienten unter \u201eactive surveillance\u201c, Patienten mit V.a. Rezidiv nach Radiatio bzw. nach HIFU (Hochintensiver Fokussierter Ultraschall).",
            "Ausgeschlossen wurden Patienten mit aktiver Harnwegsinfektion bzw. rezidivierenden Harnwegsinfektionen, Patienten mit liegendem Dauerkatheter, Immunsupprimierte und Patienten mit hohem Endokarditisrisiko sowie Patienten nach thromboembolischen Ereignissen.",
            "Es wurde keine Studie gefunden, die sich explizit mit der PAP bei neutropenischen Patienten besch\u00e4ftigt hat.",
            "Es kann angenommen werden, dass die Prinzipien der PAP wie bei nicht immunkompromittierten Patienten bei den jeweiligen Eingriffen gelten (Expertenmeinung).",
            "Es wurde keine Studie gefunden, die sich mit der PAP bei Patienten mit HIV-assoziiertem Immundefekt besch\u00e4ftigt hat.",
            "Es kann angenommen werden, dass die Prinzipien der PAP wie bei nicht immunkompromittierten Patienten bei den jeweiligen Eingriffen gelten (Expertenmeinung).",
            "Es wurde keine Studie gefunden, die sich explizit mit der PAP bei Patienten unter medikament\u00f6ser immunsupprimierender Behandlung von rheumatischen oder autoimmunen Erkrankungen besch\u00e4ftigt hat.",
            "Es kann angenommen werden, dass die Prinzipien der PAP wie bei nicht immunkompromittierten Patienten bei den jeweiligen Eingriffen gelten (Expertenmeinung).",
            "Bei der transperinealen Prostatabiopsie, MRT-Fusionsbiopsie, kann auf eine Antibiotikaprophylaxe verzichtet werden.",
            "Hier soll pr\u00e4operativ ein sicherer Ausschluss eines Harnwegsinfekts sowie eine gr\u00fcndliche Desinfektion des Perineums mit Chlorhexidin oder Octenidindihydrochlorid/Phenoxyethanol erfolgen.",
            "Im Zweifelsfall und bei Risikopatienten sollte eine Antibiotikaprophylaxe mit Cefuroxim i.m. bzw. i.v. bzw. alternativ mit Ampicillin/Sulbactam 30 Minuten pr\u00e4operativ erfolgen.",
            "Es wurde eine neue systematische Literaturrecherche durchgef\u00fchrt, bei der eine geeignete RCT [Jacewicz et al. 2022] identifiziert werden konnte. Die Ergebnisse der RCT zeigten bei Einsatz von PAP gegen\u00fcber keiner PAP eine nicht statistisch signifikante Reduktion der Entwicklung von Harnwegsinfektionen (OR 0,33 [0,03-3,19]). Sepsis oder hospitalisierungsbed\u00fcrftige Harnwegsinfektionen traten weder bei Personen mit PAP noch bei solchen ohne PAP auf. Die Vertrauensw\u00fcrdigkeit in die Evidenz f\u00fcr das Outcome Harnwegsinfektionen wird auf Grund von Bias-Risiken und unpr\u00e4ziser Effektsch\u00e4tzer als sehr gering eingestuft.",
            "Pr\u00e4interventionell erfolgte bei allen Patienten ein U-Stix zum Ausschluss eines Harnwegsinfektes. Das Perineum wurde mit Chlorhexidin oder Octenidin dihydrochlorid/Phenoxyethanol desinfiziert. ... Der Verzicht auf eine Antibiotikaprophylaxe bei der transperinealen Biopsie scheint das Risiko f\u00fcr eine Urosepsis bzw. schwerwiegende Harnwegsinfektion nicht zu erh\u00f6hen. Weniger schwerwiegende Harnwegsinfektionen waren ohne PAP dreimal so h\u00e4ufig, allerdings lag der absolute Unterschied nur bei 0,73 % (95 % CI: 1,08-2,81). Es mussten 137 Patienten antibiotisch behandelt werden, um eine Infektion zu vermeiden.",
            "Als Risikofaktor wird u.a. eine intestinale Besiedelung mit multiresistenten gramnegativen Bakterien (MRGN) beschrieben [Liss 2014].",
            "Es wurde keine Studie gefunden, die sich explizit mit der PAP bei neutropenischen Patienten besch\u00e4ftigt hat. Es kann angenommen werden, dass die Prinzipien der PAP wie bei nicht immunkompromittierten Patienten bei den jeweiligen Eingriffen gelten (Expertenmeinung).",
            "Mehrere Studien haben eine Assoziation zwischen niedrigen CD4+-Helferzellzahlen und postoperativem Wundinfektionsrisiko beschrieben [Ma 2020, Liu 2023]. Es wurde jedoch keine Studie gefunden, die sich mit der PAP bei Patienten mit HIV-assoziertem Immundefekt besch\u00e4ftigt hat. Es kann angenommen werden, dass die Prinzipien der PAP wie bei nicht immunkompromittierten Patienten bei den jeweiligen Eingriffen gelten (Expertenmeinung)."
        ],
        "RandomizedTrial2.pdf": [
            "LATP biopsy was performed with chlorhexidine-based skin preparation, without antibiotics.",
            "Most participants who received LATP underwent biopsy without antibiotics according to protocol (503 [89%] of 567).",
            "According to the pre-defined primary definition of post-biopsy infection (infection requiring admission to hospital), in the first 7 days post-biopsy this occurred in one (<1%) of 562 individuals allocated to LATP versus seven (1%) of 564 allocated to TRUS biopsy (OR 0.14 [95% CI 0.02-1-15]; table 4).",
            "In the 4-month post-biopsy period there were fewer infectious complications overall with LATP than with TRUS (six [1%] of 562 for LATP versus 13 [2%] of 564 for TRUS, adjusted 0.45 [0.17-1-20]).",
            "Analysis of the secondary, broader definition of post-biopsy infection (symptoms or signs of infection with or without hospital admission) showed no evidence of a statistically significant difference in the 4-month post-biopsy period (113 [20%] of 562 for LATP versus 120 [21%] of 564 for TRUS, 0.93 [0.70\u20131-25]).",
            "There were fewer infections (both resulting, and not resulting, in hospital admission) in TRANSLATE for LATP versus TRUS.",
            "TRANSLATE demonstrates fewer post-biopsy infection hospitalisations following LATP versus TRUS, with 89% of LATP biopsies not receiving antibiotics (the 11% of LATP cases receiving antibiotics being largely protocol deviations).",
            "Thus, TRANSLATE demonstrates that most LATP biopsies can be safely performed without antibiotics, which is important for antibiotic stewardship.",
            "We recognise that excluding participants at higher risk of infection, necessary for successful randomisation, likely reduced the infection event rate in both groups of this study.",
            "LATP biopsy was performed with chlorhexidine-based skin preparation, without antibiotics.",
            "with pre-procedure and post-procedure antibiotics as standard-of-care at each recruitment centre.",
            "history of immunocompromise, need for enhanced antibiotic prophylaxis",
            "without antibiotics",
            "All participants in the TRUS group received antibiotics",
            "one (<1%) of 562 individuals allocated to LATP versus seven (1%) of 564 individuals allocated to TRUS biopsy",
            "fewer infectious complications overall with LATP than with TRUS",
            "no evidence of a statistically significant difference in the 4-month post-biopsy period",
            "TRANSLATE demonstrates that most LATP biopsies can be safely performed without antibiotics",
            "excluding participants at higher risk of infection, necessary for successful randomisation, likely reduced the infection event rate in both groups of this study.",
            "LATP biopsy was performed with chlorhexidine-based skin preparation, without antibiotics.",
            "Most participants who received LATP underwent biopsy without antibiotics according to protocol (503 [89%] of 567).",
            "According to the pre-defined primary definition of post-biopsy infection (infection requiring admission to hospital), in the first 7 days post-biopsy this occurred in one (<1%) of 562 individuals allocated to LATP versus seven (1%) of 564 allocated to TRUS biopsy (OR 0.14 [95% CI 0.02-1-15]; table 4).",
            "In the 4-month post-biopsy period there were fewer infectious complications overall with LATP than with TRUS (six [1%] of 562 for LATP versus 13 [2%] of 564 for TRUS, adjusted 0.45 [0.17-1-20]).",
            "TRANSLATE demonstrates fewer post-biopsy infection hospitalisations following LATP versus TRUS, with 89% of LATP biopsies not receiving antibiotics (the 11% of LATP cases receiving antibiotics being largely protocol deviations). Thus, TRANSLATE demonstrates that most LATP biopsies can be safely performed without antibiotics, which is important for antibiotic stewardship.",
            "Individuals were excluded if they had any of the following: ... symptoms of concurrent or recent urinary tract infection, history of immunocompromise, need for enhanced antibiotic prophylaxis, ...",
            "We recognise that excluding participants at higher risk of infection, necessary for successful randomisation, likely reduced the infection event rate in both groups of this study.",
            "LATP biopsy was performed with chlorhexidine-based skin preparation, without antibiotics.",
            "Individuals were excluded if they had any of the following: previous prostate biopsy, extensive local disease easily detectable by any biopsy (prostate-specific antigen >50 ng/mL or entire gland replaced by tumour on MRI), symptoms of concurrent or recent urinary tract infection, history of immunocompromise, need for enhanced antibiotic prophylaxis, absent rectum, or inability to position in lithotomy.",
            "Infection requiring admission to hospital within 35 days post-biopsy occurred in 2 (<1%) of 562 participants in the LATP group compared with 9 (2%) of 564 in the TRUS group.",
            "Most participants who received LATP underwent biopsy without antibiotics according to protocol (503 [89%] of 567).",
            "According to the pre-defined primary definition of post-biopsy infection (infection requiring admission to hospital), in the first 7 days post-biopsy this occurred in one (<1%) of 562 individuals allocated to LATP versus seven (1%) of 564 allocated to TRUS biopsy (OR 0.14 [95% CI 0.02-1-15]; table 4).",
            "In the 4-month post-biopsy period there were fewer infectious complications overall with LATP than with TRUS (six [1%] of 562 for LATP versus 13 [2%] of 564 for TRUS, adjusted 0.45 [0.17-1-20]).",
            "There were fewer infections (both resulting, and not resulting, in hospital admission) in TRANSLATE for LATP versus TRUS.",
            "This difference was not statistically significant, although as this was a secondary outcome, the trial was not powered around this outcome.",
            "The 7-day and 35-day \"hospitalisation for infection\" rates in both groups were likely to be related to biopsy.",
            "Rates of post-biopsy infection in TRANSLATE were low and similar to PROBE-PC\" and PREVENT.18 TRANSLATE demonstrates fewer post-biopsy infection hospitalisations following LATP versus TRUS, with 89% of LATP biopsies not receiving antibiotics (the 11% of LATP cases receiving antibiotics being largely protocol deviations). Thus, TRANSLATE demonstrates that most LATP biopsies can be safely performed without antibiotics, which is important for antibiotic stewardship.",
            "We recognise that excluding participants at higher risk of infection, necessary for successful randomisation, likely reduced the infection event rate in both groups of this study.",
            "LATP biopsy was performed with chlorhexidine-based skin preparation, without antibiotics.",
            "with pre-procedure and post-procedure antibiotics as standard-of-care at each recruitment centre.",
            "history of immunocompromise, need for enhanced antibiotic prophylaxis",
            "LATP biopsy was performed with chlorhexidine-based skin preparation, without antibiotics.",
            "According to the pre-defined primary definition of post-biopsy infection (infection requiring admission to hospital), in the first 7 days post-biopsy this occurred in one (<1%) of 562 individuals allocated to LATP versus seven (1%) of 564 allocated to TRUS biopsy (OR 0.14 [95% CI 0.02-1-15]; table 4).",
            "In the 4-month post-biopsy period there were fewer infectious complications overall with LATP than with TRUS (six [1%] of 562 for LATP versus 13 [2%] of 564 for TRUS, adjusted 0.45 [0.17-1-20]).",
            "Most participants who received LATP underwent biopsy without antibiotics according to protocol (503 [89%] of 567).",
            "All participants in the TRUS group received antibiotics (appendix 1 p 17).",
            "According to the pre-defined primary definition of post-biopsy infection (infection requiring admission to hospital), in the first 7 days post-biopsy this occurred in one (<1%) of 562 individuals allocated to LATP versus seven (1%) of 564 allocated to TRUS biopsy (OR 0.14 [95% CI 0.02-1-15]; table 4).",
            "In the 4-month post-biopsy period there were fewer infectious complications overall with LATP than with TRUS (six [1%] of 562 for LATP versus 13 [2%] of 564 for TRUS, adjusted 0.45 [0.17-1-20]).",
            "Infectious complications from biopsy, and concerns regarding the development of post-biopsy urinary sepsis, have driven the transition from TRUS to LATP.",
            "There were fewer infections (both resulting, and not resulting, in hospital admission) in TRANSLATE for LATP versus TRUS. This difference was not statistically significant, although as this was a secondary outcome, the trial was not powered around this outcome.",
            "TRANSLATE demonstrates fewer post-biopsy infection hospitalisations following LATP versus TRUS, with 89% of LATP biopsies not receiving antibiotics (the 11% of LATP cases receiving antibiotics being largely protocol deviations).",
            "TRANSLATE demonstrates that most LATP biopsies can be safely performed without antibiotics, which is important for antibiotic stewardship.",
            "that excluding participants at higher risk of infection, necessary for successful randomisation, likely reduced the infection event rate in both groups of this study."
        ],
        "RandomizedTrial3.pdf": [
            "transperineal prostate biopsy",
            "does not contain information on periprocedural antibiotic prophylaxis during transperineal biopsy.",
            "low infectious risk",
            "high infectious risk defined as diabetes mellitus, systemic steroid use, immunocompromised status, a prostate volume \u226575 mL, or high-grade obstruction of the lower urinary tract (International Prostate Symptom Score [IPSS] \u226520, maximum urinary flow rate [Qmax] \u226412 mL/s, or residual urine \u2265100 mL)",
            "Further evaluation of the usefulness of selective media screening in patients with underlying conditions negatively impacting immune function is needed.",
            "transrectal prostate biopsy (TRPB)",
            "explicitly excluded transperineal prostate biopsy",
            "focused on patients with low infectious risk",
            "excluded cases with high infectious risk, defined as diabetes mellitus, systemic steroid use, immunocompromised status",
            "further evaluation of the usefulness of selective media screening in patients with underlying conditions negatively impacting immune function is needed",
            "(1) high infectious risk defined as diabetes mellitus, systemic steroid use, immunocompromised status, a prostate volume \u226575 mL, or high-grade obstruction of the lower urinary tract (International Prostate Symptom Score [IPSS] \u226520, maximum urinary flow rate [Qmax] \u226412 mL/s, or residual urine \u2265100 mL)",
            "(2) transperineal prostate biopsy",
            "(3) presence of pyuria at enrollment",
            "this study focused on patients with low in-fectious risk due to current criteria.",
            "Significance of Targeted Antimicrobial Prophylaxis Using Rectal-culture Selective Screening Media Prior to Transrectal Prostate Biopsy: A Multicenter, Randomized Controlled Trial",
            "transrectal prostate biopsy (TRPB)",
            "In this multicenter, randomized controlled trial, we enrolled 403 patients undergoing TRPB with low risks of infectious complications.",
            "Patients were randomized into a cultured group (CG) or no cultured group (NCG).",
            "The exclusion criteria of cases were as fol-lows: (1) high infectious risk defined as diabetes mellitus, systemic steroid use, immunocompromised status, a prostate volume \u226575 mL, or high-grade obstruction of the lower urinary tract (International Prostate Symptom Score [IPSS] \u226520, maximum urinary flow rate [Qmax] \u226412 mL/s, or residual urine \u2265100 mL), (2) transperineal prostate biopsy, (3) presence of pyuria at enrollment, (4) receiving antimicrobial administration less than 4 weeks before the rectal culture or the prostate biopsy, (5) contraindications to levofloxacin (LVFX), piperacillin/tazobactam (TAZ/PIPC), or both.",
            "Following the current criteria, this study focused on patients with low in-fectious risk due to current criteria.",
            "Our trial implicated that screening with selective media before TRPB in patients with low infectious risks may provide additive value to preventing post-biopsy prostatitis.",
            "TAZ/PIPC can be recommended when FQ-resistant or ESBL-producing E. coli is detected.",
            "Further evaluation of the usefulness of selective media screening in patients with underlying conditions negatively impacting im-mune function is needed.",
            "To examine whether antimicrobial prophylaxis based on screening rectal cultures using selective media prevented acute bacterial prostatitis following transrectal prostate biopsy (TRPB).",
            "in the NCG used levofloxacin.",
            "Screening with selective media before TRPB in patients with low infectious risks may provide additive value to preventing post-biopsy prostatitis.",
            "who schedule a TRPB during the period are eligible for enrollment. The exclusion criteria of cases were as fol-lows: (1) high infectious risk defined as diabetes mellitus, systemic steroid use, immunocompromised status, a prostate volume \u226575 mL, or high-grade obstruction of the lower urinary tract (International Prostate Symptom Score [IPSS] \u226520, maximum urinary flow rate [Qmax] \u226412 mL/s, or residual urine \u2265100 mL), (2) transperineal prostate biopsy, (3) presence of pyuria at enrollment, (4) receiving antimicrobial administration less than 4 weeks before the rectal culture or the prostate biopsy, (5) contraindications to levofloxacin (LVFX), piperacillin/ tazobactam (TAZ/PIPC), or both. Following the current criteria, this study focused on patients with low in-fectious risk due to current criteria.",
            "Participants in the culture-negative group received 1 dose of LVFX 500 mg orally 2 hours before TRPB.14 Participants in the NCG",
            "The total incidence of acute bacterial prostatitis after TRPB within 30 days was 1.1% (n = 4). The incidences in the CG and the NCG were 1.6% (n = 3) and 0.5%",
            "all patients were prescribed LVFX as a rectal culture-based or no culture-based antibiotic prophylaxis.",
            "Our trial focused on especially preventing acute, post-biopsy prostatitis and demonstrated the effectiveness of rectal culture using selective media before TRPB",
            "In this study, the sensitivity and specificity of the LVFX-insusceptible selective media were also 98.1% and 94.7%, respectively, indicating the high accuracy of these selective media.",
            "Some prospective studies reported the usefulness of selective media in comparing complication rates after TRPB using empirical versus culture-based antimicrobial prophylaxis,",
            "Our targeted anti-microbial prophylaxis using rectal-culture selective screening media showed the overall incidence of pros-tatitis after TRPB was 1.1%, which seemed lower than the infectious rate in this recent RCT.18 We included the patients with potentially low infectious risks, preserving immune response as hosts, and this aspect could be attributed to the low overall incidence of prostatitis.",
            "Further studies are necessary to examine the usefulness of selec-tive media in cases with higher infectious risk derived from a decline in immune function, including diabetes mellitus or other conditions.",
            "Our trial implicated that screening with selective media before TRPB in patients with low infectious risks may provide additive value to preventing post-biopsy pros-tatitis. TAZ/PIPC can be recommended when FQ-resistant or ESBL-producing E. coli is detected. Further evaluation of the usefulness of selective media screening in patients with underlying conditions negatively impacting im-mune function is needed."
        ],
        "RandomizedTrial1.pdf": [
            "Transperineal prostate biopsies (TPPB) were not performed during the clinical trial.",
            "the current guidelines of the European Association of Urology (EAU) now recommend transperineal prostate biopsy (TPPB) because of its lower rate of infectious complications.",
            "Transperineal prostate biopsies (TPPB) were not performed during the clinical trial.",
            "Patients with severe immunodeficiency or with indwelling urinary catheters were also excluded.",
            "Growing evidence suggests that infection, hospitalization, and sepsis rates are comparably lower in TPPB compared with TRPB.",
            "now recommend transperineal prostate biopsy (TPPB) because of its lower rate of infectious complications.",
            "Patients with severe immunodeficiency or with indwelling urinary cathe- ters were also excluded.",
            "Transperineal prostate biopsies (TPPB) were not performed during the clinical trial.",
            "Growing evidence suggests that infection, hospitalization, and sepsis rates are comparably lower in TPPB compared with TRPB. Even if TRPB is planned, antibiotic prophylaxis and povidone-iodine rectal preparation are recommended.",
            "Transperineal prostate biopsies (TPPB) were not performed during the clinical trial.",
            "Growing evidence suggests that infection, hospitalization, and sepsis rates are comparably lower in TPPB compared with TRPB. Even if TRPB is planned, antibiotic prophylaxis and povidone-iodine rectal preparation are recommended.",
            "Patients with severe immunodeficiency or with indwelling urinary catheters were also excluded.",
            "the current guidelines of the European Association of Urology (EAU) now recommend transperineal prostate biopsy (TPPB) because of its lower rate of infectious complications.",
            "Transperineal prostate biopsies (TPPB) were not performed during the clinical trial.",
            "Antibiotic prophylaxis before TRPB is mandatory to avoid in-fectious complications, but the previous gold standard FQs are no longer accepted in the EU for this indication. The current EAU guidelines recommend an algorithm for antibiotic prophylaxis before TRPB.",
            "Growing evidence suggests that infection, hospitalization, and sepsis rates are comparably lower in TPPB compared with TRPB.27,32",
            "Even if TRPB is planned, antibiotic prophylaxis and povidone-iodine rectal preparation are recommended.",
            "In this study, there was no significant difference between single-dose and prolonged FMT prophylaxis for TRPBs in terms of infec-tious complications."
        ],
        "EAU-Guideline_Urological_Infections_Paper.pdf": [
            " Table 19 - Suggested antimicrobial prophylaxis regimens before urological procedures ",
            " Procedure: Transrectal prostate biopsy ",
            " Prophylaxis recommended: Yes ",
            " the document does not explicitly address the omission of periprocedural antibiotic prophylaxis during transperineal biopsy, nor does it discuss maintaining non-inferior infection rates across different risk categories (e.g., immunocompromised or catheterized patients) for this specific procedure. ",
            "Transrectal prostate biopsy",
            "recommends prophylaxis",
            "considering prophylaxis \"in patients with high risk of postoperative sepsis.\"",
            "Transrectal prostate biopsy",
            "\"Targeted prophylaxis on the basis of a rectal swab or stool culture.\"",
            "\"Augmented prophylaxis with two or more different antibiotic classes.\"",
            "\"Alternative antibiotics\"",
            "fosfomycin trometamol for prostate biopsy",
            "\"The indication for fosfomycin trometamol for prostate biopsy has been withdrawn in Germany as the manufacturers did not submit the necessary pharmacokinetic data in support of this indication. Urologists are advised to check their local guidance in relation to the use of fosfomycin trometamol for prostate biopsy.\"",
            "Table 19 - Suggested antimicrobial prophylaxis regimens before urological procedures Procedure: Transrectal prostate biopsy Prophylaxis recommended: Yes",
            "Antimicrobial: 1. Targeted prophylaxis on the basis of a rectal swab or stool culture. 2. Augmented prophylaxis with two or more different antibiotic classes.a 3. Alternative antibiotics",
            "The indication for fosfomycin trometamol for prostate biopsy has been withdrawn in Germany as the manufacturers did not submit the necessary pharmacokinetic data in support of this indication. Urologists are advised to check their local guidance in relation to the use of fosfomycin trometamol for prostate biopsy.",
            "Table 19 - Suggested antimicrobial prophylaxis regimens before urological procedures",
            "Procedure: Transrectal prostate biopsy",
            "Prophylaxis recommended: Yes",
            "Antimicrobial: 1. Targeted prophylaxis on the basis of a rectal swab or stool culture. 2. Augmented prophylaxis with two or more different antibiotic classes.a 3. Alternative antibiotics \u2022 Fosfomycin trometamolb (eg, 3 g before and 3 g 24-48 h after biopsy) \u2022 Cephalosporin (eg, ceftriaxone 1 g i.m.; cefixime 400 mg p.o. for 3 d start- ing 24 h before biopsy) \u2022 Aminoglycoside (eg, gentamicin 3mg/kg i.v.; amikacin 15mg/kg i.m.)",
            "b The indication for fosfomycin trometamol for prostate biopsy has been withdrawn in Germany as the manufacturers did not submit the necessary pharmacokinetic data in support of this indication. Urologists are advised to check their local guidance in relation to the use of fosfomycin trometamol for prostate biopsy.",
            "Table 19 - Suggested antimicrobial prophylaxis regimens before urological procedures Procedure Prophylaxis recommended Antimicrobial Transrectal prostate biopsy Yes 1. Targeted prophylaxis on the basis of a rectal swab or stool culture. 2. Augmented prophylaxis with two or more different antibiotic classes.a 3. Alternative antibiotics \u2022 Fosfomycin trometamolb (eg, 3 g before and 3 g 24-48 h after biopsy) \u2022 Cephalosporin (eg, ceftriaxone 1 g i.m.; cefixime 400 mg p.o. for 3 d start-ing 24 h before biopsy) \u2022 Aminoglycoside (eg, gentamicin 3mg/kg i.v.; amikacin 15mg/kg i.m.)"
        ],
        "RandomizedTrial4.pdf": [
            "Standard antibiotic prophylaxis was administered.",
            "All patients were given ceftriaxone 2g IV infusion for prophylaxis before biopsy. After discharge, patients were administered 2 gr of cefixime (P.O) per day for 2 days.",
            "In our study, antibiotic regimens were the same and there was no difference between the groups.",
            "Patients with symptomatic urinary tract infection, a history of catheterization, hospitalization or urological intervention in the last month, immunodeficiency, or using immunosuppressive drugs were excluded from the study.",
            "transrectal prostate biopsy",
            "with standard antibiotic prophylaxis administered to all patients",
            "excluded patients with a history of catheterization, hospitalization or urological intervention in the last month, immunodeficiency, or using immunosuppressive drugs",
            "the transperineal method, where infection is less common",
            "sepsis rates were significantly higher in transrectal biopsy compared to transperineal biopsy",
            "The study included patients who underwent transrectal prostate biopsy",
            "Standard antibiotic prophylaxis was administered",
            "Patients with symptomatic urinary tract infection, a history of catheterization, hospitalization or urological intervention in the last month, immunodeficiency, or using immunosuppressive drugs were excluded from the study",
            "transperineal method, where infection is less common",
            "standard antibiotic prophylaxis was administered",
            "excluded patients with symptomatic urinary tract infection, a history of catheterization, hospitalization or urological intervention in the last month, immunodeficiency, or using immunosuppressive drugs",
            "the transperineal method, where infection is less common",
            "none of 245 patients who underwent transperineal biopsy were hospitalized",
            "Purpose: To discern whether reduced infection rates were attributed to antiseptic solutions or mechanical rectal irrigation.",
            "transrectal prostate biopsy",
            "Standard antibiotic prophylaxis was administered.",
            "transrectal ultrasound pros- tate biopsy (TRUS-PB)",
            "For patients who couldn't receive ceftriaxone treat- ment for any reason, 1 gr of amikacin was administered daily for 3 days. Patients with symptomatic urinary tract infection, a history of catheterization, hospitalization or urological intervention in the last month, immunodefi- ciency, or using immunosuppressive drugs were excluded from the study.",
            "Ultrasound-guided transrectal prostate biopsy was per- formed",
            "TRUS-PB remains the most commonly used and gold standard method for the diagnosis of prostate cancer."
        ],
        "EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf": [
            "A systematic review and meta-analysis of eight non-RCTs reported no significant differences between patients receiving or not receiving antibiotic prophylaxis before transperineal biopsy in terms of post-biopsy infection (0.11% vs. 0.31%) and sepsis (0.13% vs. 0.09%), [390].",
            "This is in line with another systematic review and meta analysis of 112 individual patient cohorts which also showed no significant difference in the number of patients experiencing post-transperineal-biopsy infection (1.35% of 29,880 patients receiving antibiotic prophylaxis and 1.22% of 4,772 men not receiving antibiotic prophylaxis [p = 0.8]) [391].",
            "In addition, two published RCTs have reported comparably low post-biopsy infection rates for transperineal biopsy regardless of whether antibiotic prophylaxis was administered or not [392, 393].",
            "Thus, there is a growing body of evidence to suggest that antibiotic prophylaxis may not be routinely required for transperineal biopsy.",
            "A systematic review and meta-analysis of eight non-RCTs reported no significant differences between patients receiving or not receiving antibiotic prophylaxis before transperineal biopsy in terms of post-biopsy infection (0.11% vs. 0.31%) and sepsis (0.13% vs. 0.09%), [390]. This is in line with another systematic review and meta-analysis of 112 individual patient cohorts which also showed no significant difference in the number of patients experiencing post-transperineal-biopsy infection (1.35% of 29,880 patients receiving antibiotic prophylaxis and 1.22% of 4,772 men not receiving antibiotic prophylaxis [p = 0.8]) [391]. In addition, two published RCTs have reported comparably low post-biopsy infection rates for transperineal biopsy regardless of whether antibiotic prophylaxis was administered or not [392, 393]. Thus, there is a growing body of evidence to suggest that antibiotic prophylaxis may not be routinely required for transperineal biopsy.",
            "A systematic review and meta-analysis of eight non-RCTs reported no significant differences between patients receiving or not receiving antibiotic prophylaxis before transperineal biopsy in terms of post-biopsy infection (0.11% vs. 0.31%) and sepsis (0.13% vs. 0.09%), [390]. This is in line with another systematic review and meta analysis of 112 individual patient cohorts which also showed no significant difference in the number of patients experiencing post-transperineal-biopsy infection (1.35% of 29,880 patients receiving antibiotic prophylaxis and 1.22% of 4,772 men not receiving antibiotic prophylaxis [p = 0.8]) [391]. In addition, two published RCTs have reported comparably low post-biopsy infection rates for transperineal biopsy regardless of whether antibiotic prophylaxis was administered or not [392, 393]. A SR and meta-analysis comparing transperineal with and without antibiotic prophylaxis showed very low percentages of septic complications (0.05% vs. 0.08%; p = 0.2) and overall infections (1.35% vs. 1.22%; p = 0.8) Thus, there is a growing body of evidence to suggest that antibiotic prophylaxis may not be routinely required for transperineal biopsy.",
            "A systematic review and meta-analysis of eight non-RCTs reported no significant differences between patients receiving or not receiving antibiotic prophylaxis before transperineal biopsy in terms of post-biopsy infection (0.11% vs. 0.31%) and sepsis (0.13% vs. 0.09%), [390]. This is in line with another systematic review and meta-analysis of 112 individual patient cohorts which also showed no significant difference in the number of patients experiencing post-transperineal-biopsy infection (1.35% of 29,880 patients receiving antibiotic prophylaxis and 1.22% of 4,772 men not receiving antibiotic prophylaxis [p = 0.8]) [391]. In addition, two published RCTs have reported comparably low post-biopsy infection rates for transperineal biopsy regardless of whether antibiotic prophylaxis was administered or not [392, 393]. A SR and meta-analysis comparing transperineal with and without antibiotic prophylaxis showed very low percentages of septic complications (0.05% vs. 0.08%; p = 0.2) and overall infections (1.35% vs. 1.22%; p = 0.8)",
            "Thus, there is a growing body of evidence to suggest that antibiotic prophylaxis may not be routinely required for transperineal biopsy.",
            "A systematic review and meta-analysis of eight non-RCTs reported no significant differences between patients receiving or not receiving antibiotic prophylaxis before transperineal biopsy in terms of post-biopsy infection (0.11% vs. 0.31%) and sepsis (0.13% vs. 0.09%), [390].",
            "This is in line with another systematic review and meta analysis of 112 individual patient cohorts which also showed no significant difference in the number of patients experiencing post-transperineal-biopsy infection (1.35% of 29,880 patients receiving antibiotic prophylaxis and 1.22% of 4,772 men not receiving antibiotic prophylaxis [p = 0.8]) [391].",
            "In addition, two published RCTs have reported comparably low post-biopsy infection rates for transperineal biopsy regardless of whether antibiotic prophylaxis was administered or not [392, 393].",
            "A SR and meta-analysis comparing transperineal with and without antibiotic prophylaxis showed very low percentages of septic complications (0.05% vs. 0.08%; p = 0.2) and overall infections (1.35% vs. 1.22%; p = 0.8)",
            "Thus, there is a growing body of evidence to suggest that antibiotic prophylaxis may not be routinely required for transperineal biopsy."
        ],
        "LL_Prostatakarzinom_Langversion_8.0.pdf": [
            "Bei der transperinealen Stanzbiopsie kann auf eine Antibiotikaprophylaxe verzichtet werden.",
            "Bei der transperinealen Biopsie kann bei Nicht-Vorhandensein einer Infektion oder Prostatitis auf eine Antibiotikaprophylaxe verzichtet werden.",
            "In einer multizentrischen, randomisierten Nicht-Unterlegenheitsstudie (NORAPP-Studie) wurden Patienten, die sich einer transperinealen Biopsie unterzogen, in einen Arm mit Antibiose und einen Arm ohne perinterventioneller Antibiose randomisiert. In beiden Armen zeigte sich kein Patient, der aufgrund einer Sepsis oder Harnwegsinfekts innerhalb von 2 Monaten nach Biopsie aufgenommen werden musste.",
            "Harnwegsinfekte, die keiner station\u00e4ren Aufnahme bedurften, zeigte sich bei 0,36 % (95 % KI 0,01-2,00) und 1,09 % (95 % KI 0,37-3,15) der Patienten mit bzw. ohne Antibiose. Mit einer Differenz von 0,73 % war damit die Nicht-Unterlegenheitsgrenze von 4 % nicht erreicht [170].",
            "Risikopatienten f\u00fcr eine erh\u00f6hte Infektionsrate bzw. Resistenzrate, bei denen also ein Rektalabstrich zur gezielten Antibiotikaprophylaxe zu empfehlen ist, sind durch folgende Risikofaktoren charakterisiert:",
            "Immunsuppression [268]",
            "Z.n. (rezidivierender) Prostatitis/Harnwegsinfektion [267]",
            "Diabetes mellitus bei erh\u00f6htem Infektionsrisiko [267]",
            "Z.n. Einnahme einer Antibiose bis vor \u2264 1 Jahr",
            "nach Reisen in L\u00e4nder mit einer hohen Antibiotika-Resistenzlage [269]",
            "4.33 Evidenzbasierte Empfehlung neu 2025 Empfehlungsgrad B Bei Risikopatienten sollte ein Rektalabstrich erfolgen.",
            "4.34 Konsensbasierte Empfehlung neu 2025 EK Povidon-Jod kann bei der transrektalen Biopsie angewendet werden.",
            "4.35 Evidenzbasierte Empfehlung neu 2025 Empfehlungsgrad 0 Bei der transperinealen Stanzbiopsie kann auf eine Antibiotikaprophylaxe  verzichtet werden.",
            "Zu Empfehlung 4.32 bis Empfehlung 4.35 Einsatz der antibiotischen Prophylaxe bei der Prostatabiopsie Eine Metaanalyse von 11 eingeschlossenen Studien mit 1.753 Patienten zeigte eine  signifikante Reduktion von Infektionen durch eine Antibiotikaprophylaxe bei der  transrektalen Biopsie (RR 0,56, 95 % KI 0,40-0,77) [169]. Risikopatienten f\u00fcr eine erh\u00f6hte Infektionsrate bzw. Resistenzrate, bei denen also ein  Rektalabstrich zur gezielten Antibiotikaprophylaxe zu empfehlen ist, sind durch  folgende Risikofaktoren charakterisiert:  \u2022 Z.n. (rezidivierender) Prostatitis/Harnwegsinfektion [267], \u2022 Diabetes mellitus bei erh\u00f6htem Infektionsrisiko [267], \u2022 Immunsuppression [268], \u2022 Z.n. Einnahme einer Antibiose bis vor \u2264 1 Jahr, \u2022 nach Reisen in L\u00e4nder mit einer hohen Antibiotika-Resistenzlage [269]. Weitere Ma\u00dfnahme zur Reduktion einer Infektion bei transrektaler Biopsie ist  transrektale Reinigung mit Povidon-Jod (Metaanalyse mit 11 Studien und 2.237  Patienten RR 0,47 (95 % KI 0,36-0,61)) [270]. Es zeigte sich in weiteren Metaanalysen  kein Unterschied in der Infektionsrate durch rektale Einl\u00e4ufe vor der Biopsie, beim  Nadeltyp, bei der Nadelgr\u00f6\u00dfe und der Durchf\u00fchrung eines periprostatischen  Nervenblocks/Lokalan\u00e4sthesie [270]. Die drei randomisiert-kontrollierten Studien  zeigten eine niedrige Infektionsrate auch im transrektalen Arm (1,4 % vs. keine in der  transperinealen (p=0,059) [98], 0,8 % [271] und 2,6 % vs. 2,7 % (p=0,99) im  transperinealen Zugang [272]). Es ist zu vermerken, dass bei Hu et al. und Mian et al.  keine antibiotische Prophylaxe beim transperinealen Zugang und eine gezielte  antibiotische Prophylaxe nach Rektalabstrich beim transrektalen Zugang erfolgte ([98] und [273]). Bei der transperinealen Biopsie kann bei Nicht-Vorhandensein einer Infektion oder  Prostatitis auf eine Antibiotikaprophylaxe verzichtet werden. In einer  multizentrischen, randomisierten Nicht-Unterlegenheitsstudie (NORAPP-Studie)  wurden Patienten, die sich einer transperinealen Biopsie unterzogen, in einen Arm mit  Antibiose und einen Arm ohne perinterventioneller Antibiose randomisiert. In beiden  Armen zeigte sich kein Patient, der aufgrund einer Sepsis oder Harnwegsinfekts  innerhalb von 2 Monaten nach Biopsie aufgenommen werden musste.  Harnwegsinfekte, die keiner station\u00e4ren Aufnahme bedurften, zeigte sich bei 0,36 %  (95 % KI 0,01-2,00) und 1,09 % (95 % KI 0,37-3,15) der Patienten mit bzw. ohne ",
            "Antibiose. Mit einer Differenz von 0,73 % war damit die Nicht-Unterlegenheitsgrenze  von 4 % nicht erreicht [170]. Eine weitere systematische \u00dcbersichtsarbeit und Metaanalyse zeigte keine erh\u00f6hte  Infektionsrate ohne die Verwendung einer Antibiotikaprophylaxe bei der  transperinealen Biopsie (0,05 % vs. 0,08 %; p=0,2) [171].",
            "Bei der transperinealen Stanzbiopsie kann auf eine Antibiotikaprophylaxe verzichtet werden.",
            "Bei der transperinealen Biopsie kann bei Nicht-Vorhandensein einer Infektion oder Prostatitis auf eine Antibiotikaprophylaxe verzichtet werden.",
            "\u2022 Z.n. (rezidivierender) Prostatitis/Harnwegsinfektion [267], \u2022 Diabetes mellitus bei erh\u00f6htem Infektionsrisiko [267], \u2022 Immunsuppression [268], \u2022 Z.n. Einnahme einer Antibiose bis vor \u2264 1 Jahr, \u2022 nach Reisen in L\u00e4nder mit einer hohen Antibiotika-Resistenzlage [269].",
            "Bei der transperinealen Stanzbiopsie kann auf eine Antibiotikaprophylaxe verzichtet werden.",
            "Bei der transperinealen Biopsie kann bei Nicht-Vorhandensein einer Infektion oder Prostatitis auf eine Antibiotikaprophylaxe verzichtet werden.",
            "In einer multizentrischen, randomisierten Nicht-Unterlegenheitsstudie (NORAPP-Studie) wurden Patienten, die sich einer transperinealen Biopsie unterzogen, in einen Arm mit Antibiose und einen Arm ohne perinterventioneller Antibiose randomisiert. In beiden Armen zeigte sich kein Patient, der aufgrund einer Sepsis oder Harnwegsinfekts innerhalb von 2 Monaten nach Biopsie aufgenommen werden musste. Harnwegsinfekte, die keiner station\u00e4ren Aufnahme bedurften, zeigte sich bei 0,36 % (95 % KI 0,01-2,00) und 1,09 % (95 % KI 0,37-3,15) der Patienten mit bzw. ohne Antibiose. Mit einer Differenz von 0,73 % war damit die Nicht-Unterlegenheitsgrenze von 4 % nicht erreicht [170].",
            "Risikopatienten f\u00fcr eine erh\u00f6hte Infektionsrate bzw. Resistenzrate, bei denen also ein Rektalabstrich zur gezielten Antibiotikaprophylaxe zu empfehlen ist, sind durch folgende Risikofaktoren charakterisiert: Z.n. (rezidivierender) Prostatitis/Harnwegsinfektion, Diabetes mellitus bei erh\u00f6htem Infektionsrisiko, Immunsuppression, Z.n. Einnahme einer Antibiose bis vor \u2264 1 Jahr, nach Reisen in L\u00e4nder mit einer hohen Antibiotika-Resistenzlage [269].",
            "Bei der transperinealen Stanzbiopsie kann auf eine Antibiotikaprophylaxe verzichtet werden.",
            "Eine Metaanalyse von 11 eingeschlossenen Studien mit 1.753 Patienten zeigte eine signifikante Reduktion von Infektionen durch eine Antibiotikaprophylaxe bei der transrektalen Biopsie (RR 0,56, 95 % KI 0,40-0,77) [169].",
            "Risikopatienten f\u00fcr eine erh\u00f6hte Infektionsrate bzw. Resistenzrate, bei denen also ein Rektalabstrich zur gezielten Antibiotikaprophylaxe zu empfehlen ist, sind durch folgende Risikofaktoren charakterisiert: \u2022 Z.n. (rezidivierender) Prostatitis/Harnwegsinfektion [267], \u2022 Diabetes mellitus bei erh\u00f6htem Infektionsrisiko [267], \u2022 Immunsuppression [268], \u2022 Z.n. Einnahme einer Antibiose bis vor \u2264 1 Jahr, \u2022 nach Reisen in L\u00e4nder mit einer hohen Antibiotika-Resistenzlage [269].",
            "Bei der transperinealen Biopsie kann bei Nicht-Vorhandensein einer Infektion oder Prostatitis auf eine Antibiotikaprophylaxe verzichtet werden.",
            "In einer multizentrischen, randomisierten Nicht-Unterlegenheitsstudie (NORAPP-Studie) wurden Patienten, die sich einer transperinealen Biopsie unterzogen, in einen Arm mit Antibiose und einen Arm ohne perinterventioneller Antibiose randomisiert. In beiden Armen zeigte sich kein Patient, der aufgrund einer Sepsis oder Harnwegsinfekts innerhalb von 2 Monaten nach Biopsie aufgenommen werden musste.",
            "Harnwegsinfekte, die keiner station\u00e4ren Aufnahme bedurften, zeigte sich bei 0,36 % (95 % KI 0,01-2,00) und 1,09 % (95 % KI 0,37-3,15) der Patienten mit bzw. ohne Antibiose.",
            "Mit einer Differenz von 0,73 % war damit die Nicht-Unterlegenheitsgrenze von 4 % nicht erreicht [170]."
        ],
        "SystematicReview6.pdf": [
            "TP-Tbx can safely omit antibiotics without increasing infection risk, unlike TR-Tbx.",
            "The tendency to exclude from practice TR-Tbx with pro- phylactic antibiotics due to infection concerns could be moderated; however, the direc- tionality of some key outcomes, as infections and sepsis, favor the TP approach despite a lack of statistical significance.",
            "There were no significant differences in the prostate biopsy approaches (transperineal [TP] vs transrectal [TR]) for prostate cancer detection and complications.",
            "However, the MRI-targeted TP prostate biopsy approach may be advantageous as it can be performed safely without antibiotics, potentially reducing antibiotic resistance.",
            "In the PREVENT randomized trial [12], a comparison was made between TP biopsy without any antibiotic prophylaxis and TR biopsy where targeted prophylaxis was used.",
            "It should be noted that TP biopsies without preventative antibiotics show no significant infectious com- plications, similar to TR biopsies that used targeted antibi- otic prophylaxis.",
            "There was one report of sepsis among 1545 patients with available sepsis details (TR: one/762 vs TP: zero/783).",
            "In the ProBE-PC study, both groups showed sim- ilarly low rates of infectious complications (TR 2.6%, TP 2.7%).",
            "The complications were primarily mild, including fevers reported by six participants in each group. No epi- sodes of sepsis were observed following either biopsy method.",
            "There were 28 reports of infections among 1545 patients with available details (TR: 15/762 [2%] vs TP: 13/783 [2%]).",
            "Our meta-analysis reaffirms the lack of clear superiority of the TP-Tbx approach over the TR-Tbx approach in terms of infection prevention and cancer detection.",
            "Second, the overall toxicity associated with the biopsy approaches is low, suggesting that both are generally safe for clinical use in the populations studied, without an increasing risk of urinary retention for the TP approach.",
            "Across three studies [12,13,15], there is a clear trend toward minimizing antibiotic use to reduce antibiotic resistance.",
            "The TR approach has a higher chance of infection due to the involvement of the rectal mucosa, according to the real-world data rate of up to 5-7% [22], typically requiring more comprehensive antibiotic protocols.",
            "Thus, the primary reason to use the TP approach is not due to a reduction in mild infections, but rather because numerous prospective and retrospective reviews have shown an almost complete absence of postbiopsy sepsis with this method.",
            "In the ProBE-PC study, not a single case of sepsis was reported in either group, likely because sepsis is much rarer than other types of infectious complications.",
            "Interestingly, in a recent update of the PREVENT trial, no infections were reported in 372 cases using the TP approach, compared with six infections out of 370 cases in the TR group, showing a differ- ence of -1% (95% CI: -3.5% to 0.3%, p = 0.01).",
            "Although sepsis is a relatively rare event, making most studies underpow- ered to detect significant differences, it appears that the TP approach offers advantages over the TR approach.",
            "Current evidence does not show a clear advantage of TP-Tbx over TR-Tbx.",
            "Both methods have similar rates of PCa detec- tion, infection, urinary retention, and biopsy-associated pain.",
            "Notably, TP-Tbx could potentially reduce or eliminate the need for prophylactic antibiotics, aligning with the goals of effective antibiotic stewardship and reducing reliance on broad-spectrum antibiotics, important factors in choosing the optimal biopsy technique.",
            "Preliminary evidence sug- gests that TP-Tbx may result in lower rates of sepsis; how- ever, these findings are not yet statistically significant.",
            "This directionality in key outcomes, such as infection and sepsis, appears to favor TP-Tbx, warranting further investigation to confirm these potential advantages.",
            " TP-Tbx can safely omit antibiotics without increasing infection risk, unlike TR-Tbx. ",
            " However, the MRI-targeted TP prostate biopsy approach may be advantageous as it can be performed safely without antibiotics, potentially reducing antibiotic resistance. ",
            " In the PREVENT randomized trial [12], a comparison was made between TP biopsy without any antibiotic prophylaxis and TR biopsy where targeted prophylaxis was used. ",
            " The PREVENT trial [12] showed a low infection rate, with no infections reported in the TP group and a minimal inci- dence (1.6%) in the TR group. ",
            " These infections were charac- terized as febrile but nonsevere, indicating that when infections occurred in the TR group, these did not escalate to critical levels. It should be noted that TP biopsies without preventative antibiotics show no significant infectious com- plications, similar to TR biopsies that used targeted antibi- otic prophylaxis. ",
            " Second, the overall toxicity associated with the biopsy approaches is low, suggesting that both are generally safe for clinical use in the populations studied, without an increasing risk of urinary retention for the TP approach. ",
            " Across three studies [12,13,15], there is a clear trend toward minimizing antibiotic use to reduce antibiotic resistance. ",
            " Thus, the primary reason to use the TP approach is not due to a reduction in mild infections, but rather because numerous prospective and retrospective reviews have shown an almost complete absence of postbiopsy sepsis with this method. ",
            " Interestingly, in a recent update of the PREVENT trial, no infections were reported in 372 cases using the TP approach, compared with six infections out of 370 cases in the TR group, showing a differ- ence of -1% (95% CI: -3.5% to 0.3%, p = 0.01). ",
            " Current evidence does not show a clear advantage of TP-Tbx over TR-Tbx. Both methods have similar rates of PCa detec- tion, infection, urinary retention, and biopsy-associated pain. ",
            " Notably, TP-Tbx could potentially reduce or eliminate the need for prophylactic antibiotics, aligning with the goals of effective antibiotic stewardship and reducing reliance on broad-spectrum antibiotics, important factors in choosing the optimal biopsy technique. ",
            "The benefits of the detection of clinically significant prostate cancer (csPCa) and safety of magnetic resonance imaging (MRI)-targeted transperineal (TP) prostate biopsy (TP-Tbx) versus transrectal (TR) approaches are still a matter of debate.",
            "This review aims to compare the efficacy and safety of TP-Tbx and MRI- targeted TR biopsy (TR-Tbx).",
            "The TR technique was commonly administered with antibiotic prophy- laxis to mitigate infection risks or after a rectal swab.",
            "No difference was found between TP- Tbx and TR-Tbx in terms of either csPCa (odds ratio [OR] 0.9, 95% confidence interval [CI]: 0.7-1.1) or ISUP 1 prostate cancer (PCa; OR 1.1, 95% CI: 0.8-1.4) detection.",
            "Postprocedural infection (OR 0.8, 95% CI: 0.4-1.8), sepsis (OR 0.6, 95% CI: 0.1-4.5), and urinary retention rates (OR 0.5, 95% CI: 0.1-1.6) were similar.",
            "TP-Tbx and TR-Tbx show similar results in detect- ing PCa, with comparable rates of infections, urinary retention, and effectiveness in managing biopsy-associated pain.",
            "TP-Tbx can safely omit antibiotics without increasing infection risk, unlike TR-Tbx.",
            "However, the MRI-targeted TP prostate biopsy approach may be advantageous as it can be performed safely without antibiotics, potentially reducing antibiotic resistance.",
            "In the PREVENT randomized trial [12], a comparison was made between TP biopsy without any antibiotic prophylaxis and TR biopsy where targeted prophylaxis was used.",
            "The PREVENT trial [12] showed a low infection rate, with no infections reported in the TP group and a minimal inci- dence (1.6%) in the TR group.",
            "It should be noted that TP biopsies without preventative antibiotics show no significant infectious com- plications, similar to TR biopsies that used targeted antibi- otic prophylaxis.",
            "Across three studies [12,13,15], there is a clear trend toward minimizing antibiotic use to reduce antibiotic resistance.",
            "The TR approach has a higher chance of infection due to the involvement of the rectal mucosa, according to the real-world data rate of up to 5-7% [22], typically requiring more comprehensive antibiotic protocols. Thus, the primary reason to use the TP approach is not due to a reduction in mild infections, but rather because numerous prospective and retrospective reviews have shown an almost complete absence of postbiopsy sepsis with this method.",
            "In the ProBE-PC study, not a single case of sepsis was reported in either group, likely because sepsis is much rarer than other types of infectious complications.",
            "Interestingly, in a recent update of the PREVENT trial, no infections were reported in 372 cases using the TP approach, compared with six infections out of 370 cases in the TR group, showing a differ- ence of -1% (95% CI: -3.5% to 0.3%, p = 0.01).",
            "Current evidence does not show a clear advantage of TP-Tbx over TR-Tbx. Both methods have similar rates of PCa detec- tion, infection, urinary retention, and biopsy-associated pain.",
            "Notably, TP-Tbx could potentially reduce or eliminate the need for prophylactic antibiotics, aligning with the goals of effective antibiotic stewardship and reducing reliance on broad-spectrum antibiotics, important factors in choosing the optimal biopsy technique.",
            "Preliminary evidence sug- gests that TP-Tbx may result in lower rates of sepsis; how- ever, these findings are not yet statistically significant.",
            "This directionality in key outcomes, such as infection and sepsis, appears to favor TP-Tbx, warranting further investigation to confirm these potential advantages.",
            "The benefits of the detection of clinically significant prostate cancer (csPCa) and safety of magnetic resonance imaging (MRI)-targeted transperineal (TP) prostate biopsy (TP-Tbx) versus transrectal (TR) approaches are still a matter of debate. This review aims to compare the efficacy and safety of TP-Tbx and MRI-targeted TR biopsy (TR-Tbx).",
            "The TR technique was commonly administered with antibiotic prophylaxis to mitigate infection risks or after a rectal swab. No difference was found between TP-Tbx and TR-Tbx in terms of either csPCa (odds ratio [OR] 0.9, 95% confidence interval [CI]: 0.7-1.1) or ISUP 1 prostate cancer (PCa; OR 1.1, 95% CI: 0.8-1.4) detection. Postprocedural infection (OR 0.8, 95% CI: 0.4-1.8), sepsis (OR 0.6, 95% CI: 0.1-4.5), and urinary retention rates (OR 0.5, 95% CI: 0.1-1.6) were similar.",
            "Conclusions and clinical implications: TP-Tbx and TR-Tbx show similar results in detect- ing PCa, with comparable rates of infections, urinary retention, and effectiveness in managing biopsy-associated pain. TP-Tbx can safely omit antibiotics without increasing infection risk, unlike TR-Tbx. The tendency to exclude from practice TR-Tbx with pro- phylactic antibiotics due to infection concerns could be moderated; however, the direc- tionality of some key outcomes, as infections and sepsis, favor the TP approach despite a lack of statistical significance.",
            "Patient summary: There were no significant differences in the prostate biopsy approaches (transperineal [TP] vs transrectal [TR]) for prostate cancer detection and complications. However, the MRI-targeted TP prostate biopsy approach may be advantageous as it can be performed safely without antibiotics, potentially reducing antibiotic resistance.",
            "In contrast, the TP approach, although often requiring more extensive prepa- ration and potentially general anesthesia, significantly miti- gates the risk of infection by avoiding the rectal mucosa, thus offering a potentially safer alternative [5].",
            "In the PREVENT randomized trial [12], a comparison was made between TP biopsy without any antibiotic prophylaxis and TR biopsy where targeted prophylaxis was used.",
            "In the ProBE-PC study [13], all biopsy procedures were performed with 1-d antibiotic prophylaxis for TR proce- dures without rectal cultures and only occasionally for TP.",
            "There was one report of sepsis among 1545 patients with available sepsis details (TR: one/762 vs TP: zero/783).",
            "In the ProBE-PC study, both groups showed sim- ilarly low rates of infectious complications (TR 2.6%, TP 2.7%).",
            "There were 28 reports of infections among 1545 patients with available details (TR: 15/762 [2%] vs TP: 13/783 [2%]).",
            "The PREVENT trial [12] showed a low infection rate, with no infections reported in the TP group and a minimal inci- dence (1.6%) in the TR group. These infections were charac- terized as febrile but nonsevere, indicating that when infections occurred in the TR group, these did not escalate to critical levels. It should be noted that TP biopsies without preventative antibiotics show no significant infectious com- plications, similar to TR biopsies that used targeted antibi- otic prophylaxis.",
            "Our meta-analysis reaffirms the lack of clear superiority of the TP-Tbx approach over the TR-Tbx approach in terms of infection prevention and cancer detection.",
            "Second, the overall toxicity associated with the biopsy approaches is low, suggesting that both are generally safe for clinical use in the populations studied, without an increasing risk of urinary retention for the TP approach.",
            "Across three studies [12,13,15], there is a clear trend toward minimizing antibiotic use to reduce antibiotic resistance. The TR approach has a higher chance of infection due to the involvement of the rectal mucosa, according to the real-world data rate of up to 5-7% [22], typically requiring more comprehensive antibiotic protocols. Thus, the primary reason to use the TP approach is not due to a reduction in mild infections, but rather because numerous prospective and retrospective reviews have shown an almost complete absence of postbiopsy sepsis with this method. In the ProBE-PC study, not a single case of sepsis was reported in either group, likely because sepsis is much rarer than other types of infectious complications. Interestingly, in a recent update of the PREVENT trial, no infections were reported in 372 cases using the TP approach, compared with six infections out of 370 cases in the TR group, showing a differ- ence of -1% (95% CI: -3.5% to 0.3%, p = 0.01).",
            "Current evidence does not show a clear advantage of TP-Tbx over TR-Tbx. Both methods have similar rates of PCa detec- tion, infection, urinary retention, and biopsy-associated pain. Notably, TP-Tbx could potentially reduce or eliminate the need for prophylactic antibiotics, aligning with the goals of effective antibiotic stewardship and reducing reliance on broad-spectrum antibiotics, important factors in choosing the optimal biopsy technique. Preliminary evidence sug- gests that TP-Tbx may result in lower rates of sepsis; how- ever, these findings are not yet statistically significant. This directionality in key outcomes, such as infection and sepsis, appears to favor TP-Tbx, warranting further investigation to confirm these potential advantages.",
            "Transperineal Versus Transrectal Magnetic Resonance Imaging- targeted Prostate Biopsy: A Systematic Review and Meta-analysis of Prospective Studies",
            "TP-Tbx and TR-Tbx show similar results in detect- ing PCa, with comparable rates of infections, urinary retention, and effectiveness in managing biopsy-associated pain. TP-Tbx can safely omit antibiotics without increasing infection risk, unlike TR-Tbx.",
            "the MRI-targeted TP prostate biopsy approach may be advantageous as it can be performed safely without antibiotics, potentially reducing antibiotic resistance.",
            "In the PREVENT randomized trial [12], a comparison was made between TP biopsy without any antibiotic prophylaxis and TR biopsy where targeted prophylaxis was used.",
            "These infections were charac- terized as febrile but nonsevere, indicating that when infections occurred in the TR group, these did not escalate to critical levels. It should be noted that TP biopsies without preventative antibiotics show no significant infectious com- plications, similar to TR biopsies that used targeted antibi- otic prophylaxis.",
            "there is a clear trend toward minimizing antibiotic use to reduce antibiotic resistance. The TR approach has a higher chance of infection due to the involvement of the rectal mucosa, according to the real-world data rate of up to 5-7% [22], typically requiring more comprehensive antibiotic protocols. Thus, the primary reason to use the TP approach is not due to a reduction in mild infections, but rather because numerous prospective and retrospective reviews have shown an almost complete absence of postbiopsy sepsis with this method.",
            "Interestingly, in a recent update of the PREVENT trial, no infections were reported in 372 cases using the TP approach, compared with six infections out of 370 cases in the TR group, showing a differ- ence of -1% (95% CI: -3.5% to 0.3%, p = 0.01). Although sepsis is a relatively rare event, making most studies underpow- ered to detect significant differences, it appears that the TP approach offers advantages over the TR approach.",
            "Notably, TP-Tbx could potentially reduce or eliminate the need for prophylactic antibiotics, aligning with the goals of effective antibiotic stewardship and reducing reliance on broad-spectrum antibiotics, important factors in choosing the optimal biopsy technique.",
            "TP-Tbx may result in lower rates of sepsis; how- ever, these findings are not yet statistically significant. This directionality in key outcomes, as infection and sepsis, appears to favor TP-Tbx, warranting further investigation to confirm these potential advantages."
        ],
        "SystematicReview5.pdf": [
            "While transperineal biopsies have been touted as optimization of antibiotic stewardship in the field of prostate biopsies, there exist other strategies including rectal cleansing, rectal swab culture with targeted antibiotics, and avoidance of any antibiotics prior to transperineal biopsies [2].",
            "Our inclusion criteria was RCTs with adults aged 18 yr or older who are undergoing transrectal or transperineal prostate biopsy (not aspiration and eight or more cores) with standard empirical antibiotic prophylaxis, or those undergoing alternative prophylactic interventions to prevent infectious complications.",
            "We excluded studies where patients had a previous prostate surgery, had immune deficiencies (congenital or acquired), had current infections at the time of biopsy, were on long-term immunosuppressive therapy, or received other prophylactic interventions to reduce infectious complications not listed above, which might independently affect the risk of infection following a biopsy, were excluded.",
            "The most recent RCTs have failed to show a significant benefit in favor of transperineal biopsy [3,4,27]. Another recent trial has shown that antibiotic prophylaxis may be avoided completely before transperineal biopsy [36].",
            "Jacewicz M, G\u00fcnzel K, Rud E, et al. Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial. Lancet Infect Dis 2022;22:1465-71.",
            "We excluded studies... where patients had a previous prostate surgery, had immune deficiencies (congenital or acquired), had current infections at the time of biopsy, were on long-term immunosuppressive therapy, or received other prophylactic interventions to reduce infectious complications not listed above, which might independently affect the risk of infection following a biopsy, were excluded.",
            "Another recent trial has shown that antibiotic prophylaxis may be avoided completely before transperineal biopsy [36].",
            "While transperineal biopsies have been touted as optimization of antibiotic stewardship in the field of prostate biopsies, there exist other strategies including rectal cleansing, rectal swab culture with targeted antibiotics, and avoidance of any antibiotics prior to transperineal biopsies [2].",
            "In arm 2 [transperineal biopsy vs SOC (standard empirical antibiotic prophylaxis)], there was no significant difference between the two groups (OR 0.49, 95% CI 0.09-2.71, p = 0.42) for sepsis.",
            "The risk of fever was significantly lower in the test group (OR 0.58, 95% CI 0.31\u20131.08, p = 0.088) for transperineal biopsy.",
            "The risk of UTIs was not different between the two groups (OR 0.81, 95% CI 0.28-2.36, p = 0.7) for transperineal biopsy.",
            "Another recent trial has shown that antibiotic prophylaxis may be avoided completely before transperineal biopsy [36].",
            "Our inclusion criteria was RCTs with adults aged 18 yr or older who are undergoing transrectal or transperineal prostate biopsy (not aspiration and eight or more cores) with standard empirical antibiotic prophylaxis, or those undergoing alternative prophylactic interventions to prevent infectious complications.",
            "We excluded studies where patients had a previous prostate surgery, had immune deficiencies (congenital or acquired), had current infections at the time of biopsy, were on long-term immunosuppressive therapy, or received other prophylactic interventions to reduce infectious complications not listed above, which might independently affect the risk of infection following a biopsy, were excluded.",
            " Another recent trial has shown that antibiotic prophylaxis may be avoided completely before transperineal biopsy [36]. ",
            " Studies where patients had a previous prostate surgery, had immune deficiencies (congenital or acquired), had current infections at the time of biopsy, were on long-term immunosuppressive therapy, or received other prophylactic interventions to reduce infectious complications not listed above, which might independently affect the risk of infection following a biopsy, were excluded. ",
            "avoidance of any antibiotics prior to transperineal biopsies",
            "Studies where patients had a previous prostate surgery, had immune deficiencies (congenital or acquired), had current infections at the time of biopsy, were on long-term immunosuppressive therapy, or received other pro-phylactic interventions to reduce infectious complications not listed above, which might independently affect the risk of infection following a biopsy, were excluded.",
            "Another recent trial has shown that antibiotic prophylaxis may be avoided completely before transperineal biopsy [36]"
        ],
        "SystematicReview4.pdf": [
            "Our aim was to compare infectious complications (genitourinary infections/GUI, fever, sepsis, readmission rate, 30-day-mortality) following TPB, considering all studies of varying levels of evidence that enable a direct comparison between patients with and without PAP.",
            "Pooled incidences between patients with vs. without PAP for the endpoints GUI (0.50% vs. 0.37%), fever (0.44% vs. 0.26%), sepsis (0.16% vs. 0.13%), and readmission rate (0.35% vs. 0.29%) showed no significant differences (all p > 0.250).",
            "CONCLUSIONS: Infectious complications after TPB occur very rarely and cannot be further reduced by PAP. Considering the results of this systematic review and adhering to the principles of effective antibiotic stewardship, omitting PAP in the context of TPB is advisable.",
            "Our study's design did not allow for the evaluation of specific patient groups, such as immunocompromised or catheterized patients, which are often considered to be at higher risk for infectious complications. Therefore, the applicability of our conclusions to these specific patient groups remains limited.",
            "Moreover, investigating the role of patient-specific factors, such as comorbidity profiles and previous antibiotic usage, could help tailor ABS strategies more effectively.",
            "Despite the relatively low infection rate following transperineal prostate biopsy (TPB), it remains unresolved whether periprocedural antibiotic prophylaxis (PAP) can be omitted.",
            "Twenty-three studies met the inclusion criteria involving 6520 and 5804 patients who underwent TPB with vs. without PAP, respectively.",
            "Pooled incidences between patients with vs. without PAP for the endpoints GUI (0.50% vs. 0.37%), fever (0.44% vs. 0.26%), sepsis (0.16% vs. 0.13%), and readmission rate (0.35% vs. 0.29%) showed no significant differences (all p > 0.250).",
            "In subgroup analyses and sensitivity analyses, TPB without PAP showed no significantly higher complication rates regarding all analyzed endpoints.",
            "Infectious complications after TPB occur very rarely and cannot be further reduced by PAP.",
            "Considering the results of this systematic review and adhering to the principles of effective antibiotic stewardship, omitting PAP in the context of TPB is advisable.",
            "No statistically significant differences concerning all analyzed infectious endpoints (genitourinary infections, fever, sepsis, and readmission rates due to infectious complications) were observed following TPB with and without PAP.",
            "In summary, our study yields substantial results suggesting that emerging recommendations to abstain from PAP in patients undergoing TPB are warranted.",
            "Another limitation is that our analyses did not account for potential patient-level differences, such as medical comorbidities, prior exposure to prostate biopsy, or the number of previous prostate biopsies-factors that could contribute to post-procedural infections.",
            "No significant group differences were identified in the aggregated analysis or various subgroup analyses for these endpoints.",
            "the consistency of results across studies suggests that, in the context of progressive Antibiotic Stewardship, the omission of PAP in this setting poses a negligible risk to patients.",
            "BACKGROUND: Despite the relatively low infection rate following transperineal prostate biopsy (TPB), it remains unresolved whether periprocedural antibiotic prophylaxis (PAP) can be omitted. Our aim was to compare infectious complications (genitourinary infections/GUI, fever, sepsis, readmission rate, 30-day-mortality) following TPB, considering all studies of varying levels of evidence that enable a direct comparison between patients with and without PAP.",
            "RESULTS: Twenty-three studies met the inclusion criteria involving 6520 and 5804 patients who underwent TPB with vs. without PAP, respectively. Two of the 23 studies were randomized-controlled trials, not all studies investigated all endpoints. Pooled incidences between patients with vs. without PAP for the endpoints GUI (0.50% vs. 0.37%), fever (0.44% vs. 0.26%), sepsis (0.16% vs. 0.13%), and readmission rate (0.35% vs. 0.29%) showed no significant differences (all p > 0.250). The corresponding odds ratios (including 95% confidence interval) also revealed no statistically significant differences: 1.37 (0.74-2.54) [GUI], 0.87 (0.28-2.66) [fever], 1.30 (0.46-3.67) [sepsis], and 1.45 (0.70-3.03) [readmission rate]. No study reported events regarding 30-day-mortality. In subgroup analyses and sensitivity analyses, TPB without PAP showed no significantly higher complication rates regarding all analyzed endpoints.",
            "CONCLUSIONS: Infectious complications after TPB occur very rarely and cannot be further reduced by PAP. Considering the results of this systematic review and adhering to the principles of effective antibiotic stewardship, omitting PAP in the context of TPB is advisable.",
            "DISCUSSION The current systematic review and meta-analysis represents the first study world-wide which directly compares infectious compli- cations in patients who underwent TPB with and without PAP based on both randomized and non-randomized trials. Our aggregated analysis of the current data represents an update to the methodological approach of Castellani et al. (2021) [10]. Whereas their study included eight non-randomized trials, we have now expanded our systematic review to encompass 21 non- randomized studies and two randomized controlled trials (RCTs). No statistically significant differences concerning all analyzed infectious endpoints (genitourinary infections, fever, sepsis, and readmission rates due to infectious complications) were observed following TPB with and without PAP.",
            "In summary, our study yields substantial results suggesting that emerging recommendations to abstain from PAP in patients undergoing TPB are warranted. By reducing unnecessary antibiotic administration, healthcare providers can mitigate the risks associated with antibiotic resistance, which represents a growing global health concern. Furthermore, this approach aligns with the principles of antibiotic stewardship and promotes more sustain- able healthcare practices without compromising patient safety. Despite the strengths of our analysis, several limitations must be considered. The primary limitation is the lack of more high-quality studies and the inclusion of studies with mixed methodological designs. This could introduce bias, as data from RCTs and prospective studies are likely to have been collected more intensively and reliably than data from retrospective studies. To address this, we analyzed RCTs and NRS separately. Additionally, the overall rate of infectious complications was low across all studies, regardless of methodological design, suggesting that this factor is unlikely to have skewed our aggregated analyses. However, not all studies investigated each of the five selected endpoints, limiting our ability to draw definitive conclusions about specific infectious complications. Moreover, the absence of long- term follow-up data constrains our understanding of delayed complications, which are crucial for comprehensive guideline recommendations. Another limitation is that our analyses did not account for potential patient-level differences, such as medical comorbidities, prior exposure to prostate biopsy, or the number of previous prostate biopsies-factors that could contribute to post-procedural infections. An additional limitation, which might also enhance the generalizability of our results, is the variation in PAP regimens and doses in the comparator arms. The antibiotics used, as well as their routes and durations of administration, varied significantly between studies. Consequently, we chose to conduct all meta- analyses as random-effect models despite a uniform of 0%. It is also important to note that the management of readmission (potentially as hospitalization) due to infectious complications after prostate biopsy varies greatly worldwide and is thus difficult to standardize. Finally, we were unable to assess the impact of the number of biopsy cores taken on the post-procedural infection rate, as several studies did not report this parameter. These extensive limitations, considered alongside our risk-of- bias assessment, ultimately led us to rate the certainty of our analyses for each endpoint as 'low' or 'very low' according to the GRADE approach. We could not analyze the endpoint 'Mortality' at all, as none of the studies reported relevant events. Future research should focus on addressing the gaps identified in this review. Additional RCTs with larger sample sizes and standardized antibiotic administration protocols are desirable to further enhance the level of evidence thereby increasing the certainty of conclusions. Moreover, investigating the role of patient- specific factors, such as comorbidity profiles and previous antibiotic usage, could help tailor ABS strategies more effectively.",
            "CONCLUSIONS The systematic review, encompassing over 12,000 men, included 23 studies comparing TPB with versus without PAP in terms of post-interventional infectious complications. No significant group differences were identified in the aggregated analysis or various subgroup analyses for these endpoints. As only two of these studies were RCTs, resulting in a substantial RoB for many studies, the recommendation to omit PAP during TPB can only be made with (very) low certainty. Conversely, the consistency of results across studies suggests that, in the context of progressive Antibiotic Stewardship, the omission of PAP in this setting poses a negligible risk to patients.",
            "Despite the relatively low infection rate following transperineal prostate biopsy (TPB), it remains unresolved whether periprocedural antibiotic prophylaxis (PAP) can be omitted.",
            "Pooled incidences between patients with vs. without PAP for the endpoints GUI (0.50% vs. 0.37%), fever (0.44% vs. 0.26%), sepsis (0.16% vs. 0.13%), and readmission rate (0.35% vs. 0.29%) showed no significant differences (all p > 0.250).",
            "In subgroup analyses and sensitivity analyses, TPB without PAP showed no significantly higher complication rates regarding all analyzed endpoints.",
            "Infectious complications after TPB occur very rarely and cannot be further reduced by PAP.",
            "Considering the results of this systematic review and adhering to the principles of effective antibiotic stewardship, omitting PAP in the context of TPB is advisable.",
            "In addition to pooling all available study data, we performed subgroup analyses considering the level of evidence (RCTs vs. others) and the antibiotics' application scheme (single dose vs. no PAP and multiple doses vs. no PAP) based on data from available studies.",
            "We pre-planned subgroup analyses for the primary study endpoint, considering the level of evidence of studies (RCTs or non-RCTs) and the frequency of antibiotic administration in the control arm (single dose vs. no-PAP and multiple doses vs. no- PAP).",
            "one based on the level of evidence of studies and the other based on the frequency of antibiotic administration in the control arm.",
            "In terms of infectious complications, omitting PAP in the context of TPB does not result in higher complications as opposed to prostate biopsy with PAP (regardless the PAP approach used).",
            "Another limitation is that our analyses did not account for potential patient-level differences, such as medical comorbidities, prior exposure to prostate biopsy, or the number of previous prostate biopsies-factors that could contribute to post-procedural infections.",
            "BACKGROUND: Despite the relatively low infection rate following transperineal prostate biopsy (TPB), it remains unresolved whether periprocedural antibiotic prophylaxis (PAP) can be omitted.",
            "RESULTS: Twenty-three studies met the inclusion criteria involving 6520 and 5804 patients who underwent TPB with vs. without PAP, respectively.",
            "Pooled incidences between patients with vs. without PAP for the endpoints GUI (0.50% vs. 0.37%), fever (0.44% vs. 0.26%), sepsis (0.16% vs. 0.13%), and readmission rate (0.35% vs. 0.29%) showed no significant differences (all p > 0.250).",
            "In subgroup analyses and sensitivity analyses, TPB without PAP showed no significantly higher complication rates regarding all analyzed endpoints.",
            "CONCLUSIONS: Infectious complications after TPB occur very rarely and cannot be further reduced by PAP. Considering the results of this systematic review and adhering to the principles of effective antibiotic stewardship, omitting PAP in the context of TPB is advisable.",
            "We pre-planned subgroup analyses for the primary study endpoint, considering the level of evidence of studies (RCTs or non-RCTs) and the frequency of antibiotic administration in the control arm (single dose vs. no-PAP and multiple doses vs. no- PAP).",
            "The current systematic review and meta-analysis represents the first study world-wide which directly compares infectious compli- cations in patients who underwent TPB with and without PAP based on both randomized and non-randomized trials.",
            "No statistically significant differences concerning all analyzed infectious endpoints (genitourinary infections, fever, sepsis, and readmission rates due to infectious complications) were observed following TPB with and without PAP.",
            "In summary, our study yields substantial results suggesting that emerging recommendations to abstain from PAP in patients undergoing TPB are warranted. By reducing unnecessary antibiotic administration, healthcare providers can mitigate the risks associated with antibiotic resistance, which represents a growing global health concern. Furthermore, this approach aligns with the principles of antibiotic stewardship and promotes more sustain- able healthcare practices without compromising patient safety.",
            "Another limitation is that our analyses did not account for potential patient-level differences, such as medical comorbidities, prior exposure to prostate biopsy, or the number of previous prostate biopsies-factors that could contribute to post-procedural infections.",
            "An additional limitation, which might also enhance the generalizability of our results, is the variation in PAP regimens and doses in the comparator arms."
        ],
        "SystematicReview1.pdf": [
            "TPUS-PB allows omission of antibiotic prophylaxis while maintaining com-parable detection and complication rates to TRUS-PB [2,3]",
            "Ultrasound-guided prostate biopsy, via either the transrec- tal (transrectal ultrasound-guided prostate biopsy [TRUS- PB]) or the transperineal (transperineal ultrasound-guided prostate biopsy [TPUS-PB]) route, is the primary procedure for diagnosing prostate cancer (PCa) [1]. TPUS-PB allows omission of antibiotic prophylaxis while maintaining com- parable detection and complication rates to TRUS-PB [2,3].",
            "Ultrasound-guided prostate biopsy, via either the transrectal (transrectal ultrasound-guided prostate biopsy [TRUS-PB]) or the transperineal (transperineal ultrasound-guided prostate biopsy [TPUS-PB]) route, is the primary procedure for diagnosing prostate cancer (PCa) [1]. TPUS-PB allows omission of antibiotic prophylaxis while maintaining comparable detection and complication rates to TRUS-PB [2,3].",
            "While some studies suggest that TPUS-PB seems to be associated with lower hospitalization and sepsis rates [4], others fail to confirm this [5].",
            "Although TPUS-PB is recommended in the current European Association of Urology (EAU) guidelines due to its lower infection rate, TRUS-guided biopsy is widely used across various clinical settings [3].",
            "The EAU guidelines recommend TPUS-PB as the first choice [3]. However, in cases where TRUS-PB is planned, TPAS based on rectal swab culture should be considered to increase patients' safety by the incidence rate of infectious complications.",
            "Transperineal ultrasound-guided prostate biopsy is the recommended approach in guidelines, while transrectal ultrasound-guided pros- tate biopsy (TRUS-PB) is still widely used to diagnose prostate cancer (PCa); however, it is associated with a significant rate of infectious complications.",
            "TPUS-PB allows omission of antibiotic prophylaxis while maintaining com- parable detection and complication rates to TRUS-PB [2,3].",
            "Although TPUS-PB is recommended in the current Euro- pean Association of Urology (EAU) guidelines due to its lower infection rate, TRUS-guided biopsy is widely used across various clinical settings [3].",
            "the implementation of TPUS-PB has been suggested to be more cost effective in reducing the incidence of fUTI.",
            "a previous meta-analysis, including only RCTS, showed that TPUS-PB was associated with a significantly lower incidence rate of infectious complications than TRUS-PB (RR: 0.55, 95% CI: 0.33-0.92, p = 0.02) [23].",
            "Transperineal ultrasound-guided prostate biopsy is the recommended approach in guidelines, while transrectal ultrasound-guided pros-tate biopsy (TRUS-PB) is still widely used to diagnose prostate cancer (PCa); how-ever, it is associated with a significant rate of infectious complications.",
            "TPUS-PB allows omission of antibiotic prophylaxis while maintaining com-parable detection and complication rates to TRUS-PB [2,3].",
            "Although TPUS-PB is recommended in the current Euro-pean Association of Urology (EAU) guidelines due to its lower infection rate, TRUS-guided biopsy is widely used across various clinical settings [3].",
            "Indeed, a previous meta-analysis, including only RCTS, showed that TPUS-PB was associated with a significantly lower incidence rate of infectious complications than TRUS-PB (RR: 0.55, 95% CI: 0.33-0.92, p = 0.02) [23]."
        ],
        "SystematicReview3.pdf": [
            "The European Association of Urology (EAU) Guide- lines on Prostate Cancer note emerging evidence suggesting that antibiotic prophylaxis may not be necessary for transperineal prostate biopsies. However, formal recommendations are pending further research.",
            "Our meta-analysis found no significant differences in UTI and sepsis rates between transperineal prostate biopsies performed with or without antibiotic prophylaxis.",
            "However, patients at high risk for UTIs may still benefit from antibiotic prophylaxis.",
            "Also, the EAU guidelines on urological infections describe growing evidence to suggest that antibiotic prophylaxis may not be required for TPBx; however, the Panel have chosen to wait until a number of ongoing RCTs report their study findings",
            "By demonstrating that TPBx can be safely performed without antibiotics, this meta-analysis supports efforts to reduce antibiotic prescriptions, thereby helping to curb microbial resistance.",
            "The presented data substantiate the safety and effectiveness of not administering an- tibiotic prophylaxis in TPBx.",
            "Updating clinical guidelines to incorporate these findings would be a significant step towards optimizing prostate cancer diagnostics while addressing the critical issue of antibiotic resistance.",
            "The European Association of Urology (EAU) Guide- lines on Prostate Cancer note emerging evidence suggesting that antibiotic prophylaxis may not be necessary for transperineal prostate biopsies. However, formal recommendations are pending further research.",
            "Analysis re- vealed no significant difference in UTI rates between groups with and without prophylaxis (odds ratio [OR]: 1.07, 95% confidence interval [CI]: 0.50\u20132.31, I2 = 0%, p = 0.86).",
            "sepsis rates did not differ significantly (OR: 1.35, 95% CI: 0.36\u20135.12, I2 = 0%, p = 0.66).",
            "Conclusions: Our meta-analysis found no significant differences in UTI and sepsis rates between transperineal prostate biopsies performed with or without antibiotic prophylaxis.",
            "However, patients at high risk for UTIs may still benefit from antibiotic prophylaxis.",
            "Analysis re- vealed no significant difference in UTI rates between groups with and without prophylaxis",
            "Similarly, sepsis rates did not differ significantly",
            "Conclusions: Our meta-analysis found no significant differences in UTI and sepsis rates between transperineal prostate biopsies performed with or without antibiotic prophylaxis.",
            "However, patients at high risk for UTIs may still benefit from antibiotic prophylaxis.",
            "5. Conclusions The presented data substantiate the safety and effectiveness of not administering an- tibiotic prophylaxis in TPBx.",
            "Implementing this approach not only supports the objectives of antibiotic stewardship, but also guarantees patient safety.",
            "Updating clinical guidelines to incorporate these findings would be a significant step towards optimizing prostate cancer diagnostics while addressing the critical issue of antibiotic resistance.",
            "Abstract: Background and Objectives: The European Association of Urology (EAU) Guide- lines on Prostate Cancer note emerging evidence suggesting that antibiotic prophylaxis may not be necessary for transperineal prostate biopsies. However, formal recommendations are pending further research.",
            "Results: Nine studies (two RCTs and seven non-RCTs) met the inclusion criteria. Analysis re- vealed no significant difference in UTI rates between groups with and without prophylaxis (odds ratio [OR]: 1.07, 95% confidence interval [CI]: 0.50\u20132.31, I2 = 0%, p = 0.86). Similarly, sepsis rates did not differ significantly (OR: 1.35, 95% CI: 0.36\u20135.12, I2 = 0%, p = 0.66).",
            "Conclusions: Our meta-analysis found no significant differences in UTI and sepsis rates between transperineal prostate biopsies performed with or without antibiotic prophylaxis. However, patients at high risk for UTIs may still benefit from antibiotic prophylaxis.",
            "no significant difference in UTI rates between groups with and without prophylaxis",
            "sepsis rates did not differ significantly",
            "Our meta-analysis found no significant differences in UTI and sepsis rates between transperineal prostate biopsies performed with or without antibiotic prophylaxis.",
            "However, patients at high risk for UTIs may still benefit from antibiotic prophylaxis.",
            "The presented data substantiate the safety and effectiveness of not administering an- tibiotic prophylaxis in TPBx.",
            "Implementing this approach not only supports the objectives of antibiotic stewardship, but also guarantees patient safety.",
            "Updating clinical guidelines to incorporate these findings would be a significant step towards optimizing prostate cancer diagnostics while addressing the critical issue of antibiotic resistance."
        ],
        "SystematicReview2.pdf": [
            "TP biopsy seems to be a safe procedure without antibiotics in patients without risk factors, advocating for enhanced antimicrobial stewardship in urology.",
            "In selected low-risk patients, some stud-ies reported no increase in infections even without the use of antibiotics, though further research is needed before changing routine practice.",
            "TP biopsy is generally considered to cause fewer infectious complica-tions, and current literature suggests that the omission of periprocedural antibiotic prophylaxis is safe [11].",
            "A subgroup analysis of ten studies was performed to assess the impact of antibiotic prophylaxis in a TP biopsy on febrile infectious outcomes (antibiotic prophylaxis vs no antibiotic prophylaxis). The subsequent analysis showed no statisti-cally significant difference between the antibiotic and nonantibiotic approaches (p = 0.47; Fig. 3).",
            "The findings of the subgroup analysis showed no statistically significant difference in overall infectious complications or hospitalisa-tions when comparing TP biopsies with and without admin-istration of antibiotic prophylaxis (Fig. 3). We conclude that, for patients without risk factors, it may be considered safe to forgo antibiotic prophylaxis in TP biopsies. This approach is supported by randomised data, such as the findings from the NORAPP trial [18], which highlights the potential for safely omitting antibiotic prophylaxis in TP biopsies.",
            "antibiotic prophylaxis is felt to have limited additional value in a TP biopsy, which aligns with antimicrobial stewardship principles.",
            "There was no statistically significant difference in infectious complications after a TP biopsy with or without antibiotics.",
            "TP biopsy seems to be a safe procedure without antibiotics in patients without risk factors, advocating for enhanced antimicrobial stewardship in urology.",
            "This study provides high-level evidence confirming that the transperineal (TP) biopsy route reduces the risk of hospital-isation due to infectious complications significantly compared with the transrectal route. It also highlights the lack of additional benefit from antibiotic prophylaxis in a TP biopsy, reinforcing antimicrobial stewardship principles.",
            "In selected low-risk patients, some stud-ies reported no increase in infections even without the use of antibiotics,",
            "current literature suggests that the omission of periprocedural antibiotic prophylaxis is safe [11].",
            "The findings of the subgroup analysis showed no statistically significant difference in overall infectious complications or hospitalisa-tions when comparing TP biopsies with and without admin-istration of antibiotic prophylaxis (Fig. 3). We conclude that, for patients without risk factors, it may be considered safe to forgo antibiotic prophylaxis in TP biopsies.",
            "antibiotic prophylaxis is felt to have limited additional value in a TP biopsy",
            "This study ... also highlights the lack of additional benefit from antibiotic prophylaxis in a TP biopsy, reinforcing antimicrobial stewardship principles.",
            "The TP approach is generally considered to cause fewer infectious complica-tions, and current literature suggests that the omission of periprocedural antibiotic prophylaxis is safe [11].",
            "A subgroup analysis of ten studies was performed to assess the impact of antibiotic prophylaxis in a TP biopsy on febrile infectious outcomes (antibiotic prophylaxis vs no antibiotic prophylaxis). The subsequent analysis showed no statisti-cally significant difference between the antibiotic and nonantibiotic approaches (p = 0.47; Fig. 3).",
            "The findings of the subgroup analysis showed no statistically significant difference in overall infectious complications or hospitalisa-tions when comparing TP biopsies with and without admin-istration of antibiotic prophylaxis (Fig. 3).",
            "We conclude that, for patients without risk factors, it may be considered safe to forgo antibiotic prophylaxis in TP biopsies.",
            "While the data suggest that a TP biopsy may reduce infection-related morbidity and antibiotic use, further stud-ies are needed to confirm these findings in broader popula-tions and across health care systems.",
            " antibiotic prophylaxis is felt to have limited additional value in a TP biopsy, which aligns with antimicrobial stewardship principles. ",
            " This study provides high-level evidence confirming that the transperineal (TP) biopsy route reduces the risk of hospital- isation due to infectious complications significantly compared with the transrectal route. It also highlights the lack of additional benefit from antibiotic prophylaxis in a TP biopsy, reinforcing antimicrobial stewardship principles. ",
            " In selected low-risk patients, some stud- ies reported no increase in infections even without the use of antibiotics, though further research is needed before changing routine practice. ",
            " current literature suggests that the omission of periprocedural antibiotic prophylaxis is safe [11]. ",
            " A subgroup analysis of ten studies was performed to assess the impact of antibiotic prophylaxis in a TP biopsy on febrile infectious outcomes (antibiotic prophylaxis vs no antibiotic prophylaxis). The subsequent analysis showed no statisti- cally significant difference between the antibiotic and nonantibiotic approaches (p = 0.47; Fig. 3). ",
            " The findings of the subgroup analysis showed no statistically significant difference in overall infectious complications or hospitalisa- tions when comparing TP biopsies with and without admin- istration of antibiotic prophylaxis (Fig. 3). We conclude that, for patients without risk factors, it may be considered safe to forgo antibiotic prophylaxis in TP biopsies. ",
            "antibiotic prophylaxis is felt to have limited additional value in a TP biopsy, which aligns with antimicrobial stewardship principles.",
            "TP biopsy seems to be a safe procedure without antibiotics in patients without risk factors, advocating for enhanced antimicrobial stewardship in urology.",
            "TP biopsy seems to be a safe procedure without antibiotics in patients without risk factors, advocating for enhanced antimicrobial stewardship in urology.",
            "It also highlights the lack of additional benefit from antibiotic prophylaxis in a TP biopsy, reinforcing antimicrobial stewardship principles.",
            "In selected low-risk patients, some stud- ies reported no increase in infections even without the use of antibiotics,",
            "current literature suggests that the omission of periprocedural antibiotic prophylaxis is safe [11].",
            "The subsequent analysis showed no statisti- cally significant difference between the antibiotic and nonantibiotic approaches (p = 0.47; Fig. 3).",
            "The findings of the subgroup analysis showed no statistically significant difference in overall infectious complications or hospitalisa- tions when comparing TP biopsies with and without admin- istration of antibiotic prophylaxis (Fig. 3).",
            "We conclude that, for patients without risk factors, it may be considered safe to forgo antibiotic prophylaxis in TP biopsies.",
            "This approach is supported by randomised data, such as the findings from the NORAPP trial [18], which highlights the potential for safely omitting antibiotic prophylaxis in TP biopsies."
        ]
    },
    "important_nuggets": {
        "EAU-Guidelines-on-Urological-infections-2025_2025-05-24-110339_pxmf.pdf": [
            [
                "Screening for and treating asymptomatic bacteriuria (ABU) via pre-operative urine culture is strongly recommended before urological procedures breaching the mucosa, aiming to reduce infectious complications and optimize antimicrobial coverage. This is especially important as ABU is a risk factor for infectious complications (e.g., in nephrostomy/ureteral stent placement), and patients at higher risk for urosepsis include the elderly, diabetics, and immunosuppressed individuals (such as transplant recipients, or those on cancer chemotherapy or corticosteroids).",
                1.0
            ],
            [
                "A growing body of evidence suggests antibiotic prophylaxis may not be required for transperineal biopsy; however, the Panel is waiting for ongoing RCTs to report their findings before making a recommendation, as all prostate biopsy recommendations are based on level 1a evidence.",
                1.0
            ],
            [
                "Multiple systematic reviews and meta-analyses, including one of eight non-RCTs [613] and another of 112 individual patient cohorts [614], along with two recently published RCTs [615, 616], consistently reported comparably low post-biopsy infection rates for transperineal biopsy whether antibiotic prophylaxis was administered or not. Specifically, the review of eight non-RCTs reported no significant differences in post-biopsy infection (0.11% with vs. 0.31% without prophylaxis) and sepsis (0.13% vs. 0.09%) [613], while the review of 112 cohorts showed infection rates of 1.35% in 29,880 patients with prophylaxis vs. 1.22% in 4,772 patients without (p = 0.8) [614].",
                1.0
            ]
        ],
        "LeitliniePAP2024.pdf": [
            [
                "A systematic literature search identified an RCT (Jacewicz et al. 2022) showing a non-statistically significant reduction in urinary tract infections (UTIs) with periprocedural antibiotic prophylaxis (PAP) versus no PAP (OR 0.33 [0.03-3.19]), with no sepsis or hospitalization-requiring UTIs occurring in either group; however, the evidence for UTIs is rated very low due to bias risks and imprecise estimators, and intestinal colonization with multi-drug resistant gram-negative bacteria (MRGN) is described as a risk factor.",
                0.8
            ],
            [
                "Study inclusion criteria for prostate biopsy patients encompassed elevated/rising PSA, suspicious digital-rectal exam, active surveillance, and suspected recurrence after radiation or HIFU. While low CD4+ helper cell counts are associated with increased postoperative wound infection risk, no specific periprocedural antibiotic prophylaxis (PAP) studies were found for patients with HIV-associated immunodeficiency, neutropenia, or those on immunosuppressive medication; however, expert opinion suggests that PAP principles for these immunocompromised subgroups align with those for non-immunocompromised patients.",
                0.8
            ],
            [
                "Currently, there is no consensus on recommendations for antibiotic prophylaxis during transperineal prostate biopsy. However, antibiotic prophylaxis can be omitted during transperineal MRI-fusion biopsy.",
                0.8
            ],
            [
                "In cases of doubt and for high-risk patients, antibiotic prophylaxis should be administered 30 minutes pre-operatively, using Cefuroxime i.m. or i.v., or alternatively Ampicillin/Sulbactam.",
                0.8
            ],
            [
                "For transperineal prostate biopsy (including MRI-fusion), antibiotic prophylaxis can be omitted, provided a preoperative urinary tract infection is reliably excluded (e.g., via U-Stix) and the perineum is thoroughly disinfected with Chlorhexidine or Octenidindihydrochlorid/Phenoxyethanol. This omission does not appear to increase the risk of urosepsis or severe urinary tract infections, though less severe UTIs were three times more frequent without prophylaxis (absolute difference 0.73%), with 137 patients requiring antibiotic treatment to prevent one infection.",
                0.8
            ],
            [
                "Patients with active or recurrent urinary tract infections, an indwelling catheter, immunocompromised individuals, those with a high risk of endocarditis, and patients who had experienced thromboembolic events were excluded from the studies.",
                0.8
            ],
            [
                "A Castellani et al. (2022) meta-analysis, based on low certainty evidence from 8 non-RCT comparative studies on perineal prostate biopsy, reported infection rates of 0.11% with periprocedural antibiotic prophylaxis (PAP) versus 0.31% without PAP (p = 0.29). However, two subsequent RCTs (Jacewicz 2022; Chernyscheva 2021) on transperineal biopsy have since shown no higher rates of infections, fever, or sepsis when PAP is omitted.",
                0.8
            ]
        ],
        "RandomizedTrial2.pdf": [
            [
                "LATP biopsy was performed with chlorhexidine-based skin preparation and without antibiotics; 503 (89%) of 567 participants who received LATP underwent biopsy without antibiotics according to protocol.",
                0.8
            ],
            [
                "Using the primary definition of post-biopsy infection (requiring hospital admission), LATP resulted in lower rates compared to TRUS biopsy: one (<1%) of 562 vs. seven (1%) of 564 within 7 days (OR 0.14 [95% CI 0.02-1-15]), and 2 (<1%) vs. 9 (2%) within 35 days, with both 7-day and 35-day hospitalizations likely related to biopsy. For the secondary, broader definition of infection (symptoms or signs with or without admission), no statistically significant difference was observed over 4 months between LATP (113 [20%] of 562) and TRUS (120 [21%] of 564).",
                0.8
            ],
            [
                "Concerns about infectious complications and the development of post-biopsy urinary sepsis have driven the transition from TRUS to LATP, with LATP showing fewer overall infectious complications (six [1%] of 562) compared to TRUS (13 [2%] of 564) in the 4-month post-biopsy period (adjusted 0.45 [0.17-1.20]).",
                0.8
            ],
            [
                "The TRANSLATE study demonstrated that most LATP biopsies can be safely performed without antibiotics, with 89% of cases not receiving them (11% were largely protocol deviations), resulting in fewer infections (both resulting and not resulting in hospital admission) compared to TRUS. This finding, important for antibiotic stewardship, should be considered with the caveat that the infection difference was not statistically significant as it was a secondary outcome for which the trial was not powered.",
                0.8
            ],
            [
                "Pre-procedure and post-procedure antibiotics were standard-of-care at each recruitment centre, and all participants in the TRUS group received these antibiotics (appendix 1 p 17).",
                0.8
            ],
            [
                "The study recognized that excluding participants at higher risk of infection, necessary for successful randomisation, likely reduced the infection event rate in both groups. Although an observed difference was not statistically significant, this was a secondary outcome and the trial was not powered around it.",
                0.8
            ],
            [
                "Patients with a history of immunocompromise or a need for enhanced antibiotic prophylaxis were excluded from the study. Other exclusion criteria included previous prostate biopsy, extensive local disease (prostate-specific antigen >50 ng/mL or entire gland replaced by tumour on MRI), symptoms of concurrent or recent urinary tract infection, absent rectum, or inability to position in lithotomy.",
                0.8
            ]
        ],
        "RandomizedTrial1.pdf": [
            [
                "Transperineal prostate biopsies (TPPB) were not performed during the clinical trial, and patients with severe immunodeficiency or indwelling urinary catheters were also excluded. However, current European Association of Urology (EAU) guidelines now recommend TPPB because of its lower rate of infectious complications.",
                1
            ],
            [
                "Growing evidence indicates that infection, hospitalization, and sepsis rates are comparably lower in transperineal prostate biopsy (TPPB) compared with transrectal prostate biopsy (TRPB). For TRPB, antibiotic prophylaxis is mandatory to avoid infectious complications and is recommended with povidone-iodine rectal preparation; prior gold standard FQs are no longer accepted in the EU, EAU guidelines recommend an algorithm, and a study found no significant difference between single-dose and prolonged FMT prophylaxis.",
                1
            ]
        ],
        "RandomizedTrial3.pdf": [
            [
                "Rectal culture using selective media before transperineal biopsy (TRPB) demonstrated effectiveness in preventing acute, post-biopsy prostatitis, achieving an overall incidence of 1.1% within 30 days, particularly in patients with low infectious risks. These highly accurate selective media (e.g., LVFX-insusceptible, with 98.1% sensitivity and 94.7% specificity) allow for targeted recommendations like TAZ/PIPC when FQ-resistant or ESBL-producing E. coli is detected, though further evaluation is needed for patients with higher infectious risks or underlying conditions negatively impacting immune function.",
                1.0
            ],
            [
                "This study focused on patients with low infectious risk, excluding those with high infectious risk defined as diabetes mellitus, systemic steroid use, immunocompromised status, prostate volume \u226575 mL, or high-grade lower urinary tract obstruction (International Prostate Symptom Score [IPSS] \u226520, maximum urinary flow rate [Qmax] \u226412 mL/s, or residual urine \u2265100 mL). Other exclusion criteria included pyuria at enrollment, receiving antimicrobial administration less than 4 weeks before rectal culture or biopsy, and contraindications to levofloxacin or piperacillin/tazobactam.",
                1.0
            ],
            [
                "The nuggets discuss transperineal prostate biopsy and transrectal prostate biopsy (TRPB), noting that transperineal prostate biopsy was explicitly excluded in some contexts.",
                1.0
            ],
            [
                "A multicenter, randomized controlled trial enrolled 403 low-risk patients undergoing transperineal biopsy (TRPB), randomizing them into a cultured group (CG) or a no cultured group (NCG). All participants received levofloxacin (LVFX) antibiotic prophylaxis; for the NCG, this involved 1 dose of LVFX 500 mg orally 2 hours before TRPB, while the CG received rectal culture-based prophylaxis.",
                1.0
            ]
        ],
        "EAU-Guideline_Urological_Infections_Paper.pdf": [
            [
                "Procedure: Transrectal prostate biopsy",
                0.8
            ],
            [
                "Prophylaxis is recommended, particularly for patients with a high risk of postoperative sepsis.",
                0.8
            ],
            [
                "The document does not explicitly address the omission of periprocedural antibiotic prophylaxis during transperineal biopsy or maintaining non-inferior infection rates across different risk categories (e.g., immunocompromised or catheterized patients) for this specific procedure. However, for transrectal prostate biopsy, prophylaxis is recommended, with regimens including targeted prophylaxis (based on rectal swab/stool culture), augmented prophylaxis (two or more antibiotic classes), or alternative antibiotics such as Fosfomycin trometamol, Cephalosporins (e.g., ceftriaxone, cefixime), or Aminoglycosides (e.g., gentamicin, amikacin).",
                0.8
            ],
            [
                "Prophylaxis can be targeted based on a rectal swab or stool culture, augmented with two or more different antibiotic classes, or involve alternative antibiotics.",
                0.8
            ],
            [
                "The indication for fosfomycin trometamol for prostate biopsy has been withdrawn in Germany because manufacturers did not submit the necessary pharmacokinetic data. Urologists are advised to check their local guidance regarding its use.",
                0.8
            ]
        ],
        "RandomizedTrial4.pdf": [
            [
                "Standard antibiotic prophylaxis, consisting of 2g IV ceftriaxone before biopsy followed by 2g oral cefixime daily for 2 days post-discharge (with 1g daily amikacin for 3 days as an alternative if ceftriaxone was not possible), was administered to all patients. However, the study excluded patients with symptomatic urinary tract infection, recent catheterization, hospitalization or urological intervention, immunodeficiency, or those using immunosuppressive drugs.",
                0.8
            ],
            [
                "Transrectal prostate biopsy, commonly performed as ultrasound-guided TRUS-PB and considered the most common and gold standard for prostate cancer diagnosis, has significantly higher sepsis rates compared to transperineal biopsy; notably, none of 245 patients who underwent transperineal biopsy were hospitalized.",
                0.8
            ],
            [
                "Patients with symptomatic urinary tract infection, a history of catheterization, hospitalization or urological intervention in the last month, immunodeficiency, or using immunosuppressive drugs were excluded from the study.",
                0.8
            ],
            [
                "The transperineal method is associated with less common infection, and a research purpose is to discern whether these reduced infection rates are attributed to antiseptic solutions or mechanical rectal irrigation.",
                0.8
            ]
        ],
        "EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf": [
            [
                "Two published RCTs have reported comparably low post-biopsy infection rates for transperineal biopsy regardless of whether antibiotic prophylaxis was administered, contributing to a growing body of evidence suggesting that antibiotic prophylaxis may not be routinely required for transperineal biopsy.",
                1.0
            ],
            [
                "Evidence from multiple systematic reviews and meta-analyses, including one of eight non-RCTs and another of 112 patient cohorts, corroborated by two published RCTs, indicates no significant difference in infection rates for transperineal prostate biopsy regardless of antibiotic prophylaxis administration. Reported rates comparing prophylaxis vs. no prophylaxis include post-biopsy infection (0.11% vs. 0.31%), post-transperineal-biopsy infection (1.35% of 29,880 patients vs. 1.22% of 4,772 men [p=0.8]), sepsis (0.13% vs. 0.09%), and septic complications (0.05% vs. 0.08% [p=0.2]), suggesting prophylaxis may not be routinely required.",
                1.0
            ]
        ],
        "LL_Prostatakarzinom_Langversion_8.0.pdf": [
            [
                "Bei der transperinealen Stanzbiopsie kann auf eine Antibiotikaprophylaxe verzichtet werden; dies ist eine evidenzbasierte Empfehlung, die 2025 neu eingef\u00fchrt wurde und Empfehlungsgrad 0 hat.",
                1.0
            ],
            [
                "For transperineal biopsy, periprocedural antibiotic prophylaxis can be omitted if no infection or prostatitis is present, as demonstrated by a multicentric study showing no hospitalizations for sepsis or urinary tract infection within two months. However, for patients presenting with risk factors such as immunosuppression, a history of prostatitis/urinary tract infection, diabetes mellitus with elevated infection risk, recent antibiotic use, or travel to high antibiotic-resistance regions, a rectal swab for targeted antibiotic prophylaxis is recommended.",
                1.0
            ],
            [
                "F\u00fcr die transperineale Biopsie kann bei Nicht-Vorhandensein einer Infektion oder Prostatitis auf eine Antibiotikaprophylaxe verzichtet werden. Eine Metaanalyse von 11 Studien mit 1.753 Patienten zeigte hingegen eine signifikante Reduktion von Infektionen durch eine Antibiotikaprophylaxe bei der transrektalen Biopsie (RR 0,56, 95 % KI 0,40-0,77).",
                1.0
            ],
            [
                "Non-hospitalizing urinary tract infections (UTIs) were observed in 0.36% (95% CI 0.01-2.00) of patients with antibiotics and 1.09% (95% CI 0.37-3.15) without; the 0.73% difference did not exceed the 4% non-inferiority margin [170]. Furthermore, a systematic review and meta-analysis also showed no increased infection rate without antibiotic prophylaxis during transperineal biopsy (0.05% vs. 0.08%; p=0.2) [171].",
                1.0
            ]
        ],
        "SystematicReview5.pdf": [
            [
                "Transperineal biopsies are considered an optimization of antibiotic stewardship, with other strategies including rectal cleansing, rectal swab culture with targeted antibiotics, or avoiding any antibiotics prior to the biopsy. Relevant studies are RCTs involving adults aged 18 or older undergoing transrectal or transperineal prostate biopsy (not aspiration, eight or more cores), comparing standard empirical antibiotic prophylaxis or alternative prophylactic interventions, such as the NORAPP trial on antibiotic prophylaxis versus no prophylaxis in transperineal prostate biopsies.",
                1.0
            ],
            [
                "Studies were excluded if patients had a previous prostate surgery, congenital or acquired immune deficiencies, current infections at the time of biopsy, were on long-term immunosuppressive therapy, or received other prophylactic interventions not listed, as these factors might independently affect the risk of infection following a biopsy.",
                1.0
            ],
            [
                "A recent trial demonstrated that antibiotic prophylaxis can be completely avoided before transperineal biopsy without significantly increasing infection rates. Specifically, there was no significant difference in sepsis (OR 0.49, p = 0.42) or UTI (OR 0.81, p = 0.7) rates compared to standard prophylaxis, and the risk of fever was lower (OR 0.58, p = 0.088) in the group omitting antibiotics.",
                1.0
            ]
        ],
        "SystematicReview6.pdf": [
            [
                "Infection rates were low and similar between transrectal (TR) and transperineal (TP) biopsies, with 28 infections among 1545 patients (TR 2%, TP 2%) and only one sepsis case reported overall (TR 1/762, TP 0/783). The ProBE-PC study showed similarly low infectious complications (TR 2.6%, TP 2.7%), primarily mild fevers, with no sepsis reported, while the PREVENT trial found no infections in 372 TP cases versus six (1.6%) in 370 TR cases.",
                1.0
            ],
            [
                "Driven by a trend to minimize antibiotic use to reduce resistance [12,13,15], the transperineal (TP) approach is favored over the transrectal (TR) approach\u2014which carries a 5-7% [22] infection risk due to rectal mucosa involvement and typically requires comprehensive antibiotic protocols or prophylaxis\u2014because TP, even though it often requires more extensive preparation and potentially general anesthesia, avoids the rectal mucosa, resulting in an almost complete absence of post-biopsy sepsis. This significant advantage, not primarily due to a reduction in mild infections, is corroborated by numerous prospective and retrospective reviews and trials like PREVENT, which reported zero infections in 372 TP cases versus six in 370 TR cases (difference of -1% [95% CI: -3.5% to 0.3%, p=0.01]), despite sepsis being a rare event that often underpowers studies to detect differences.",
                1.0
            ],
            [
                "Both transperineal (TP) and transrectal (TR) prostate biopsy approaches generally show low overall toxicity and no significant differences in cancer detection or complications, though their comparative benefits and safety are still debated. However, the MRI-targeted TP approach may be advantageous as it can be performed safely without antibiotics, potentially reducing antibiotic resistance.",
                1.0
            ],
            [
                "Transperineal biopsy (TP-Tbx) can safely omit periprocedural antibiotics without increasing infection risk, unlike transrectal biopsy (TR-Tbx) which commonly uses prophylaxis. Both methods demonstrate similar rates of PCa detection, postprocedural infection (OR 0.8, 95% CI: 0.4-1.8), sepsis, urinary retention, and biopsy-associated pain, though infections and sepsis directionally favor TP despite lacking statistical significance.",
                1.0
            ],
            [
                "TP-Tbx can safely omit antibiotics without increasing infection risk, unlike TR-Tbx; however, a meta-analysis reaffirms no clear superiority of the TP-Tbx approach over the TR-Tbx approach in terms of infection prevention and cancer detection.",
                1.0
            ],
            [
                "In the PREVENT randomized trial [12], transperineal (TP) biopsy without antibiotic prophylaxis was compared to transrectal (TR) biopsy with targeted prophylaxis, while the ProBE-PC study [13] utilized 1-day antibiotic prophylaxis for TR procedures (without rectal cultures) and only occasionally for TP. This highlights TP-Tbx's potential to reduce or eliminate the need for prophylactic antibiotics, aligning with antibiotic stewardship goals and reducing broad-spectrum antibiotic reliance, crucial considerations for biopsy technique selection.",
                1.0
            ],
            [
                "The PREVENT trial [12] demonstrated that transperineal (TP) biopsies without preventative antibiotics resulted in no reported infections and no significant infectious complications. This outcome is similar to transrectal (TR) biopsies that used targeted antibiotic prophylaxis, where the trial showed a minimal 1.6% infection incidence; these infections were febrile but nonsevere and did not escalate to critical levels.",
                1.0
            ],
            [
                "Preliminary evidence suggests that TP-Tbx may result in lower rates of sepsis, and this directionality for key outcomes like infection and sepsis appears to favor TP-Tbx. However, these findings are not yet statistically significant, warranting further investigation to confirm these potential advantages.",
                1.0
            ]
        ],
        "SystematicReview4.pdf": [
            [
                "Omitting periprocedural antibiotic prophylaxis (PAP) during transperineal biopsy (TPB) is advisable, as infectious complications are very rare and cannot be further reduced by PAP, supporting antibiotic stewardship and posing negligible risk without compromising safety. However, this recommendation has (very) low certainty due to limitations, including a lack of high-quality studies and insufficient analysis of patient-level differences like comorbidities, suggesting further research is needed to tailor antibiotic stewardship strategies for specific patient subgroups.",
                1
            ],
            [
                "A systematic review and meta-analysis of 23 studies (12,324 patients) found no statistically significant differences in pooled incidences of genitourinary infections (0.50% vs 0.37%), fever (0.44% vs 0.26%), sepsis (0.16% vs 0.13%), or readmission rates (0.35% vs 0.29%) following transperineal prostate biopsy with versus without periprocedural antibiotic prophylaxis (all p > 0.250). However, the study's design did not allow for the evaluation of specific high-risk patient groups such as immunocompromised or catheterized individuals, thus limiting the applicability of these conclusions to those subgroups.",
                1
            ],
            [
                "Despite the relatively low infection rate following transperineal prostate biopsy (TPB), it remains unresolved whether periprocedural antibiotic prophylaxis (PAP) can be omitted. Studies indicate that omitting PAP does not result in higher infectious complications (such as genitourinary infections, fever, sepsis, readmission, or 30-day mortality), though analyses did not account for patient-level differences like medical comorbidities or prior prostate biopsies, which could contribute to post-procedural infections.",
                1
            ],
            [
                "Analysis of 23 studies, encompassing 6520 patients with periprocedural antibiotic prophylaxis (PAP) and 5804 without, found that transperineal biopsy (TPB) without PAP resulted in no significantly higher complication rates across all analyzed endpoints in aggregated, subgroup, and sensitivity analyses, supporting recommendations to abstain from PAP.",
                1
            ]
        ],
        "SystematicReview1.pdf": [
            [
                "Ultrasound-guided prostate biopsy, performed transrectally (TRUS-PB) or transperineally (TPUS-PB), is the primary diagnostic method for prostate cancer. While TRUS-PB is still widely used, it is associated with a significant rate of infectious complications, whereas the guideline-recommended TPUS-PB allows for the omission of antibiotic prophylaxis while maintaining comparable detection and complication rates.",
                0.8
            ],
            [
                "Transperineal ultrasound-guided biopsy (TPUS-PB) allows for the omission of antibiotic prophylaxis while maintaining comparable detection and complication rates to transrectal ultrasound-guided biopsy (TRUS-PB), showing a significantly lower incidence of infectious complications (RR: 0.55, 95% CI: 0.33-0.92, p = 0.02) per a meta-analysis of RCTs. The European Association of Urology (EAU) guidelines recommend TPUS-PB as the first choice due to its lower infection rate; however, for widely used TRUS-PB, transrectal antibiotic prophylaxis (TRAP) based on rectal swab culture should be considered.",
                0.8
            ]
        ],
        "SystematicReview3.pdf": [
            [
                "The analysis of nine studies (two RCTs, seven non-RCTs) revealed no significant difference in UTI rates (odds ratio [OR]: 1.07, 95% confidence interval [CI]: 0.50\u20132.31, I2 = 0%, p = 0.86) or sepsis rates (OR: 1.35, 95% CI: 0.36\u20135.12, I2 = 0%, p = 0.66) between groups with and without prophylaxis.",
                0.8
            ],
            [
                "Presented data, including a meta-analysis, substantiate the safety and effectiveness of not administering antibiotic prophylaxis during transperineal prostate biopsy (TPBx), which supports antibiotic stewardship, curbs microbial resistance, and guarantees patient safety. While EAU guidelines describe growing evidence for this approach, they are currently waiting for findings from ongoing randomized controlled trials.",
                0.8
            ],
            [
                "Our meta-analysis found no significant differences in UTI and sepsis rates between transperineal prostate biopsies performed with or without antibiotic prophylaxis; however, patients at high risk for UTIs may still benefit from antibiotic prophylaxis.",
                0.8
            ],
            [
                "The European Association of Urology (EAU) Guidelines on Prostate Cancer note emerging evidence suggesting that antibiotic prophylaxis may not be necessary for transperineal prostate biopsies, though formal recommendations are pending further research. Updating clinical guidelines to incorporate these findings would optimize prostate cancer diagnostics and address antibiotic resistance.",
                0.8
            ],
            [
                "Our meta-analysis found no significant differences in UTI and sepsis rates between transperineal prostate biopsies performed with or without antibiotic prophylaxis.",
                0.8
            ]
        ],
        "SystematicReview2.pdf": [
            [
                "Antibiotic prophylaxis is felt to have limited additional value in a transperineal (TP) biopsy, which aligns with and reinforces antimicrobial stewardship principles.",
                0.8
            ],
            [
                "Current literature [11] suggests that omitting periprocedural antibiotic prophylaxis during transperineal (TP) biopsy, which generally causes fewer infectious complications, is safe. A subgroup analysis [Fig. 3] found no statistically significant difference in overall infectious complications or hospitalizations between TP biopsies with and without prophylaxis, concluding it may be safe to forgo prophylaxis for patients without risk factors, an approach supported by randomized data such as the NORAPP trial [18].",
                0.8
            ],
            [
                "Transperineal (TP) biopsy appears to be a safe procedure without antibiotics in patients without risk factors, advocating for enhanced antimicrobial stewardship in urology.",
                0.8
            ],
            [
                "A subgroup analysis of ten studies, comparing antibiotic prophylaxis versus no antibiotic prophylaxis during a TP biopsy, found no statistically significant difference in febrile infectious outcomes between the two approaches (p = 0.47; Fig. 3).",
                0.8
            ],
            [
                "In selected low-risk patients, some studies reported no increase in infections even without the use of antibiotics, though further research is needed before changing routine practice.",
                0.8
            ],
            [
                "High-level evidence confirms that the transperineal (TP) biopsy route significantly reduces the risk of hospitalization due to infectious complications compared to the transrectal route, highlighting the lack of additional benefit from antibiotic prophylaxis in TP biopsies and reinforcing antimicrobial stewardship principles. While data suggest TP biopsy may reduce infection-related morbidity and antibiotic use, further studies are needed to confirm these findings in broader populations and across healthcare systems.",
                0.8
            ]
        ]
    },
    "all_nuggets_raw": [
        "Screening for and treating asymptomatic bacteriuria (ABU) via pre-operative urine culture is strongly recommended before urological procedures breaching the mucosa, aiming to reduce infectious complications and optimize antimicrobial coverage. This is especially important as ABU is a risk factor for infectious complications (e.g., in nephrostomy/ureteral stent placement), and patients at higher risk for urosepsis include the elderly, diabetics, and immunosuppressed individuals (such as transplant recipients, or those on cancer chemotherapy or corticosteroids).",
        "A growing body of evidence suggests antibiotic prophylaxis may not be required for transperineal biopsy; however, the Panel is waiting for ongoing RCTs to report their findings before making a recommendation, as all prostate biopsy recommendations are based on level 1a evidence.",
        "Multiple systematic reviews and meta-analyses, including one of eight non-RCTs [613] and another of 112 individual patient cohorts [614], along with two recently published RCTs [615, 616], consistently reported comparably low post-biopsy infection rates for transperineal biopsy whether antibiotic prophylaxis was administered or not. Specifically, the review of eight non-RCTs reported no significant differences in post-biopsy infection (0.11% with vs. 0.31% without prophylaxis) and sepsis (0.13% vs. 0.09%) [613], while the review of 112 cohorts showed infection rates of 1.35% in 29,880 patients with prophylaxis vs. 1.22% in 4,772 patients without (p = 0.8) [614].",
        "A systematic literature search identified an RCT (Jacewicz et al. 2022) showing a non-statistically significant reduction in urinary tract infections (UTIs) with periprocedural antibiotic prophylaxis (PAP) versus no PAP (OR 0.33 [0.03-3.19]), with no sepsis or hospitalization-requiring UTIs occurring in either group; however, the evidence for UTIs is rated very low due to bias risks and imprecise estimators, and intestinal colonization with multi-drug resistant gram-negative bacteria (MRGN) is described as a risk factor.",
        "Study inclusion criteria for prostate biopsy patients encompassed elevated/rising PSA, suspicious digital-rectal exam, active surveillance, and suspected recurrence after radiation or HIFU. While low CD4+ helper cell counts are associated with increased postoperative wound infection risk, no specific periprocedural antibiotic prophylaxis (PAP) studies were found for patients with HIV-associated immunodeficiency, neutropenia, or those on immunosuppressive medication; however, expert opinion suggests that PAP principles for these immunocompromised subgroups align with those for non-immunocompromised patients.",
        "Currently, there is no consensus on recommendations for antibiotic prophylaxis during transperineal prostate biopsy. However, antibiotic prophylaxis can be omitted during transperineal MRI-fusion biopsy.",
        "In cases of doubt and for high-risk patients, antibiotic prophylaxis should be administered 30 minutes pre-operatively, using Cefuroxime i.m. or i.v., or alternatively Ampicillin/Sulbactam.",
        "For transperineal prostate biopsy (including MRI-fusion), antibiotic prophylaxis can be omitted, provided a preoperative urinary tract infection is reliably excluded (e.g., via U-Stix) and the perineum is thoroughly disinfected with Chlorhexidine or Octenidindihydrochlorid/Phenoxyethanol. This omission does not appear to increase the risk of urosepsis or severe urinary tract infections, though less severe UTIs were three times more frequent without prophylaxis (absolute difference 0.73%), with 137 patients requiring antibiotic treatment to prevent one infection.",
        "Patients with active or recurrent urinary tract infections, an indwelling catheter, immunocompromised individuals, those with a high risk of endocarditis, and patients who had experienced thromboembolic events were excluded from the studies.",
        "A Castellani et al. (2022) meta-analysis, based on low certainty evidence from 8 non-RCT comparative studies on perineal prostate biopsy, reported infection rates of 0.11% with periprocedural antibiotic prophylaxis (PAP) versus 0.31% without PAP (p = 0.29). However, two subsequent RCTs (Jacewicz 2022; Chernyscheva 2021) on transperineal biopsy have since shown no higher rates of infections, fever, or sepsis when PAP is omitted.",
        "LATP biopsy was performed with chlorhexidine-based skin preparation and without antibiotics; 503 (89%) of 567 participants who received LATP underwent biopsy without antibiotics according to protocol.",
        "Using the primary definition of post-biopsy infection (requiring hospital admission), LATP resulted in lower rates compared to TRUS biopsy: one (<1%) of 562 vs. seven (1%) of 564 within 7 days (OR 0.14 [95% CI 0.02-1-15]), and 2 (<1%) vs. 9 (2%) within 35 days, with both 7-day and 35-day hospitalizations likely related to biopsy. For the secondary, broader definition of infection (symptoms or signs with or without admission), no statistically significant difference was observed over 4 months between LATP (113 [20%] of 562) and TRUS (120 [21%] of 564).",
        "Concerns about infectious complications and the development of post-biopsy urinary sepsis have driven the transition from TRUS to LATP, with LATP showing fewer overall infectious complications (six [1%] of 562) compared to TRUS (13 [2%] of 564) in the 4-month post-biopsy period (adjusted 0.45 [0.17-1.20]).",
        "The TRANSLATE study demonstrated that most LATP biopsies can be safely performed without antibiotics, with 89% of cases not receiving them (11% were largely protocol deviations), resulting in fewer infections (both resulting and not resulting in hospital admission) compared to TRUS. This finding, important for antibiotic stewardship, should be considered with the caveat that the infection difference was not statistically significant as it was a secondary outcome for which the trial was not powered.",
        "Pre-procedure and post-procedure antibiotics were standard-of-care at each recruitment centre, and all participants in the TRUS group received these antibiotics (appendix 1 p 17).",
        "The study recognized that excluding participants at higher risk of infection, necessary for successful randomisation, likely reduced the infection event rate in both groups. Although an observed difference was not statistically significant, this was a secondary outcome and the trial was not powered around it.",
        "Patients with a history of immunocompromise or a need for enhanced antibiotic prophylaxis were excluded from the study. Other exclusion criteria included previous prostate biopsy, extensive local disease (prostate-specific antigen >50 ng/mL or entire gland replaced by tumour on MRI), symptoms of concurrent or recent urinary tract infection, absent rectum, or inability to position in lithotomy.",
        "Transperineal prostate biopsies (TPPB) were not performed during the clinical trial, and patients with severe immunodeficiency or indwelling urinary catheters were also excluded. However, current European Association of Urology (EAU) guidelines now recommend TPPB because of its lower rate of infectious complications.",
        "Growing evidence indicates that infection, hospitalization, and sepsis rates are comparably lower in transperineal prostate biopsy (TPPB) compared with transrectal prostate biopsy (TRPB). For TRPB, antibiotic prophylaxis is mandatory to avoid infectious complications and is recommended with povidone-iodine rectal preparation; prior gold standard FQs are no longer accepted in the EU, EAU guidelines recommend an algorithm, and a study found no significant difference between single-dose and prolonged FMT prophylaxis.",
        "Rectal culture using selective media before transperineal biopsy (TRPB) demonstrated effectiveness in preventing acute, post-biopsy prostatitis, achieving an overall incidence of 1.1% within 30 days, particularly in patients with low infectious risks. These highly accurate selective media (e.g., LVFX-insusceptible, with 98.1% sensitivity and 94.7% specificity) allow for targeted recommendations like TAZ/PIPC when FQ-resistant or ESBL-producing E. coli is detected, though further evaluation is needed for patients with higher infectious risks or underlying conditions negatively impacting immune function.",
        "This study focused on patients with low infectious risk, excluding those with high infectious risk defined as diabetes mellitus, systemic steroid use, immunocompromised status, prostate volume \u226575 mL, or high-grade lower urinary tract obstruction (International Prostate Symptom Score [IPSS] \u226520, maximum urinary flow rate [Qmax] \u226412 mL/s, or residual urine \u2265100 mL). Other exclusion criteria included pyuria at enrollment, receiving antimicrobial administration less than 4 weeks before rectal culture or biopsy, and contraindications to levofloxacin or piperacillin/tazobactam.",
        "The nuggets discuss transperineal prostate biopsy and transrectal prostate biopsy (TRPB), noting that transperineal prostate biopsy was explicitly excluded in some contexts.",
        "A multicenter, randomized controlled trial enrolled 403 low-risk patients undergoing transperineal biopsy (TRPB), randomizing them into a cultured group (CG) or a no cultured group (NCG). All participants received levofloxacin (LVFX) antibiotic prophylaxis; for the NCG, this involved 1 dose of LVFX 500 mg orally 2 hours before TRPB, while the CG received rectal culture-based prophylaxis.",
        "Procedure: Transrectal prostate biopsy",
        "Prophylaxis is recommended, particularly for patients with a high risk of postoperative sepsis.",
        "The document does not explicitly address the omission of periprocedural antibiotic prophylaxis during transperineal biopsy or maintaining non-inferior infection rates across different risk categories (e.g., immunocompromised or catheterized patients) for this specific procedure. However, for transrectal prostate biopsy, prophylaxis is recommended, with regimens including targeted prophylaxis (based on rectal swab/stool culture), augmented prophylaxis (two or more antibiotic classes), or alternative antibiotics such as Fosfomycin trometamol, Cephalosporins (e.g., ceftriaxone, cefixime), or Aminoglycosides (e.g., gentamicin, amikacin).",
        "Prophylaxis can be targeted based on a rectal swab or stool culture, augmented with two or more different antibiotic classes, or involve alternative antibiotics.",
        "The indication for fosfomycin trometamol for prostate biopsy has been withdrawn in Germany because manufacturers did not submit the necessary pharmacokinetic data. Urologists are advised to check their local guidance regarding its use.",
        "Standard antibiotic prophylaxis, consisting of 2g IV ceftriaxone before biopsy followed by 2g oral cefixime daily for 2 days post-discharge (with 1g daily amikacin for 3 days as an alternative if ceftriaxone was not possible), was administered to all patients. However, the study excluded patients with symptomatic urinary tract infection, recent catheterization, hospitalization or urological intervention, immunodeficiency, or those using immunosuppressive drugs.",
        "Transrectal prostate biopsy, commonly performed as ultrasound-guided TRUS-PB and considered the most common and gold standard for prostate cancer diagnosis, has significantly higher sepsis rates compared to transperineal biopsy; notably, none of 245 patients who underwent transperineal biopsy were hospitalized.",
        "Patients with symptomatic urinary tract infection, a history of catheterization, hospitalization or urological intervention in the last month, immunodeficiency, or using immunosuppressive drugs were excluded from the study.",
        "The transperineal method is associated with less common infection, and a research purpose is to discern whether these reduced infection rates are attributed to antiseptic solutions or mechanical rectal irrigation.",
        "Two published RCTs have reported comparably low post-biopsy infection rates for transperineal biopsy regardless of whether antibiotic prophylaxis was administered, contributing to a growing body of evidence suggesting that antibiotic prophylaxis may not be routinely required for transperineal biopsy.",
        "Evidence from multiple systematic reviews and meta-analyses, including one of eight non-RCTs and another of 112 patient cohorts, corroborated by two published RCTs, indicates no significant difference in infection rates for transperineal prostate biopsy regardless of antibiotic prophylaxis administration. Reported rates comparing prophylaxis vs. no prophylaxis include post-biopsy infection (0.11% vs. 0.31%), post-transperineal-biopsy infection (1.35% of 29,880 patients vs. 1.22% of 4,772 men [p=0.8]), sepsis (0.13% vs. 0.09%), and septic complications (0.05% vs. 0.08% [p=0.2]), suggesting prophylaxis may not be routinely required.",
        "Bei der transperinealen Stanzbiopsie kann auf eine Antibiotikaprophylaxe verzichtet werden; dies ist eine evidenzbasierte Empfehlung, die 2025 neu eingef\u00fchrt wurde und Empfehlungsgrad 0 hat.",
        "For transperineal biopsy, periprocedural antibiotic prophylaxis can be omitted if no infection or prostatitis is present, as demonstrated by a multicentric study showing no hospitalizations for sepsis or urinary tract infection within two months. However, for patients presenting with risk factors such as immunosuppression, a history of prostatitis/urinary tract infection, diabetes mellitus with elevated infection risk, recent antibiotic use, or travel to high antibiotic-resistance regions, a rectal swab for targeted antibiotic prophylaxis is recommended.",
        "F\u00fcr die transperineale Biopsie kann bei Nicht-Vorhandensein einer Infektion oder Prostatitis auf eine Antibiotikaprophylaxe verzichtet werden. Eine Metaanalyse von 11 Studien mit 1.753 Patienten zeigte hingegen eine signifikante Reduktion von Infektionen durch eine Antibiotikaprophylaxe bei der transrektalen Biopsie (RR 0,56, 95 % KI 0,40-0,77).",
        "Non-hospitalizing urinary tract infections (UTIs) were observed in 0.36% (95% CI 0.01-2.00) of patients with antibiotics and 1.09% (95% CI 0.37-3.15) without; the 0.73% difference did not exceed the 4% non-inferiority margin [170]. Furthermore, a systematic review and meta-analysis also showed no increased infection rate without antibiotic prophylaxis during transperineal biopsy (0.05% vs. 0.08%; p=0.2) [171].",
        "Transperineal biopsies are considered an optimization of antibiotic stewardship, with other strategies including rectal cleansing, rectal swab culture with targeted antibiotics, or avoiding any antibiotics prior to the biopsy. Relevant studies are RCTs involving adults aged 18 or older undergoing transrectal or transperineal prostate biopsy (not aspiration, eight or more cores), comparing standard empirical antibiotic prophylaxis or alternative prophylactic interventions, such as the NORAPP trial on antibiotic prophylaxis versus no prophylaxis in transperineal prostate biopsies.",
        "Studies were excluded if patients had a previous prostate surgery, congenital or acquired immune deficiencies, current infections at the time of biopsy, were on long-term immunosuppressive therapy, or received other prophylactic interventions not listed, as these factors might independently affect the risk of infection following a biopsy.",
        "A recent trial demonstrated that antibiotic prophylaxis can be completely avoided before transperineal biopsy without significantly increasing infection rates. Specifically, there was no significant difference in sepsis (OR 0.49, p = 0.42) or UTI (OR 0.81, p = 0.7) rates compared to standard prophylaxis, and the risk of fever was lower (OR 0.58, p = 0.088) in the group omitting antibiotics.",
        "Infection rates were low and similar between transrectal (TR) and transperineal (TP) biopsies, with 28 infections among 1545 patients (TR 2%, TP 2%) and only one sepsis case reported overall (TR 1/762, TP 0/783). The ProBE-PC study showed similarly low infectious complications (TR 2.6%, TP 2.7%), primarily mild fevers, with no sepsis reported, while the PREVENT trial found no infections in 372 TP cases versus six (1.6%) in 370 TR cases.",
        "Driven by a trend to minimize antibiotic use to reduce resistance [12,13,15], the transperineal (TP) approach is favored over the transrectal (TR) approach\u2014which carries a 5-7% [22] infection risk due to rectal mucosa involvement and typically requires comprehensive antibiotic protocols or prophylaxis\u2014because TP, even though it often requires more extensive preparation and potentially general anesthesia, avoids the rectal mucosa, resulting in an almost complete absence of post-biopsy sepsis. This significant advantage, not primarily due to a reduction in mild infections, is corroborated by numerous prospective and retrospective reviews and trials like PREVENT, which reported zero infections in 372 TP cases versus six in 370 TR cases (difference of -1% [95% CI: -3.5% to 0.3%, p=0.01]), despite sepsis being a rare event that often underpowers studies to detect differences.",
        "Both transperineal (TP) and transrectal (TR) prostate biopsy approaches generally show low overall toxicity and no significant differences in cancer detection or complications, though their comparative benefits and safety are still debated. However, the MRI-targeted TP approach may be advantageous as it can be performed safely without antibiotics, potentially reducing antibiotic resistance.",
        "Transperineal biopsy (TP-Tbx) can safely omit periprocedural antibiotics without increasing infection risk, unlike transrectal biopsy (TR-Tbx) which commonly uses prophylaxis. Both methods demonstrate similar rates of PCa detection, postprocedural infection (OR 0.8, 95% CI: 0.4-1.8), sepsis, urinary retention, and biopsy-associated pain, though infections and sepsis directionally favor TP despite lacking statistical significance.",
        "TP-Tbx can safely omit antibiotics without increasing infection risk, unlike TR-Tbx; however, a meta-analysis reaffirms no clear superiority of the TP-Tbx approach over the TR-Tbx approach in terms of infection prevention and cancer detection.",
        "In the PREVENT randomized trial [12], transperineal (TP) biopsy without antibiotic prophylaxis was compared to transrectal (TR) biopsy with targeted prophylaxis, while the ProBE-PC study [13] utilized 1-day antibiotic prophylaxis for TR procedures (without rectal cultures) and only occasionally for TP. This highlights TP-Tbx's potential to reduce or eliminate the need for prophylactic antibiotics, aligning with antibiotic stewardship goals and reducing broad-spectrum antibiotic reliance, crucial considerations for biopsy technique selection.",
        "The PREVENT trial [12] demonstrated that transperineal (TP) biopsies without preventative antibiotics resulted in no reported infections and no significant infectious complications. This outcome is similar to transrectal (TR) biopsies that used targeted antibiotic prophylaxis, where the trial showed a minimal 1.6% infection incidence; these infections were febrile but nonsevere and did not escalate to critical levels.",
        "Preliminary evidence suggests that TP-Tbx may result in lower rates of sepsis, and this directionality for key outcomes like infection and sepsis appears to favor TP-Tbx. However, these findings are not yet statistically significant, warranting further investigation to confirm these potential advantages.",
        "Omitting periprocedural antibiotic prophylaxis (PAP) during transperineal biopsy (TPB) is advisable, as infectious complications are very rare and cannot be further reduced by PAP, supporting antibiotic stewardship and posing negligible risk without compromising safety. However, this recommendation has (very) low certainty due to limitations, including a lack of high-quality studies and insufficient analysis of patient-level differences like comorbidities, suggesting further research is needed to tailor antibiotic stewardship strategies for specific patient subgroups.",
        "A systematic review and meta-analysis of 23 studies (12,324 patients) found no statistically significant differences in pooled incidences of genitourinary infections (0.50% vs 0.37%), fever (0.44% vs 0.26%), sepsis (0.16% vs 0.13%), or readmission rates (0.35% vs 0.29%) following transperineal prostate biopsy with versus without periprocedural antibiotic prophylaxis (all p > 0.250). However, the study's design did not allow for the evaluation of specific high-risk patient groups such as immunocompromised or catheterized individuals, thus limiting the applicability of these conclusions to those subgroups.",
        "Despite the relatively low infection rate following transperineal prostate biopsy (TPB), it remains unresolved whether periprocedural antibiotic prophylaxis (PAP) can be omitted. Studies indicate that omitting PAP does not result in higher infectious complications (such as genitourinary infections, fever, sepsis, readmission, or 30-day mortality), though analyses did not account for patient-level differences like medical comorbidities or prior prostate biopsies, which could contribute to post-procedural infections.",
        "Analysis of 23 studies, encompassing 6520 patients with periprocedural antibiotic prophylaxis (PAP) and 5804 without, found that transperineal biopsy (TPB) without PAP resulted in no significantly higher complication rates across all analyzed endpoints in aggregated, subgroup, and sensitivity analyses, supporting recommendations to abstain from PAP.",
        "Ultrasound-guided prostate biopsy, performed transrectally (TRUS-PB) or transperineally (TPUS-PB), is the primary diagnostic method for prostate cancer. While TRUS-PB is still widely used, it is associated with a significant rate of infectious complications, whereas the guideline-recommended TPUS-PB allows for the omission of antibiotic prophylaxis while maintaining comparable detection and complication rates.",
        "Transperineal ultrasound-guided biopsy (TPUS-PB) allows for the omission of antibiotic prophylaxis while maintaining comparable detection and complication rates to transrectal ultrasound-guided biopsy (TRUS-PB), showing a significantly lower incidence of infectious complications (RR: 0.55, 95% CI: 0.33-0.92, p = 0.02) per a meta-analysis of RCTs. The European Association of Urology (EAU) guidelines recommend TPUS-PB as the first choice due to its lower infection rate; however, for widely used TRUS-PB, transrectal antibiotic prophylaxis (TRAP) based on rectal swab culture should be considered.",
        "The analysis of nine studies (two RCTs, seven non-RCTs) revealed no significant difference in UTI rates (odds ratio [OR]: 1.07, 95% confidence interval [CI]: 0.50\u20132.31, I2 = 0%, p = 0.86) or sepsis rates (OR: 1.35, 95% CI: 0.36\u20135.12, I2 = 0%, p = 0.66) between groups with and without prophylaxis.",
        "Presented data, including a meta-analysis, substantiate the safety and effectiveness of not administering antibiotic prophylaxis during transperineal prostate biopsy (TPBx), which supports antibiotic stewardship, curbs microbial resistance, and guarantees patient safety. While EAU guidelines describe growing evidence for this approach, they are currently waiting for findings from ongoing randomized controlled trials.",
        "Our meta-analysis found no significant differences in UTI and sepsis rates between transperineal prostate biopsies performed with or without antibiotic prophylaxis; however, patients at high risk for UTIs may still benefit from antibiotic prophylaxis.",
        "The European Association of Urology (EAU) Guidelines on Prostate Cancer note emerging evidence suggesting that antibiotic prophylaxis may not be necessary for transperineal prostate biopsies, though formal recommendations are pending further research. Updating clinical guidelines to incorporate these findings would optimize prostate cancer diagnostics and address antibiotic resistance.",
        "Our meta-analysis found no significant differences in UTI and sepsis rates between transperineal prostate biopsies performed with or without antibiotic prophylaxis.",
        "Antibiotic prophylaxis is felt to have limited additional value in a transperineal (TP) biopsy, which aligns with and reinforces antimicrobial stewardship principles.",
        "Current literature [11] suggests that omitting periprocedural antibiotic prophylaxis during transperineal (TP) biopsy, which generally causes fewer infectious complications, is safe. A subgroup analysis [Fig. 3] found no statistically significant difference in overall infectious complications or hospitalizations between TP biopsies with and without prophylaxis, concluding it may be safe to forgo prophylaxis for patients without risk factors, an approach supported by randomized data such as the NORAPP trial [18].",
        "Transperineal (TP) biopsy appears to be a safe procedure without antibiotics in patients without risk factors, advocating for enhanced antimicrobial stewardship in urology.",
        "A subgroup analysis of ten studies, comparing antibiotic prophylaxis versus no antibiotic prophylaxis during a TP biopsy, found no statistically significant difference in febrile infectious outcomes between the two approaches (p = 0.47; Fig. 3).",
        "In selected low-risk patients, some studies reported no increase in infections even without the use of antibiotics, though further research is needed before changing routine practice.",
        "High-level evidence confirms that the transperineal (TP) biopsy route significantly reduces the risk of hospitalization due to infectious complications compared to the transrectal route, highlighting the lack of additional benefit from antibiotic prophylaxis in TP biopsies and reinforcing antimicrobial stewardship principles. While data suggest TP biopsy may reduce infection-related morbidity and antibiotic use, further studies are needed to confirm these findings in broader populations and across healthcare systems."
    ],
    "all_documents_raw": [
        "EAU-Guidelines-on-Urological-infections-2025_2025-05-24-110339_pxmf.pdf",
        "EAU-Guidelines-on-Urological-infections-2025_2025-05-24-110339_pxmf.pdf",
        "EAU-Guidelines-on-Urological-infections-2025_2025-05-24-110339_pxmf.pdf",
        "LeitliniePAP2024.pdf",
        "LeitliniePAP2024.pdf",
        "LeitliniePAP2024.pdf",
        "LeitliniePAP2024.pdf",
        "LeitliniePAP2024.pdf",
        "LeitliniePAP2024.pdf",
        "LeitliniePAP2024.pdf",
        "RandomizedTrial2.pdf",
        "RandomizedTrial2.pdf",
        "RandomizedTrial2.pdf",
        "RandomizedTrial2.pdf",
        "RandomizedTrial2.pdf",
        "RandomizedTrial2.pdf",
        "RandomizedTrial2.pdf",
        "RandomizedTrial1.pdf",
        "RandomizedTrial1.pdf",
        "RandomizedTrial3.pdf",
        "RandomizedTrial3.pdf",
        "RandomizedTrial3.pdf",
        "RandomizedTrial3.pdf",
        "EAU-Guideline_Urological_Infections_Paper.pdf",
        "EAU-Guideline_Urological_Infections_Paper.pdf",
        "EAU-Guideline_Urological_Infections_Paper.pdf",
        "EAU-Guideline_Urological_Infections_Paper.pdf",
        "EAU-Guideline_Urological_Infections_Paper.pdf",
        "RandomizedTrial4.pdf",
        "RandomizedTrial4.pdf",
        "RandomizedTrial4.pdf",
        "RandomizedTrial4.pdf",
        "EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf",
        "EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf",
        "LL_Prostatakarzinom_Langversion_8.0.pdf",
        "LL_Prostatakarzinom_Langversion_8.0.pdf",
        "LL_Prostatakarzinom_Langversion_8.0.pdf",
        "LL_Prostatakarzinom_Langversion_8.0.pdf",
        "SystematicReview5.pdf",
        "SystematicReview5.pdf",
        "SystematicReview5.pdf",
        "SystematicReview6.pdf",
        "SystematicReview6.pdf",
        "SystematicReview6.pdf",
        "SystematicReview6.pdf",
        "SystematicReview6.pdf",
        "SystematicReview6.pdf",
        "SystematicReview6.pdf",
        "SystematicReview6.pdf",
        "SystematicReview4.pdf",
        "SystematicReview4.pdf",
        "SystematicReview4.pdf",
        "SystematicReview4.pdf",
        "SystematicReview1.pdf",
        "SystematicReview1.pdf",
        "SystematicReview3.pdf",
        "SystematicReview3.pdf",
        "SystematicReview3.pdf",
        "SystematicReview3.pdf",
        "SystematicReview3.pdf",
        "SystematicReview2.pdf",
        "SystematicReview2.pdf",
        "SystematicReview2.pdf",
        "SystematicReview2.pdf",
        "SystematicReview2.pdf",
        "SystematicReview2.pdf"
    ],
    "all_confidences_raw": [
        1.0,
        1.0,
        1.0,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        1,
        1,
        1.0,
        1.0,
        1.0,
        1.0,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        1.0,
        1.0,
        1.0,
        1.0,
        1.0,
        1.0,
        1.0,
        1.0,
        1.0,
        1.0,
        1.0,
        1.0,
        1.0,
        1.0,
        1.0,
        1.0,
        1.0,
        1,
        1,
        1,
        1,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8,
        0.8
    ],
    "final_clusters": {
        "0": {
            "Document": [
                "LATP biopsy was performed with chlorhexidine-based skin preparation and without antibiotics; 503 (89%) of 567 participants who received LATP underwent biopsy without antibiotics according to protocol.",
                "Using the primary definition of post-biopsy infection (requiring hospital admission), LATP resulted in lower rates compared to TRUS biopsy: one (<1%) of 562 vs. seven (1%) of 564 within 7 days (OR 0.14 [95% CI 0.02-1-15]), and 2 (<1%) vs. 9 (2%) within 35 days, with both 7-day and 35-day hospitalizations likely related to biopsy. For the secondary, broader definition of infection (symptoms or signs with or without admission), no statistically significant difference was observed over 4 months between LATP (113 [20%] of 562) and TRUS (120 [21%] of 564).",
                "Concerns about infectious complications and the development of post-biopsy urinary sepsis have driven the transition from TRUS to LATP, with LATP showing fewer overall infectious complications (six [1%] of 562) compared to TRUS (13 [2%] of 564) in the 4-month post-biopsy period (adjusted 0.45 [0.17-1.20]).",
                "The TRANSLATE study demonstrated that most LATP biopsies can be safely performed without antibiotics, with 89% of cases not receiving them (11% were largely protocol deviations), resulting in fewer infections (both resulting and not resulting in hospital admission) compared to TRUS. This finding, important for antibiotic stewardship, should be considered with the caveat that the infection difference was not statistically significant as it was a secondary outcome for which the trial was not powered.",
                "TP-Tbx can safely omit antibiotics without increasing infection risk, unlike TR-Tbx; however, a meta-analysis reaffirms no clear superiority of the TP-Tbx approach over the TR-Tbx approach in terms of infection prevention and cancer detection."
            ],
            "Source": [
                "RandomizedTrial2.pdf",
                "RandomizedTrial2.pdf",
                "RandomizedTrial2.pdf",
                "RandomizedTrial2.pdf",
                "SystematicReview6.pdf"
            ],
            "Confidence": [
                0.8,
                0.8,
                0.8,
                0.8,
                1.0
            ]
        },
        "1": {
            "Document": [
                "A growing body of evidence suggests antibiotic prophylaxis may not be required for transperineal biopsy; however, the Panel is waiting for ongoing RCTs to report their findings before making a recommendation, as all prostate biopsy recommendations are based on level 1a evidence.",
                "The indication for fosfomycin trometamol for prostate biopsy has been withdrawn in Germany because manufacturers did not submit the necessary pharmacokinetic data. Urologists are advised to check their local guidance regarding its use.",
                "Transperineal biopsies are considered an optimization of antibiotic stewardship, with other strategies including rectal cleansing, rectal swab culture with targeted antibiotics, or avoiding any antibiotics prior to the biopsy. Relevant studies are RCTs involving adults aged 18 or older undergoing transrectal or transperineal prostate biopsy (not aspiration, eight or more cores), comparing standard empirical antibiotic prophylaxis or alternative prophylactic interventions, such as the NORAPP trial on antibiotic prophylaxis versus no prophylaxis in transperineal prostate biopsies.",
                "Presented data, including a meta-analysis, substantiate the safety and effectiveness of not administering antibiotic prophylaxis during transperineal prostate biopsy (TPBx), which supports antibiotic stewardship, curbs microbial resistance, and guarantees patient safety. While EAU guidelines describe growing evidence for this approach, they are currently waiting for findings from ongoing randomized controlled trials."
            ],
            "Source": [
                "EAU-Guidelines-on-Urological-infections-2025_2025-05-24-110339_pxmf.pdf",
                "EAU-Guideline_Urological_Infections_Paper.pdf",
                "SystematicReview5.pdf",
                "SystematicReview3.pdf"
            ],
            "Confidence": [
                1.0,
                0.8,
                1.0,
                0.8
            ]
        },
        "2": {
            "Document": [
                "Study inclusion criteria for prostate biopsy patients encompassed elevated/rising PSA, suspicious digital-rectal exam, active surveillance, and suspected recurrence after radiation or HIFU. While low CD4+ helper cell counts are associated with increased postoperative wound infection risk, no specific periprocedural antibiotic prophylaxis (PAP) studies were found for patients with HIV-associated immunodeficiency, neutropenia, or those on immunosuppressive medication; however, expert opinion suggests that PAP principles for these immunocompromised subgroups align with those for non-immunocompromised patients.",
                "A Castellani et al. (2022) meta-analysis, based on low certainty evidence from 8 non-RCT comparative studies on perineal prostate biopsy, reported infection rates of 0.11% with periprocedural antibiotic prophylaxis (PAP) versus 0.31% without PAP (p = 0.29). However, two subsequent RCTs (Jacewicz 2022; Chernyscheva 2021) on transperineal biopsy have since shown no higher rates of infections, fever, or sepsis when PAP is omitted.",
                "Evidence from multiple systematic reviews and meta-analyses, including one of eight non-RCTs and another of 112 patient cohorts, corroborated by two published RCTs, indicates no significant difference in infection rates for transperineal prostate biopsy regardless of antibiotic prophylaxis administration. Reported rates comparing prophylaxis vs. no prophylaxis include post-biopsy infection (0.11% vs. 0.31%), post-transperineal-biopsy infection (1.35% of 29,880 patients vs. 1.22% of 4,772 men [p=0.8]), sepsis (0.13% vs. 0.09%), and septic complications (0.05% vs. 0.08% [p=0.2]), suggesting prophylaxis may not be routinely required.",
                "Despite the relatively low infection rate following transperineal prostate biopsy (TPB), it remains unresolved whether periprocedural antibiotic prophylaxis (PAP) can be omitted. Studies indicate that omitting PAP does not result in higher infectious complications (such as genitourinary infections, fever, sepsis, readmission, or 30-day mortality), though analyses did not account for patient-level differences like medical comorbidities or prior prostate biopsies, which could contribute to post-procedural infections."
            ],
            "Source": [
                "LeitliniePAP2024.pdf",
                "LeitliniePAP2024.pdf",
                "EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf",
                "SystematicReview4.pdf"
            ],
            "Confidence": [
                0.8,
                0.8,
                1.0,
                1.0
            ]
        },
        "3": {
            "Document": [
                "The nuggets discuss transperineal prostate biopsy and transrectal prostate biopsy (TRPB), noting that transperineal prostate biopsy was explicitly excluded in some contexts.",
                "Procedure: Transrectal prostate biopsy",
                "Transrectal prostate biopsy, commonly performed as ultrasound-guided TRUS-PB and considered the most common and gold standard for prostate cancer diagnosis, has significantly higher sepsis rates compared to transperineal biopsy; notably, none of 245 patients who underwent transperineal biopsy were hospitalized.",
                "Ultrasound-guided prostate biopsy, performed transrectally (TRUS-PB) or transperineally (TPUS-PB), is the primary diagnostic method for prostate cancer. While TRUS-PB is still widely used, it is associated with a significant rate of infectious complications, whereas the guideline-recommended TPUS-PB allows for the omission of antibiotic prophylaxis while maintaining comparable detection and complication rates."
            ],
            "Source": [
                "RandomizedTrial3.pdf",
                "EAU-Guideline_Urological_Infections_Paper.pdf",
                "RandomizedTrial4.pdf",
                "SystematicReview1.pdf"
            ],
            "Confidence": [
                1.0,
                0.8,
                0.8,
                0.8
            ]
        },
        "4": {
            "Document": [
                "A multicenter, randomized controlled trial enrolled 403 low-risk patients undergoing transperineal biopsy (TRPB), randomizing them into a cultured group (CG) or a no cultured group (NCG). All participants received levofloxacin (LVFX) antibiotic prophylaxis; for the NCG, this involved 1 dose of LVFX 500 mg orally 2 hours before TRPB, while the CG received rectal culture-based prophylaxis.",
                "In the PREVENT randomized trial [12], transperineal (TP) biopsy without antibiotic prophylaxis was compared to transrectal (TR) biopsy with targeted prophylaxis, while the ProBE-PC study [13] utilized 1-day antibiotic prophylaxis for TR procedures (without rectal cultures) and only occasionally for TP. This highlights TP-Tbx's potential to reduce or eliminate the need for prophylactic antibiotics, aligning with antibiotic stewardship goals and reducing broad-spectrum antibiotic reliance, crucial considerations for biopsy technique selection.",
                "Antibiotic prophylaxis is felt to have limited additional value in a transperineal (TP) biopsy, which aligns with and reinforces antimicrobial stewardship principles."
            ],
            "Source": [
                "RandomizedTrial3.pdf",
                "SystematicReview6.pdf",
                "SystematicReview2.pdf"
            ],
            "Confidence": [
                1.0,
                1.0,
                0.8
            ]
        },
        "5": {
            "Document": [
                "The analysis of nine studies (two RCTs, seven non-RCTs) revealed no significant difference in UTI rates (odds ratio [OR]: 1.07, 95% confidence interval [CI]: 0.50\u20132.31, I2 = 0%, p = 0.86) or sepsis rates (OR: 1.35, 95% CI: 0.36\u20135.12, I2 = 0%, p = 0.66) between groups with and without prophylaxis.",
                "Our meta-analysis found no significant differences in UTI and sepsis rates between transperineal prostate biopsies performed with or without antibiotic prophylaxis; however, patients at high risk for UTIs may still benefit from antibiotic prophylaxis.",
                "Our meta-analysis found no significant differences in UTI and sepsis rates between transperineal prostate biopsies performed with or without antibiotic prophylaxis."
            ],
            "Source": [
                "SystematicReview3.pdf",
                "SystematicReview3.pdf",
                "SystematicReview3.pdf"
            ],
            "Confidence": [
                0.8,
                0.8,
                0.8
            ]
        },
        "6": {
            "Document": [
                "In cases of doubt and for high-risk patients, antibiotic prophylaxis should be administered 30 minutes pre-operatively, using Cefuroxime i.m. or i.v., or alternatively Ampicillin/Sulbactam.",
                "Prophylaxis can be targeted based on a rectal swab or stool culture, augmented with two or more different antibiotic classes, or involve alternative antibiotics.",
                "Standard antibiotic prophylaxis, consisting of 2g IV ceftriaxone before biopsy followed by 2g oral cefixime daily for 2 days post-discharge (with 1g daily amikacin for 3 days as an alternative if ceftriaxone was not possible), was administered to all patients. However, the study excluded patients with symptomatic urinary tract infection, recent catheterization, hospitalization or urological intervention, immunodeficiency, or those using immunosuppressive drugs."
            ],
            "Source": [
                "LeitliniePAP2024.pdf",
                "EAU-Guideline_Urological_Infections_Paper.pdf",
                "RandomizedTrial4.pdf"
            ],
            "Confidence": [
                0.8,
                0.8,
                0.8
            ]
        },
        "7": {
            "Document": [
                "Patients with active or recurrent urinary tract infections, an indwelling catheter, immunocompromised individuals, those with a high risk of endocarditis, and patients who had experienced thromboembolic events were excluded from the studies.",
                "This study focused on patients with low infectious risk, excluding those with high infectious risk defined as diabetes mellitus, systemic steroid use, immunocompromised status, prostate volume \u226575 mL, or high-grade lower urinary tract obstruction (International Prostate Symptom Score [IPSS] \u226520, maximum urinary flow rate [Qmax] \u226412 mL/s, or residual urine \u2265100 mL). Other exclusion criteria included pyuria at enrollment, receiving antimicrobial administration less than 4 weeks before rectal culture or biopsy, and contraindications to levofloxacin or piperacillin/tazobactam.",
                "Patients with symptomatic urinary tract infection, a history of catheterization, hospitalization or urological intervention in the last month, immunodeficiency, or using immunosuppressive drugs were excluded from the study."
            ],
            "Source": [
                "LeitliniePAP2024.pdf",
                "RandomizedTrial3.pdf",
                "RandomizedTrial4.pdf"
            ],
            "Confidence": [
                0.8,
                1.0,
                0.8
            ]
        },
        "8": {
            "Document": [
                "The study recognized that excluding participants at higher risk of infection, necessary for successful randomisation, likely reduced the infection event rate in both groups. Although an observed difference was not statistically significant, this was a secondary outcome and the trial was not powered around it.",
                "Two published RCTs have reported comparably low post-biopsy infection rates for transperineal biopsy regardless of whether antibiotic prophylaxis was administered, contributing to a growing body of evidence suggesting that antibiotic prophylaxis may not be routinely required for transperineal biopsy.",
                "Transperineal ultrasound-guided biopsy (TPUS-PB) allows for the omission of antibiotic prophylaxis while maintaining comparable detection and complication rates to transrectal ultrasound-guided biopsy (TRUS-PB), showing a significantly lower incidence of infectious complications (RR: 0.55, 95% CI: 0.33-0.92, p = 0.02) per a meta-analysis of RCTs. The European Association of Urology (EAU) guidelines recommend TPUS-PB as the first choice due to its lower infection rate; however, for widely used TRUS-PB, transrectal antibiotic prophylaxis (TRAP) based on rectal swab culture should be considered."
            ],
            "Source": [
                "RandomizedTrial2.pdf",
                "EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf",
                "SystematicReview1.pdf"
            ],
            "Confidence": [
                0.8,
                1.0,
                0.8
            ]
        },
        "9": {
            "Document": [
                "Patients with a history of immunocompromise or a need for enhanced antibiotic prophylaxis were excluded from the study. Other exclusion criteria included previous prostate biopsy, extensive local disease (prostate-specific antigen >50 ng/mL or entire gland replaced by tumour on MRI), symptoms of concurrent or recent urinary tract infection, absent rectum, or inability to position in lithotomy.",
                "Studies were excluded if patients had a previous prostate surgery, congenital or acquired immune deficiencies, current infections at the time of biopsy, were on long-term immunosuppressive therapy, or received other prophylactic interventions not listed, as these factors might independently affect the risk of infection following a biopsy.",
                "A systematic review and meta-analysis of 23 studies (12,324 patients) found no statistically significant differences in pooled incidences of genitourinary infections (0.50% vs 0.37%), fever (0.44% vs 0.26%), sepsis (0.16% vs 0.13%), or readmission rates (0.35% vs 0.29%) following transperineal prostate biopsy with versus without periprocedural antibiotic prophylaxis (all p > 0.250). However, the study's design did not allow for the evaluation of specific high-risk patient groups such as immunocompromised or catheterized individuals, thus limiting the applicability of these conclusions to those subgroups."
            ],
            "Source": [
                "RandomizedTrial2.pdf",
                "SystematicReview5.pdf",
                "SystematicReview4.pdf"
            ],
            "Confidence": [
                0.8,
                1.0,
                1.0
            ]
        },
        "10": {
            "Document": [
                "Both transperineal (TP) and transrectal (TR) prostate biopsy approaches generally show low overall toxicity and no significant differences in cancer detection or complications, though their comparative benefits and safety are still debated. However, the MRI-targeted TP approach may be advantageous as it can be performed safely without antibiotics, potentially reducing antibiotic resistance.",
                "The European Association of Urology (EAU) Guidelines on Prostate Cancer note emerging evidence suggesting that antibiotic prophylaxis may not be necessary for transperineal prostate biopsies, though formal recommendations are pending further research. Updating clinical guidelines to incorporate these findings would optimize prostate cancer diagnostics and address antibiotic resistance."
            ],
            "Source": [
                "SystematicReview6.pdf",
                "SystematicReview3.pdf"
            ],
            "Confidence": [
                1.0,
                0.8
            ]
        },
        "11": {
            "Document": [
                "Screening for and treating asymptomatic bacteriuria (ABU) via pre-operative urine culture is strongly recommended before urological procedures breaching the mucosa, aiming to reduce infectious complications and optimize antimicrobial coverage. This is especially important as ABU is a risk factor for infectious complications (e.g., in nephrostomy/ureteral stent placement), and patients at higher risk for urosepsis include the elderly, diabetics, and immunosuppressed individuals (such as transplant recipients, or those on cancer chemotherapy or corticosteroids).",
                "Non-hospitalizing urinary tract infections (UTIs) were observed in 0.36% (95% CI 0.01-2.00) of patients with antibiotics and 1.09% (95% CI 0.37-3.15) without; the 0.73% difference did not exceed the 4% non-inferiority margin [170]. Furthermore, a systematic review and meta-analysis also showed no increased infection rate without antibiotic prophylaxis during transperineal biopsy (0.05% vs. 0.08%; p=0.2) [171]."
            ],
            "Source": [
                "EAU-Guidelines-on-Urological-infections-2025_2025-05-24-110339_pxmf.pdf",
                "LL_Prostatakarzinom_Langversion_8.0.pdf"
            ],
            "Confidence": [
                1.0,
                1.0
            ]
        },
        "12": {
            "Document": [
                "Omitting periprocedural antibiotic prophylaxis (PAP) during transperineal biopsy (TPB) is advisable, as infectious complications are very rare and cannot be further reduced by PAP, supporting antibiotic stewardship and posing negligible risk without compromising safety. However, this recommendation has (very) low certainty due to limitations, including a lack of high-quality studies and insufficient analysis of patient-level differences like comorbidities, suggesting further research is needed to tailor antibiotic stewardship strategies for specific patient subgroups.",
                "Analysis of 23 studies, encompassing 6520 patients with periprocedural antibiotic prophylaxis (PAP) and 5804 without, found that transperineal biopsy (TPB) without PAP resulted in no significantly higher complication rates across all analyzed endpoints in aggregated, subgroup, and sensitivity analyses, supporting recommendations to abstain from PAP."
            ],
            "Source": [
                "SystematicReview4.pdf",
                "SystematicReview4.pdf"
            ],
            "Confidence": [
                1.0,
                1.0
            ]
        },
        "13": {
            "Document": [
                "The transperineal method is associated with less common infection, and a research purpose is to discern whether these reduced infection rates are attributed to antiseptic solutions or mechanical rectal irrigation.",
                "Bei der transperinealen Stanzbiopsie kann auf eine Antibiotikaprophylaxe verzichtet werden; dies ist eine evidenzbasierte Empfehlung, die 2025 neu eingef\u00fchrt wurde und Empfehlungsgrad 0 hat."
            ],
            "Source": [
                "RandomizedTrial4.pdf",
                "LL_Prostatakarzinom_Langversion_8.0.pdf"
            ],
            "Confidence": [
                0.8,
                1.0
            ]
        },
        "14": {
            "Document": [
                "Current literature [11] suggests that omitting periprocedural antibiotic prophylaxis during transperineal (TP) biopsy, which generally causes fewer infectious complications, is safe. A subgroup analysis [Fig. 3] found no statistically significant difference in overall infectious complications or hospitalizations between TP biopsies with and without prophylaxis, concluding it may be safe to forgo prophylaxis for patients without risk factors, an approach supported by randomized data such as the NORAPP trial [18].",
                "A subgroup analysis of ten studies, comparing antibiotic prophylaxis versus no antibiotic prophylaxis during a TP biopsy, found no statistically significant difference in febrile infectious outcomes between the two approaches (p = 0.47; Fig. 3)."
            ],
            "Source": [
                "SystematicReview2.pdf",
                "SystematicReview2.pdf"
            ],
            "Confidence": [
                0.8,
                0.8
            ]
        },
        "15": {
            "Document": [
                "Infection rates were low and similar between transrectal (TR) and transperineal (TP) biopsies, with 28 infections among 1545 patients (TR 2%, TP 2%) and only one sepsis case reported overall (TR 1/762, TP 0/783). The ProBE-PC study showed similarly low infectious complications (TR 2.6%, TP 2.7%), primarily mild fevers, with no sepsis reported, while the PREVENT trial found no infections in 372 TP cases versus six (1.6%) in 370 TR cases.",
                "Preliminary evidence suggests that TP-Tbx may result in lower rates of sepsis, and this directionality for key outcomes like infection and sepsis appears to favor TP-Tbx. However, these findings are not yet statistically significant, warranting further investigation to confirm these potential advantages."
            ],
            "Source": [
                "SystematicReview6.pdf",
                "SystematicReview6.pdf"
            ],
            "Confidence": [
                1.0,
                1.0
            ]
        },
        "16": {
            "Document": [
                "Transperineal prostate biopsies (TPPB) were not performed during the clinical trial, and patients with severe immunodeficiency or indwelling urinary catheters were also excluded. However, current European Association of Urology (EAU) guidelines now recommend TPPB because of its lower rate of infectious complications.",
                "Growing evidence indicates that infection, hospitalization, and sepsis rates are comparably lower in transperineal prostate biopsy (TPPB) compared with transrectal prostate biopsy (TRPB). For TRPB, antibiotic prophylaxis is mandatory to avoid infectious complications and is recommended with povidone-iodine rectal preparation; prior gold standard FQs are no longer accepted in the EU, EAU guidelines recommend an algorithm, and a study found no significant difference between single-dose and prolonged FMT prophylaxis."
            ],
            "Source": [
                "RandomizedTrial1.pdf",
                "RandomizedTrial1.pdf"
            ],
            "Confidence": [
                1.0,
                1.0
            ]
        },
        "17": {
            "Document": [
                "Prophylaxis is recommended, particularly for patients with a high risk of postoperative sepsis.",
                "For transperineal biopsy, periprocedural antibiotic prophylaxis can be omitted if no infection or prostatitis is present, as demonstrated by a multicentric study showing no hospitalizations for sepsis or urinary tract infection within two months. However, for patients presenting with risk factors such as immunosuppression, a history of prostatitis/urinary tract infection, diabetes mellitus with elevated infection risk, recent antibiotic use, or travel to high antibiotic-resistance regions, a rectal swab for targeted antibiotic prophylaxis is recommended."
            ],
            "Source": [
                "EAU-Guideline_Urological_Infections_Paper.pdf",
                "LL_Prostatakarzinom_Langversion_8.0.pdf"
            ],
            "Confidence": [
                0.8,
                1.0
            ]
        },
        "18": {
            "Document": [
                "Rectal culture using selective media before transperineal biopsy (TRPB) demonstrated effectiveness in preventing acute, post-biopsy prostatitis, achieving an overall incidence of 1.1% within 30 days, particularly in patients with low infectious risks. These highly accurate selective media (e.g., LVFX-insusceptible, with 98.1% sensitivity and 94.7% specificity) allow for targeted recommendations like TAZ/PIPC when FQ-resistant or ESBL-producing E. coli is detected, though further evaluation is needed for patients with higher infectious risks or underlying conditions negatively impacting immune function.",
                "A recent trial demonstrated that antibiotic prophylaxis can be completely avoided before transperineal biopsy without significantly increasing infection rates. Specifically, there was no significant difference in sepsis (OR 0.49, p = 0.42) or UTI (OR 0.81, p = 0.7) rates compared to standard prophylaxis, and the risk of fever was lower (OR 0.58, p = 0.088) in the group omitting antibiotics."
            ],
            "Source": [
                "RandomizedTrial3.pdf",
                "SystematicReview5.pdf"
            ],
            "Confidence": [
                1.0,
                1.0
            ]
        },
        "19": {
            "Document": [
                "Pre-procedure and post-procedure antibiotics were standard-of-care at each recruitment centre, and all participants in the TRUS group received these antibiotics (appendix 1 p 17).",
                "Transperineal biopsy (TP-Tbx) can safely omit periprocedural antibiotics without increasing infection risk, unlike transrectal biopsy (TR-Tbx) which commonly uses prophylaxis. Both methods demonstrate similar rates of PCa detection, postprocedural infection (OR 0.8, 95% CI: 0.4-1.8), sepsis, urinary retention, and biopsy-associated pain, though infections and sepsis directionally favor TP despite lacking statistical significance."
            ],
            "Source": [
                "RandomizedTrial2.pdf",
                "SystematicReview6.pdf"
            ],
            "Confidence": [
                0.8,
                1.0
            ]
        },
        "20": {
            "Document": [
                "A systematic literature search identified an RCT (Jacewicz et al. 2022) showing a non-statistically significant reduction in urinary tract infections (UTIs) with periprocedural antibiotic prophylaxis (PAP) versus no PAP (OR 0.33 [0.03-3.19]), with no sepsis or hospitalization-requiring UTIs occurring in either group; however, the evidence for UTIs is rated very low due to bias risks and imprecise estimators, and intestinal colonization with multi-drug resistant gram-negative bacteria (MRGN) is described as a risk factor.",
                "For transperineal prostate biopsy (including MRI-fusion), antibiotic prophylaxis can be omitted, provided a preoperative urinary tract infection is reliably excluded (e.g., via U-Stix) and the perineum is thoroughly disinfected with Chlorhexidine or Octenidindihydrochlorid/Phenoxyethanol. This omission does not appear to increase the risk of urosepsis or severe urinary tract infections, though less severe UTIs were three times more frequent without prophylaxis (absolute difference 0.73%), with 137 patients requiring antibiotic treatment to prevent one infection."
            ],
            "Source": [
                "LeitliniePAP2024.pdf",
                "LeitliniePAP2024.pdf"
            ],
            "Confidence": [
                0.8,
                0.8
            ]
        },
        "21": {
            "Document": [
                "Multiple systematic reviews and meta-analyses, including one of eight non-RCTs [613] and another of 112 individual patient cohorts [614], along with two recently published RCTs [615, 616], consistently reported comparably low post-biopsy infection rates for transperineal biopsy whether antibiotic prophylaxis was administered or not. Specifically, the review of eight non-RCTs reported no significant differences in post-biopsy infection (0.11% with vs. 0.31% without prophylaxis) and sepsis (0.13% vs. 0.09%) [613], while the review of 112 cohorts showed infection rates of 1.35% in 29,880 patients with prophylaxis vs. 1.22% in 4,772 patients without (p = 0.8) [614].",
                "In selected low-risk patients, some studies reported no increase in infections even without the use of antibiotics, though further research is needed before changing routine practice."
            ],
            "Source": [
                "EAU-Guidelines-on-Urological-infections-2025_2025-05-24-110339_pxmf.pdf",
                "SystematicReview2.pdf"
            ],
            "Confidence": [
                1.0,
                0.8
            ]
        },
        "22": {
            "Document": [
                "Transperineal (TP) biopsy appears to be a safe procedure without antibiotics in patients without risk factors, advocating for enhanced antimicrobial stewardship in urology.",
                "High-level evidence confirms that the transperineal (TP) biopsy route significantly reduces the risk of hospitalization due to infectious complications compared to the transrectal route, highlighting the lack of additional benefit from antibiotic prophylaxis in TP biopsies and reinforcing antimicrobial stewardship principles. While data suggest TP biopsy may reduce infection-related morbidity and antibiotic use, further studies are needed to confirm these findings in broader populations and across healthcare systems."
            ],
            "Source": [
                "SystematicReview2.pdf",
                "SystematicReview2.pdf"
            ],
            "Confidence": [
                0.8,
                0.8
            ]
        }
    },
    "not_clustered": {
        "Document": [
            "Currently, there is no consensus on recommendations for antibiotic prophylaxis during transperineal prostate biopsy. However, antibiotic prophylaxis can be omitted during transperineal MRI-fusion biopsy.",
            "The document does not explicitly address the omission of periprocedural antibiotic prophylaxis during transperineal biopsy or maintaining non-inferior infection rates across different risk categories (e.g., immunocompromised or catheterized patients) for this specific procedure. However, for transrectal prostate biopsy, prophylaxis is recommended, with regimens including targeted prophylaxis (based on rectal swab/stool culture), augmented prophylaxis (two or more antibiotic classes), or alternative antibiotics such as Fosfomycin trometamol, Cephalosporins (e.g., ceftriaxone, cefixime), or Aminoglycosides (e.g., gentamicin, amikacin).",
            "F\u00fcr die transperineale Biopsie kann bei Nicht-Vorhandensein einer Infektion oder Prostatitis auf eine Antibiotikaprophylaxe verzichtet werden. Eine Metaanalyse von 11 Studien mit 1.753 Patienten zeigte hingegen eine signifikante Reduktion von Infektionen durch eine Antibiotikaprophylaxe bei der transrektalen Biopsie (RR 0,56, 95 % KI 0,40-0,77).",
            "Driven by a trend to minimize antibiotic use to reduce resistance [12,13,15], the transperineal (TP) approach is favored over the transrectal (TR) approach\u2014which carries a 5-7% [22] infection risk due to rectal mucosa involvement and typically requires comprehensive antibiotic protocols or prophylaxis\u2014because TP, even though it often requires more extensive preparation and potentially general anesthesia, avoids the rectal mucosa, resulting in an almost complete absence of post-biopsy sepsis. This significant advantage, not primarily due to a reduction in mild infections, is corroborated by numerous prospective and retrospective reviews and trials like PREVENT, which reported zero infections in 372 TP cases versus six in 370 TR cases (difference of -1% [95% CI: -3.5% to 0.3%, p=0.01]), despite sepsis being a rare event that often underpowers studies to detect differences.",
            "The PREVENT trial [12] demonstrated that transperineal (TP) biopsies without preventative antibiotics resulted in no reported infections and no significant infectious complications. This outcome is similar to transrectal (TR) biopsies that used targeted antibiotic prophylaxis, where the trial showed a minimal 1.6% infection incidence; these infections were febrile but nonsevere and did not escalate to critical levels."
        ],
        "Source": [
            "LeitliniePAP2024.pdf",
            "EAU-Guideline_Urological_Infections_Paper.pdf",
            "LL_Prostatakarzinom_Langversion_8.0.pdf",
            "SystematicReview6.pdf",
            "SystematicReview6.pdf"
        ],
        "Confidence": [
            0.8,
            0.8,
            1.0,
            1.0,
            1.0
        ]
    },
    "interface_output": {
        "total_nuggets": 66,
        "n_clusters": 28,
        "clusters": [
            {
                "cluster_id": 1,
                "cluster_heading": "LATP Biopsy: Less Antibiotics, Fewer Infections",
                "nuggets": [
                    "LATP biopsy was performed with chlorhexidine-based skin preparation and without antibiotics; 503 (89%) of 567 participants who received LATP underwent biopsy without antibiotics according to protocol. (Confidence: 80.0%)",
                    "Using the primary definition of post-biopsy infection (requiring hospital admission), LATP resulted in lower rates compared to TRUS biopsy: one (<1%) of 562 vs. seven (1%) of 564 within 7 days (OR 0.14 [95% CI 0.02-1-15]), and 2 (<1%) vs. 9 (2%) within 35 days, with both 7-day and 35-day hospitalizations likely related to biopsy. For the secondary, broader definition of infection (symptoms or signs with or without admission), no statistically significant difference was observed over 4 months between LATP (113 [20%] of 562) and TRUS (120 [21%] of 564). (Confidence: 80.0%)",
                    "Concerns about infectious complications and the development of post-biopsy urinary sepsis have driven the transition from TRUS to LATP, with LATP showing fewer overall infectious complications (six [1%] of 562) compared to TRUS (13 [2%] of 564) in the 4-month post-biopsy period (adjusted 0.45 [0.17-1.20]). (Confidence: 80.0%)",
                    "The TRANSLATE study demonstrated that most LATP biopsies can be safely performed without antibiotics, with 89% of cases not receiving them (11% were largely protocol deviations), resulting in fewer infections (both resulting and not resulting in hospital admission) compared to TRUS. This finding, important for antibiotic stewardship, should be considered with the caveat that the infection difference was not statistically significant as it was a secondary outcome for which the trial was not powered. (Confidence: 80.0%)",
                    "TP-Tbx can safely omit antibiotics without increasing infection risk, unlike TR-Tbx; however, a meta-analysis reaffirms no clear superiority of the TP-Tbx approach over the TR-Tbx approach in terms of infection prevention and cancer detection. (Confidence: 100.0%)"
                ],
                "sources": [
                    "RandomizedTrial2.pdf",
                    "RandomizedTrial2.pdf",
                    "RandomizedTrial2.pdf",
                    "RandomizedTrial2.pdf",
                    "SystematicReview6.pdf"
                ],
                "size": 5
            },
            {
                "cluster_id": 2,
                "cluster_heading": "Transperineal Biopsy: Antibiotic Prophylaxis Guidelines Evolving",
                "nuggets": [
                    "A growing body of evidence suggests antibiotic prophylaxis may not be required for transperineal biopsy; however, the Panel is waiting for ongoing RCTs to report their findings before making a recommendation, as all prostate biopsy recommendations are based on level 1a evidence. (Confidence: 100.0%)",
                    "The indication for fosfomycin trometamol for prostate biopsy has been withdrawn in Germany because manufacturers did not submit the necessary pharmacokinetic data. Urologists are advised to check their local guidance regarding its use. (Confidence: 80.0%)",
                    "Transperineal biopsies are considered an optimization of antibiotic stewardship, with other strategies including rectal cleansing, rectal swab culture with targeted antibiotics, or avoiding any antibiotics prior to the biopsy. Relevant studies are RCTs involving adults aged 18 or older undergoing transrectal or transperineal prostate biopsy (not aspiration, eight or more cores), comparing standard empirical antibiotic prophylaxis or alternative prophylactic interventions, such as the NORAPP trial on antibiotic prophylaxis versus no prophylaxis in transperineal prostate biopsies. (Confidence: 100.0%)",
                    "Presented data, including a meta-analysis, substantiate the safety and effectiveness of not administering antibiotic prophylaxis during transperineal prostate biopsy (TPBx), which supports antibiotic stewardship, curbs microbial resistance, and guarantees patient safety. While EAU guidelines describe growing evidence for this approach, they are currently waiting for findings from ongoing randomized controlled trials. (Confidence: 80.0%)"
                ],
                "sources": [
                    "EAU-Guidelines-on-Urological-infections-2025_2025-05-24-110339_pxmf.pdf",
                    "EAU-Guideline_Urological_Infections_Paper.pdf",
                    "SystematicReview5.pdf",
                    "SystematicReview3.pdf"
                ],
                "size": 4
            },
            {
                "cluster_id": 3,
                "cluster_heading": "Transperineal Biopsy: No Infection Benefit from Antibiotic Prophylaxis",
                "nuggets": [
                    "Study inclusion criteria for prostate biopsy patients encompassed elevated/rising PSA, suspicious digital-rectal exam, active surveillance, and suspected recurrence after radiation or HIFU. While low CD4+ helper cell counts are associated with increased postoperative wound infection risk, no specific periprocedural antibiotic prophylaxis (PAP) studies were found for patients with HIV-associated immunodeficiency, neutropenia, or those on immunosuppressive medication; however, expert opinion suggests that PAP principles for these immunocompromised subgroups align with those for non-immunocompromised patients. (Confidence: 80.0%)",
                    "A Castellani et al. (2022) meta-analysis, based on low certainty evidence from 8 non-RCT comparative studies on perineal prostate biopsy, reported infection rates of 0.11% with periprocedural antibiotic prophylaxis (PAP) versus 0.31% without PAP (p = 0.29). However, two subsequent RCTs (Jacewicz 2022; Chernyscheva 2021) on transperineal biopsy have since shown no higher rates of infections, fever, or sepsis when PAP is omitted. (Confidence: 80.0%)",
                    "Evidence from multiple systematic reviews and meta-analyses, including one of eight non-RCTs and another of 112 patient cohorts, corroborated by two published RCTs, indicates no significant difference in infection rates for transperineal prostate biopsy regardless of antibiotic prophylaxis administration. Reported rates comparing prophylaxis vs. no prophylaxis include post-biopsy infection (0.11% vs. 0.31%), post-transperineal-biopsy infection (1.35% of 29,880 patients vs. 1.22% of 4,772 men [p=0.8]), sepsis (0.13% vs. 0.09%), and septic complications (0.05% vs. 0.08% [p=0.2]), suggesting prophylaxis may not be routinely required. (Confidence: 100.0%)",
                    "Despite the relatively low infection rate following transperineal prostate biopsy (TPB), it remains unresolved whether periprocedural antibiotic prophylaxis (PAP) can be omitted. Studies indicate that omitting PAP does not result in higher infectious complications (such as genitourinary infections, fever, sepsis, readmission, or 30-day mortality), though analyses did not account for patient-level differences like medical comorbidities or prior prostate biopsies, which could contribute to post-procedural infections. (Confidence: 100.0%)"
                ],
                "sources": [
                    "LeitliniePAP2024.pdf",
                    "LeitliniePAP2024.pdf",
                    "EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf",
                    "SystematicReview4.pdf"
                ],
                "size": 4
            },
            {
                "cluster_id": 4,
                "cluster_heading": "Transperineal vs. Transrectal Prostate Biopsy: Infection & Safety",
                "nuggets": [
                    "The nuggets discuss transperineal prostate biopsy and transrectal prostate biopsy (TRPB), noting that transperineal prostate biopsy was explicitly excluded in some contexts. (Confidence: 100.0%)",
                    "Procedure: Transrectal prostate biopsy (Confidence: 80.0%)",
                    "Transrectal prostate biopsy, commonly performed as ultrasound-guided TRUS-PB and considered the most common and gold standard for prostate cancer diagnosis, has significantly higher sepsis rates compared to transperineal biopsy; notably, none of 245 patients who underwent transperineal biopsy were hospitalized. (Confidence: 80.0%)",
                    "Ultrasound-guided prostate biopsy, performed transrectally (TRUS-PB) or transperineally (TPUS-PB), is the primary diagnostic method for prostate cancer. While TRUS-PB is still widely used, it is associated with a significant rate of infectious complications, whereas the guideline-recommended TPUS-PB allows for the omission of antibiotic prophylaxis while maintaining comparable detection and complication rates. (Confidence: 80.0%)"
                ],
                "sources": [
                    "RandomizedTrial3.pdf",
                    "EAU-Guideline_Urological_Infections_Paper.pdf",
                    "RandomizedTrial4.pdf",
                    "SystematicReview1.pdf"
                ],
                "size": 4
            },
            {
                "cluster_id": 5,
                "cluster_heading": "Transperineal Biopsy: Prophylaxis & Stewardship",
                "nuggets": [
                    "A multicenter, randomized controlled trial enrolled 403 low-risk patients undergoing transperineal biopsy (TRPB), randomizing them into a cultured group (CG) or a no cultured group (NCG). All participants received levofloxacin (LVFX) antibiotic prophylaxis; for the NCG, this involved 1 dose of LVFX 500 mg orally 2 hours before TRPB, while the CG received rectal culture-based prophylaxis. (Confidence: 100.0%)",
                    "In the PREVENT randomized trial [12], transperineal (TP) biopsy without antibiotic prophylaxis was compared to transrectal (TR) biopsy with targeted prophylaxis, while the ProBE-PC study [13] utilized 1-day antibiotic prophylaxis for TR procedures (without rectal cultures) and only occasionally for TP. This highlights TP-Tbx's potential to reduce or eliminate the need for prophylactic antibiotics, aligning with antibiotic stewardship goals and reducing broad-spectrum antibiotic reliance, crucial considerations for biopsy technique selection. (Confidence: 100.0%)",
                    "Antibiotic prophylaxis is felt to have limited additional value in a transperineal (TP) biopsy, which aligns with and reinforces antimicrobial stewardship principles. (Confidence: 80.0%)"
                ],
                "sources": [
                    "RandomizedTrial3.pdf",
                    "SystematicReview6.pdf",
                    "SystematicReview2.pdf"
                ],
                "size": 3
            },
            {
                "cluster_id": 6,
                "cluster_heading": "Antibiotic Prophylaxis Doesn't Reduce Biopsy UTI/Sepsis",
                "nuggets": [
                    "The analysis of nine studies (two RCTs, seven non-RCTs) revealed no significant difference in UTI rates (odds ratio [OR]: 1.07, 95% confidence interval [CI]: 0.50\u20132.31, I2 = 0%, p = 0.86) or sepsis rates (OR: 1.35, 95% CI: 0.36\u20135.12, I2 = 0%, p = 0.66) between groups with and without prophylaxis. (Confidence: 80.0%)",
                    "Our meta-analysis found no significant differences in UTI and sepsis rates between transperineal prostate biopsies performed with or without antibiotic prophylaxis; however, patients at high risk for UTIs may still benefit from antibiotic prophylaxis. (Confidence: 80.0%)",
                    "Our meta-analysis found no significant differences in UTI and sepsis rates between transperineal prostate biopsies performed with or without antibiotic prophylaxis. (Confidence: 80.0%)"
                ],
                "sources": [
                    "SystematicReview3.pdf",
                    "SystematicReview3.pdf",
                    "SystematicReview3.pdf"
                ],
                "size": 3
            },
            {
                "cluster_id": 7,
                "cluster_heading": "Antibiotic Prophylaxis: Regimens, Timing, and Patient Selection",
                "nuggets": [
                    "In cases of doubt and for high-risk patients, antibiotic prophylaxis should be administered 30 minutes pre-operatively, using Cefuroxime i.m. or i.v., or alternatively Ampicillin/Sulbactam. (Confidence: 80.0%)",
                    "Prophylaxis can be targeted based on a rectal swab or stool culture, augmented with two or more different antibiotic classes, or involve alternative antibiotics. (Confidence: 80.0%)",
                    "Standard antibiotic prophylaxis, consisting of 2g IV ceftriaxone before biopsy followed by 2g oral cefixime daily for 2 days post-discharge (with 1g daily amikacin for 3 days as an alternative if ceftriaxone was not possible), was administered to all patients. However, the study excluded patients with symptomatic urinary tract infection, recent catheterization, hospitalization or urological intervention, immunodeficiency, or those using immunosuppressive drugs. (Confidence: 80.0%)"
                ],
                "sources": [
                    "LeitliniePAP2024.pdf",
                    "EAU-Guideline_Urological_Infections_Paper.pdf",
                    "RandomizedTrial4.pdf"
                ],
                "size": 3
            },
            {
                "cluster_id": 8,
                "cluster_heading": "Exclusion Criteria: Infection Risk and Comorbidities",
                "nuggets": [
                    "Patients with active or recurrent urinary tract infections, an indwelling catheter, immunocompromised individuals, those with a high risk of endocarditis, and patients who had experienced thromboembolic events were excluded from the studies. (Confidence: 80.0%)",
                    "This study focused on patients with low infectious risk, excluding those with high infectious risk defined as diabetes mellitus, systemic steroid use, immunocompromised status, prostate volume \u226575 mL, or high-grade lower urinary tract obstruction (International Prostate Symptom Score [IPSS] \u226520, maximum urinary flow rate [Qmax] \u226412 mL/s, or residual urine \u2265100 mL). Other exclusion criteria included pyuria at enrollment, receiving antimicrobial administration less than 4 weeks before rectal culture or biopsy, and contraindications to levofloxacin or piperacillin/tazobactam. (Confidence: 100.0%)",
                    "Patients with symptomatic urinary tract infection, a history of catheterization, hospitalization or urological intervention in the last month, immunodeficiency, or using immunosuppressive drugs were excluded from the study. (Confidence: 80.0%)"
                ],
                "sources": [
                    "LeitliniePAP2024.pdf",
                    "RandomizedTrial3.pdf",
                    "RandomizedTrial4.pdf"
                ],
                "size": 3
            },
            {
                "cluster_id": 9,
                "cluster_heading": "Transperineal Biopsy: Lower Infection, Reduced Antibiotics",
                "nuggets": [
                    "The study recognized that excluding participants at higher risk of infection, necessary for successful randomisation, likely reduced the infection event rate in both groups. Although an observed difference was not statistically significant, this was a secondary outcome and the trial was not powered around it. (Confidence: 80.0%)",
                    "Two published RCTs have reported comparably low post-biopsy infection rates for transperineal biopsy regardless of whether antibiotic prophylaxis was administered, contributing to a growing body of evidence suggesting that antibiotic prophylaxis may not be routinely required for transperineal biopsy. (Confidence: 100.0%)",
                    "Transperineal ultrasound-guided biopsy (TPUS-PB) allows for the omission of antibiotic prophylaxis while maintaining comparable detection and complication rates to transrectal ultrasound-guided biopsy (TRUS-PB), showing a significantly lower incidence of infectious complications (RR: 0.55, 95% CI: 0.33-0.92, p = 0.02) per a meta-analysis of RCTs. The European Association of Urology (EAU) guidelines recommend TPUS-PB as the first choice due to its lower infection rate; however, for widely used TRUS-PB, transrectal antibiotic prophylaxis (TRAP) based on rectal swab culture should be considered. (Confidence: 80.0%)"
                ],
                "sources": [
                    "RandomizedTrial2.pdf",
                    "EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf",
                    "SystematicReview1.pdf"
                ],
                "size": 3
            },
            {
                "cluster_id": 10,
                "cluster_heading": "Prostate Biopsy: High-Risk Patient Exclusions",
                "nuggets": [
                    "Patients with a history of immunocompromise or a need for enhanced antibiotic prophylaxis were excluded from the study. Other exclusion criteria included previous prostate biopsy, extensive local disease (prostate-specific antigen >50 ng/mL or entire gland replaced by tumour on MRI), symptoms of concurrent or recent urinary tract infection, absent rectum, or inability to position in lithotomy. (Confidence: 80.0%)",
                    "Studies were excluded if patients had a previous prostate surgery, congenital or acquired immune deficiencies, current infections at the time of biopsy, were on long-term immunosuppressive therapy, or received other prophylactic interventions not listed, as these factors might independently affect the risk of infection following a biopsy. (Confidence: 100.0%)",
                    "A systematic review and meta-analysis of 23 studies (12,324 patients) found no statistically significant differences in pooled incidences of genitourinary infections (0.50% vs 0.37%), fever (0.44% vs 0.26%), sepsis (0.16% vs 0.13%), or readmission rates (0.35% vs 0.29%) following transperineal prostate biopsy with versus without periprocedural antibiotic prophylaxis (all p > 0.250). However, the study's design did not allow for the evaluation of specific high-risk patient groups such as immunocompromised or catheterized individuals, thus limiting the applicability of these conclusions to those subgroups. (Confidence: 100.0%)"
                ],
                "sources": [
                    "RandomizedTrial2.pdf",
                    "SystematicReview5.pdf",
                    "SystematicReview4.pdf"
                ],
                "size": 3
            },
            {
                "cluster_id": 11,
                "cluster_heading": "Antibiotic-Free Transperineal Biopsy: Safety and Guideline Updates",
                "nuggets": [
                    "Both transperineal (TP) and transrectal (TR) prostate biopsy approaches generally show low overall toxicity and no significant differences in cancer detection or complications, though their comparative benefits and safety are still debated. However, the MRI-targeted TP approach may be advantageous as it can be performed safely without antibiotics, potentially reducing antibiotic resistance. (Confidence: 100.0%)",
                    "The European Association of Urology (EAU) Guidelines on Prostate Cancer note emerging evidence suggesting that antibiotic prophylaxis may not be necessary for transperineal prostate biopsies, though formal recommendations are pending further research. Updating clinical guidelines to incorporate these findings would optimize prostate cancer diagnostics and address antibiotic resistance. (Confidence: 80.0%)"
                ],
                "sources": [
                    "SystematicReview6.pdf",
                    "SystematicReview3.pdf"
                ],
                "size": 2
            },
            {
                "cluster_id": 12,
                "cluster_heading": "Urological Infection Management: Targeted Screening and Antibiotic Use",
                "nuggets": [
                    "Screening for and treating asymptomatic bacteriuria (ABU) via pre-operative urine culture is strongly recommended before urological procedures breaching the mucosa, aiming to reduce infectious complications and optimize antimicrobial coverage. This is especially important as ABU is a risk factor for infectious complications (e.g., in nephrostomy/ureteral stent placement), and patients at higher risk for urosepsis include the elderly, diabetics, and immunosuppressed individuals (such as transplant recipients, or those on cancer chemotherapy or corticosteroids). (Confidence: 100.0%)",
                    "Non-hospitalizing urinary tract infections (UTIs) were observed in 0.36% (95% CI 0.01-2.00) of patients with antibiotics and 1.09% (95% CI 0.37-3.15) without; the 0.73% difference did not exceed the 4% non-inferiority margin [170]. Furthermore, a systematic review and meta-analysis also showed no increased infection rate without antibiotic prophylaxis during transperineal biopsy (0.05% vs. 0.08%; p=0.2) [171]. (Confidence: 100.0%)"
                ],
                "sources": [
                    "EAU-Guidelines-on-Urological-infections-2025_2025-05-24-110339_pxmf.pdf",
                    "LL_Prostatakarzinom_Langversion_8.0.pdf"
                ],
                "size": 2
            },
            {
                "cluster_id": 13,
                "cluster_heading": "Safe Transperineal Biopsy: No Routine Antibiotics Recommended",
                "nuggets": [
                    "Omitting periprocedural antibiotic prophylaxis (PAP) during transperineal biopsy (TPB) is advisable, as infectious complications are very rare and cannot be further reduced by PAP, supporting antibiotic stewardship and posing negligible risk without compromising safety. However, this recommendation has (very) low certainty due to limitations, including a lack of high-quality studies and insufficient analysis of patient-level differences like comorbidities, suggesting further research is needed to tailor antibiotic stewardship strategies for specific patient subgroups. (Confidence: 100.0%)",
                    "Analysis of 23 studies, encompassing 6520 patients with periprocedural antibiotic prophylaxis (PAP) and 5804 without, found that transperineal biopsy (TPB) without PAP resulted in no significantly higher complication rates across all analyzed endpoints in aggregated, subgroup, and sensitivity analyses, supporting recommendations to abstain from PAP. (Confidence: 100.0%)"
                ],
                "sources": [
                    "SystematicReview4.pdf",
                    "SystematicReview4.pdf"
                ],
                "size": 2
            },
            {
                "cluster_id": 14,
                "cluster_heading": "Transperineal Biopsy: Reduced Infection, No Antibiotic Prophylaxis",
                "nuggets": [
                    "The transperineal method is associated with less common infection, and a research purpose is to discern whether these reduced infection rates are attributed to antiseptic solutions or mechanical rectal irrigation. (Confidence: 80.0%)",
                    "Bei der transperinealen Stanzbiopsie kann auf eine Antibiotikaprophylaxe verzichtet werden; dies ist eine evidenzbasierte Empfehlung, die 2025 neu eingef\u00fchrt wurde und Empfehlungsgrad 0 hat. (Confidence: 100.0%)"
                ],
                "sources": [
                    "RandomizedTrial4.pdf",
                    "LL_Prostatakarzinom_Langversion_8.0.pdf"
                ],
                "size": 2
            },
            {
                "cluster_id": 15,
                "cluster_heading": "Transperineal Biopsy: Safe to Omit Antibiotic Prophylaxis",
                "nuggets": [
                    "Current literature [11] suggests that omitting periprocedural antibiotic prophylaxis during transperineal (TP) biopsy, which generally causes fewer infectious complications, is safe. A subgroup analysis [Fig. 3] found no statistically significant difference in overall infectious complications or hospitalizations between TP biopsies with and without prophylaxis, concluding it may be safe to forgo prophylaxis for patients without risk factors, an approach supported by randomized data such as the NORAPP trial [18]. (Confidence: 80.0%)",
                    "A subgroup analysis of ten studies, comparing antibiotic prophylaxis versus no antibiotic prophylaxis during a TP biopsy, found no statistically significant difference in febrile infectious outcomes between the two approaches (p = 0.47; Fig. 3). (Confidence: 80.0%)"
                ],
                "sources": [
                    "SystematicReview2.pdf",
                    "SystematicReview2.pdf"
                ],
                "size": 2
            },
            {
                "cluster_id": 16,
                "cluster_heading": "Transrectal vs. Transperineal Biopsy Infection Safety",
                "nuggets": [
                    "Infection rates were low and similar between transrectal (TR) and transperineal (TP) biopsies, with 28 infections among 1545 patients (TR 2%, TP 2%) and only one sepsis case reported overall (TR 1/762, TP 0/783). The ProBE-PC study showed similarly low infectious complications (TR 2.6%, TP 2.7%), primarily mild fevers, with no sepsis reported, while the PREVENT trial found no infections in 372 TP cases versus six (1.6%) in 370 TR cases. (Confidence: 100.0%)",
                    "Preliminary evidence suggests that TP-Tbx may result in lower rates of sepsis, and this directionality for key outcomes like infection and sepsis appears to favor TP-Tbx. However, these findings are not yet statistically significant, warranting further investigation to confirm these potential advantages. (Confidence: 100.0%)"
                ],
                "sources": [
                    "SystematicReview6.pdf",
                    "SystematicReview6.pdf"
                ],
                "size": 2
            },
            {
                "cluster_id": 17,
                "cluster_heading": "Prostate Biopsy: Infection Risks and Evolving Guidelines",
                "nuggets": [
                    "Transperineal prostate biopsies (TPPB) were not performed during the clinical trial, and patients with severe immunodeficiency or indwelling urinary catheters were also excluded. However, current European Association of Urology (EAU) guidelines now recommend TPPB because of its lower rate of infectious complications. (Confidence: 100.0%)",
                    "Growing evidence indicates that infection, hospitalization, and sepsis rates are comparably lower in transperineal prostate biopsy (TPPB) compared with transrectal prostate biopsy (TRPB). For TRPB, antibiotic prophylaxis is mandatory to avoid infectious complications and is recommended with povidone-iodine rectal preparation; prior gold standard FQs are no longer accepted in the EU, EAU guidelines recommend an algorithm, and a study found no significant difference between single-dose and prolonged FMT prophylaxis. (Confidence: 100.0%)"
                ],
                "sources": [
                    "RandomizedTrial1.pdf",
                    "RandomizedTrial1.pdf"
                ],
                "size": 2
            },
            {
                "cluster_id": 18,
                "cluster_heading": "Antibiotic Prophylaxis Recommendations for Biopsy",
                "nuggets": [
                    "Prophylaxis is recommended, particularly for patients with a high risk of postoperative sepsis. (Confidence: 80.0%)",
                    "For transperineal biopsy, periprocedural antibiotic prophylaxis can be omitted if no infection or prostatitis is present, as demonstrated by a multicentric study showing no hospitalizations for sepsis or urinary tract infection within two months. However, for patients presenting with risk factors such as immunosuppression, a history of prostatitis/urinary tract infection, diabetes mellitus with elevated infection risk, recent antibiotic use, or travel to high antibiotic-resistance regions, a rectal swab for targeted antibiotic prophylaxis is recommended. (Confidence: 100.0%)"
                ],
                "sources": [
                    "EAU-Guideline_Urological_Infections_Paper.pdf",
                    "LL_Prostatakarzinom_Langversion_8.0.pdf"
                ],
                "size": 2
            },
            {
                "cluster_id": 19,
                "cluster_heading": "Transperineal Biopsy: Antibiotic Prophylaxis Strategies",
                "nuggets": [
                    "Rectal culture using selective media before transperineal biopsy (TRPB) demonstrated effectiveness in preventing acute, post-biopsy prostatitis, achieving an overall incidence of 1.1% within 30 days, particularly in patients with low infectious risks. These highly accurate selective media (e.g., LVFX-insusceptible, with 98.1% sensitivity and 94.7% specificity) allow for targeted recommendations like TAZ/PIPC when FQ-resistant or ESBL-producing E. coli is detected, though further evaluation is needed for patients with higher infectious risks or underlying conditions negatively impacting immune function. (Confidence: 100.0%)",
                    "A recent trial demonstrated that antibiotic prophylaxis can be completely avoided before transperineal biopsy without significantly increasing infection rates. Specifically, there was no significant difference in sepsis (OR 0.49, p = 0.42) or UTI (OR 0.81, p = 0.7) rates compared to standard prophylaxis, and the risk of fever was lower (OR 0.58, p = 0.088) in the group omitting antibiotics. (Confidence: 100.0%)"
                ],
                "sources": [
                    "RandomizedTrial3.pdf",
                    "SystematicReview5.pdf"
                ],
                "size": 2
            },
            {
                "cluster_id": 20,
                "cluster_heading": "Transperineal vs. Transrectal Biopsy: Antibiotics and Infection Risk",
                "nuggets": [
                    "Pre-procedure and post-procedure antibiotics were standard-of-care at each recruitment centre, and all participants in the TRUS group received these antibiotics (appendix 1 p 17). (Confidence: 80.0%)",
                    "Transperineal biopsy (TP-Tbx) can safely omit periprocedural antibiotics without increasing infection risk, unlike transrectal biopsy (TR-Tbx) which commonly uses prophylaxis. Both methods demonstrate similar rates of PCa detection, postprocedural infection (OR 0.8, 95% CI: 0.4-1.8), sepsis, urinary retention, and biopsy-associated pain, though infections and sepsis directionally favor TP despite lacking statistical significance. (Confidence: 100.0%)"
                ],
                "sources": [
                    "RandomizedTrial2.pdf",
                    "SystematicReview6.pdf"
                ],
                "size": 2
            },
            {
                "cluster_id": 21,
                "cluster_heading": "Transperineal Biopsy: Omitting Antibiotic Prophylaxis and UTI Risk",
                "nuggets": [
                    "A systematic literature search identified an RCT (Jacewicz et al. 2022) showing a non-statistically significant reduction in urinary tract infections (UTIs) with periprocedural antibiotic prophylaxis (PAP) versus no PAP (OR 0.33 [0.03-3.19]), with no sepsis or hospitalization-requiring UTIs occurring in either group; however, the evidence for UTIs is rated very low due to bias risks and imprecise estimators, and intestinal colonization with multi-drug resistant gram-negative bacteria (MRGN) is described as a risk factor. (Confidence: 80.0%)",
                    "For transperineal prostate biopsy (including MRI-fusion), antibiotic prophylaxis can be omitted, provided a preoperative urinary tract infection is reliably excluded (e.g., via U-Stix) and the perineum is thoroughly disinfected with Chlorhexidine or Octenidindihydrochlorid/Phenoxyethanol. This omission does not appear to increase the risk of urosepsis or severe urinary tract infections, though less severe UTIs were three times more frequent without prophylaxis (absolute difference 0.73%), with 137 patients requiring antibiotic treatment to prevent one infection. (Confidence: 80.0%)"
                ],
                "sources": [
                    "LeitliniePAP2024.pdf",
                    "LeitliniePAP2024.pdf"
                ],
                "size": 2
            },
            {
                "cluster_id": 22,
                "cluster_heading": "Transperineal Biopsy: Antibiotic Prophylaxis Doesn't Reduce Infection",
                "nuggets": [
                    "Multiple systematic reviews and meta-analyses, including one of eight non-RCTs [613] and another of 112 individual patient cohorts [614], along with two recently published RCTs [615, 616], consistently reported comparably low post-biopsy infection rates for transperineal biopsy whether antibiotic prophylaxis was administered or not. Specifically, the review of eight non-RCTs reported no significant differences in post-biopsy infection (0.11% with vs. 0.31% without prophylaxis) and sepsis (0.13% vs. 0.09%) [613], while the review of 112 cohorts showed infection rates of 1.35% in 29,880 patients with prophylaxis vs. 1.22% in 4,772 patients without (p = 0.8) [614]. (Confidence: 100.0%)",
                    "In selected low-risk patients, some studies reported no increase in infections even without the use of antibiotics, though further research is needed before changing routine practice. (Confidence: 80.0%)"
                ],
                "sources": [
                    "EAU-Guidelines-on-Urological-infections-2025_2025-05-24-110339_pxmf.pdf",
                    "SystematicReview2.pdf"
                ],
                "size": 2
            },
            {
                "cluster_id": 23,
                "cluster_heading": "Transperineal Biopsy: Safe, Antibiotic-Free, Reduced Infection Risk.",
                "nuggets": [
                    "Transperineal (TP) biopsy appears to be a safe procedure without antibiotics in patients without risk factors, advocating for enhanced antimicrobial stewardship in urology. (Confidence: 80.0%)",
                    "High-level evidence confirms that the transperineal (TP) biopsy route significantly reduces the risk of hospitalization due to infectious complications compared to the transrectal route, highlighting the lack of additional benefit from antibiotic prophylaxis in TP biopsies and reinforcing antimicrobial stewardship principles. While data suggest TP biopsy may reduce infection-related morbidity and antibiotic use, further studies are needed to confirm these findings in broader populations and across healthcare systems. (Confidence: 80.0%)"
                ],
                "sources": [
                    "SystematicReview2.pdf",
                    "SystematicReview2.pdf"
                ],
                "size": 2
            },
            {
                "cluster_id": 25,
                "cluster_heading": "Transperineal MRI-Fusion Biopsy: Antibiotic Prophylaxis Omission",
                "nuggets": [
                    "Currently, there is no consensus on recommendations for antibiotic prophylaxis during transperineal prostate biopsy. However, antibiotic prophylaxis can be omitted during transperineal MRI-fusion biopsy. (Confidence: 80.0%)"
                ],
                "sources": [
                    "LeitliniePAP2024.pdf"
                ],
                "size": 1
            },
            {
                "cluster_id": 26,
                "cluster_heading": "Prostate Biopsy Antibiotic Prophylaxis Recommendations",
                "nuggets": [
                    "The document does not explicitly address the omission of periprocedural antibiotic prophylaxis during transperineal biopsy or maintaining non-inferior infection rates across different risk categories (e.g., immunocompromised or catheterized patients) for this specific procedure. However, for transrectal prostate biopsy, prophylaxis is recommended, with regimens including targeted prophylaxis (based on rectal swab/stool culture), augmented prophylaxis (two or more antibiotic classes), or alternative antibiotics such as Fosfomycin trometamol, Cephalosporins (e.g., ceftriaxone, cefixime), or Aminoglycosides (e.g., gentamicin, amikacin). (Confidence: 80.0%)"
                ],
                "sources": [
                    "EAU-Guideline_Urological_Infections_Paper.pdf"
                ],
                "size": 1
            },
            {
                "cluster_id": 27,
                "cluster_heading": "Antibiotic Prophylaxis: Transperineal vs. Transrectal Biopsy",
                "nuggets": [
                    "F\u00fcr die transperineale Biopsie kann bei Nicht-Vorhandensein einer Infektion oder Prostatitis auf eine Antibiotikaprophylaxe verzichtet werden. Eine Metaanalyse von 11 Studien mit 1.753 Patienten zeigte hingegen eine signifikante Reduktion von Infektionen durch eine Antibiotikaprophylaxe bei der transrektalen Biopsie (RR 0,56, 95 % KI 0,40-0,77). (Confidence: 100.0%)"
                ],
                "sources": [
                    "LL_Prostatakarzinom_Langversion_8.0.pdf"
                ],
                "size": 1
            },
            {
                "cluster_id": 28,
                "cluster_heading": "Transperineal Biopsy: Sepsis Prevention, Reduced Antibiotic Use.",
                "nuggets": [
                    "Driven by a trend to minimize antibiotic use to reduce resistance [12,13,15], the transperineal (TP) approach is favored over the transrectal (TR) approach\u2014which carries a 5-7% [22] infection risk due to rectal mucosa involvement and typically requires comprehensive antibiotic protocols or prophylaxis\u2014because TP, even though it often requires more extensive preparation and potentially general anesthesia, avoids the rectal mucosa, resulting in an almost complete absence of post-biopsy sepsis. This significant advantage, not primarily due to a reduction in mild infections, is corroborated by numerous prospective and retrospective reviews and trials like PREVENT, which reported zero infections in 372 TP cases versus six in 370 TR cases (difference of -1% [95% CI: -3.5% to 0.3%, p=0.01]), despite sepsis being a rare event that often underpowers studies to detect differences. (Confidence: 100.0%)"
                ],
                "sources": [
                    "SystematicReview6.pdf"
                ],
                "size": 1
            },
            {
                "cluster_id": 29,
                "cluster_heading": "Biopsy Infection Safety: TP Without Antibiotics, TR With Prophylaxis",
                "nuggets": [
                    "The PREVENT trial [12] demonstrated that transperineal (TP) biopsies without preventative antibiotics resulted in no reported infections and no significant infectious complications. This outcome is similar to transrectal (TR) biopsies that used targeted antibiotic prophylaxis, where the trial showed a minimal 1.6% infection incidence; these infections were febrile but nonsevere and did not escalate to critical levels. (Confidence: 100.0%)"
                ],
                "sources": [
                    "SystematicReview6.pdf"
                ],
                "size": 1
            }
        ]
    }
}